**CURRICULUM VITAE**

**STANLEY J. SZEFLER, M.D.**

1. **Biographical Sketch**

Current Position: Professor of Pediatrics

 University of Colorado School of Medicine

Office Address: Children’s Hospital Colorado

 13123 East 16th Avenue, B395

 Aurora, CO 80045

 Phone: 720-777-0985

 Fax: 720-777-7284

 Email: stanley.szefler@childrenscolorado.org

1. **Education**

1966-1968 Canisius College, Buffalo, New York

1968-1971 School of Pharmacy, SUNY at Buffalo, B.S, Pharmacy

1971-1975 School of Medicine, SUNY at Buffalo, Doctor of Medicine

1975-1977 Resident in Pediatrics, Children's Hospital, Buffalo, NY

1977-1979 Fellow in Clinical Pharmacology, State University of New York at Buffalo,

 Departments of Pharmacology and Therapeutics and Pediatrics

(additional training in allergy/immunology under the direction of Elliot F. Ellis, M.D. and Elliott Middleton, Jr., M.D.)

1. **Academic Appointments**

1991-present Professor of Pediatrics (1990-present) (with Tenure 2016) and Pharmacology (1991-2013), University of Colorado Health Sciences Center.

1983-1991 Associate Professor of Pediatrics (l982-1990) and Pharmacology (l983-1991), University of Colorado Health Sciences Center.

1980-1982 Assistant Professor of Pediatrics and of Pharmacology and Therapeutics

School of Medicine, and of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo.

1979-1980 Research Assistant Professor of Pediatrics and of Pharmacology and Therapeutics

 School of Medicine, and of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo.

1. **Hospital, Government or other Professional Positions**

2020-prsent Interim, Medical Director, Research Institute, Children’s Hospital Colorado

2018- present Pediatric Pulmonary Training Program – Research Drector, Secton of Pediatric Pulmonary and Sleep Medicine, Deparment of Pediatrics, University of Colorado School of medicine, Anschutz Medical Campus

2015- present Research Medical Director, The Breathing Institute, Sections of Pulmonary Medicine and of Allergy and Immunology, Department of Pediatrics, Children’s Hospital Colorado, University of Colorado Denver School of Medicine.

2013-present Director, Pediatric Asthma Research, The Breathing Institute, Sections of Pulmonary Medicine and of Allergy and Immunology, Department of Pediatrics, Children’s Hospital Colorado, University of Colorado Denver School of Medicine.

2011-2013 Director of Fellowship Training in Allergy and Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine.

1998-2013 Director, Weinberg Clinical Research Unit/Pediatrics Section, National Jewish Medical and Research Center.

1995-2013 Helen Wohlberg & Herman Lambert Chair in Pharmacokinetics, National Jewish Center for Immunology and Respiratory Medicine.

1995-2013 Director of Pediatric Clinical Trials Center, Department of Pediatrics, National Jewish Center for Immunology and Respiratory Medicine.

1989-1995 Director of Fellowship Training, Department of Pediatrics, Allergy and Immunology Program, National Jewish Center for Immunology and Respiratory Medicine.

1982-2013 Director of Clinical Pharmacology, Departments of Pediatrics (l982-2013 and Medicine - l986-1995) National Jewish Center for Immunology and Respiratory Medicine.

1980-1982 Chief, Division of Pediatric Clinical Pharmacology and Pharmacokinetics

 Children's Hospital.

1979-1980 Acting Chief, Division of Pediatric Clinical Pharmacology and Pharmacokinetics

 Children's Hospital.

1977-1988 Military -- Major, United States Army Medical Reserve

1. **Honors, Special Recognitions and Awards**

A. SCHOLARSHIPS AND FELLOWSHIPS

New York State Regents Scholarship - July l966

United Way Summer Research Fellowship, SUNY at Buffalo School of Medicine -- l973

Pharmaceutical Manufacturers Association Foundation Fellowship in Clinical Pharmacology -- July l977 to June l979

B. SPECIAL RECOGNITIONS

Pharmacy School:

Rho Chi Honor Society Award for High Scholastic Achievement for Academic years l967-68 and l968-69.

Dr. Roger Mantsavinos Award for Excellence in Biochemistry

Dr. Eino Nelson Award for Excellence in Biopharmaceutics

Dr. James A. Lemon Award for Excellence in Biochemical Pharmacology

Aesculapius Award from Kappa Psi Pharmaceutical Fraternity for Outstanding Academic Performance

Leadership Award from Kappa Psi for l969-l970

Scholarship Certificate from Kappa Psi for Academic Performance -- l969-l970

Grand Council Scholarship Key -- Kappa Psi for Highest Scholastic Average in Class of l97l School of Pharmacy, SUNY at Buffalo

Graduation -- Magna Cum Laude

Medical School:

Induction into James A. Gibson Anatomical Society for Performance in Anatomical Sciences -- April l973

Induction into Alpha Omega Alpha Honor Society -- l975

Pediatric Residency:

Children's Hospital Award for Outstanding Performance During Internship Year l975-l976

Children's Hospital Award for Outstanding Performance During Residency Year l976-l977

Faculty:

Faculty Development Award, Buswell Fellowship

 State University of New York at Buffalo l979-l980

Helen Wohlberg & Herman Lambert Chair in Pharmacokinetics 1995

Presidential Award, National Jewish Faculty Award 2001

Outstanding Scientific Achievement in Clinical Research, National Jewish Faculty Award 2001

Special Recognition Award for Outstanding Dedication and Service to the Residency Recruitment and Retention Committee, Department of Pediatrics, University of Colorado School of Medicine 2017

Visiting Professor:

University of Oklahoma Children's Hospital (1986)

University of Wisconsin (1990)

Northwestern University/Children's Hospital, Chicago (1990)

Medical College of Philadelphia (1990)

University of Iowa College of Medicine (1992)

Baylor College of Medicine and University of Texas at Galveston (1993)

Rainbow Babies Hospital, Cleveland, Ohio (1994)

Walter Reed Army Medical Center, Bethesda, Maryland (1995)

Nassau County Medical Center (1996)

Bethesda Naval Hospital and Walter Reed Army Medical Center, Bethesda, Maryland (1997)

Children's Hospital, Omaha, Nebraska (1998)

Medical University of South Carolina (1999)

Medical College of Georgia (2000)

Rainbow Children’s Hospital, Cleveland, Ohio (2001)

University of Arkansas at Little Rock (2002)

University of Vermont (2002)

University of Cincinnati (2003)

Ohio State University (2005)

Washington University, St. Louis (2006)

Rush Medical Center University (2006)

Johns Hopkins University (2006)

Walter Reed Army Medical center (2006)

Indiana University (2007)

Children’s Hospital of Norfolk, Virginia (2007)

University of Virginia (2007)

Medical University of South Carolina (2007)

University of Kansas, Children’s Medical Center Hospital (2007)

Mayo Clinic, Rochester, Minnesota (2008)

Imperial College and Brompton Hospital, London, England (2008)

McGill University, Montreal Children’s Hospital, Allergy and Immunology Program (2008)

University of California at San Francisco (2008)

University of California at Davis (2008)

Johns Hopkins University, Department of Pediatrics (2009)

Children’s Medical Center, Northwestern University, Chicago (2010)

University of Florida at Gainesville, Department of Pediatrics and School of Pharmacy (2011)

University of Washington, Department of Pediatrics Allergy and Immunology Division (2011)

University of Miami, Department of Pediatrics Pulmonary Division (2012)

National Institutes of Allergy and Infectious Diseases Program (2013)

University of Indiana, Department of Pediatrics, Children’s Hospital Pulmonary Division (2013)

University of Connecticut, Children’s Medical Center, Hartford, CT (2014)

Emory University, Department of Pediatrics Pulmonary Section (2014)

Stanford University, Lucille Packard Children’s Hospital (2015)

University of Iowa (2015)

University of California, Irvine (2019)

Local:

Colorado School Nurse Association. School Nurse Advocate of the Year 2014

National Recognition:

Carl Arbesman Memorial Lecture - Buffalo Allergy Society May 1990

Director - American Board of Allergy and Immunology 1991-1996.

Best Doctors in America 1992 - present

Goodman Lecturer

 American College of Allergy and Immunology Annual Meeting 1994

Jerome Glaser Memorial Lectureship

 American Academy of Allergy, Asthma and Immunology Annual Meeting 1995

Who's Who in Medicine and Healthcare 1996

Best Doctors in America: Central Region 1996-present

American Health Magazine/Best Doctors in America 1996

Food and Drug Administration, Member of Pulmonary-Allergy Drugs

 Advisory Committee 1996 – 2000

Pfizer Visiting Professor in Pediatrics Medical University of South Carolina 1999

Philip Fireman Lecture Children’s Hospital of Pittsburgh 1999

Elliott Middleton Memorial Lecture

 Buffalo Allergy and Immunology Continuing Education Program 1999

Bernard Berman Lecture - American College of Asthma, Allergy, and Asthma 1999

NHLBI/Technical Advisory Group for Evidence-Based Review of Asthma Therapy 2000-2001

NHLBI/National Asthma Education and Prevention Program,

 Science Base Committee 2001-2016

Bret Ratner Award, American Academy of Pediatrics, Section for Allergy and Immunology 2002

Elliott Middleton Memorial Lecture - Buffalo Allergy and Immunology Society Continuing Education Program 2002

NHLBI/National Asthma Education and Prevention Program, Expert Panel Advisory Board for update of asthma management in pregnancy guidelines 2003-2004

Los Angeles Children’s Hospital Warren Richards Lectureship 2003

Park-Nicollet Clinical, Minneapolis, Minnesota, Norman A. Sterrie Lectureship 2004

Arizona Respiratory Center Benjamin Burrows Lung Immunology Seminar Series 2004

Elliot F. Ellis Lectureship, American Academy of Allergy, Asthma and Immunology 2005

Philip Fireman Lectureship, Nemacolin Conference 2008

Alvin Wert Lecture, Doerbecher Children’s Hospital, Portland, Oregon 2008

Distinguished Clinician Award, American Academy of Allergy, Asthma and Immunology 2009

William Pearson Lectureship, Washington State Allergy, Asthma and Immunology Society and Seattle Children’s Hospital 2011

University of Miami Pulmonary Section 2012

National Institutes of Allergy and Infectious Diseases 2013

Colorado Association of School Nurses, Advocate of the Year Award 2014

Keynote Speaker, Nationawide Columbus Children’s Hospital, Asthma Program 2015

Pediatric Pharmacy Advocacy Group, Summer Yaffe Lifetime Achievement Award in Pediatric Clinical Pharmacology 2016

Presidential Symposium, John P. McGovern lectureship, American College of Allergy, Asthma and Immunology 2018 2018

International Recognition

World Allergy Organization, Outstanding Clinician Award 2009

Scientific Advisory Committee, Global Initiative for Asthma 2013-2017

Board of Directors, Global Initiative for Asthma 2015-2017

1. **Memberships in Professional Organizations**

 Rho Chi Honor Society -- Pharmacy School Inducted May l970

 James A. Gibson Anatomical Society Inducted April l973

 Alpha Omega Alpha Honor Society Inducted l975

 American Academy of Pediatrics l976-present

 American Society for Clinical Pharmacology and Therapeutics Full member 1978-1995

 American Academy of Allergy, Asthma and Immunology l980-present (fellow-1989)

American Academy of Pediatrics, Clinical Pharmacology and Therapeutics Section Member, 1980-present

 Society of Pediatric Research l983-present

 American Society of Pharmacology and Experimental Therapeutics l984-2008

 Colorado Allergy and Asthma Society - (l983-present)

 American College of Allergy, Asthma and Immunology 1986-2014 (fellow-1988)

 Allergy and Immunology Section Member, American Academy of Pediatrics 1988-present

 American Thoracic Society 1995-present

 Colorado Trudeau Society/Medical Section of the American Lung

 Association of Colorado 1995-2013

 European Respiratory Society 1996-2002

 Colorado Association of School-Based Health Care 2009-2013

1. **Major Committee and Service Responsibilities**

A. Hospital

 1. Children's Hospital Buffalo, N.Y.

 a. Pharmacy and Therapeutics Committee l976-1982

 b. Drug Formulary Committee l978-1982

 c. Investigational Drug Committee l979-1982

 d. Antibiotic Surveillance Committee l979-1982

 f. Core Curriculum Committee, Research Council l980-1982

 g. Steering Committee, Research Council l980-1982

 2. National Jewish Health

 a. Pharmacy and Therapeutics Committee, Chairman l983-1999

 b. By-Laws Committee, Chairman l983-1985

 c. Clinical Investigation Committee, Member l985-1990

 d. Patient Education Advisory Committee, Member 1987-1990

 e. Medical Illustrations Advisory Committee, Member 1988-1991

 f. Biostatics Advisory Committee, Member 1989-1992

 g. Executive Committee, Department of Pediatrics, Member 1989-2013

 h. Fellowship Program Training Committee,

 Department of Pediatrics 1990-2013

 i. Research Task Force, Institutional Committee 1990-1994

 j. Patent Committee, member 1990-1994

 k. Non-Clinical Funding Task Force 1994-1996

 l. Disease Management Program, Department of Pediatrics 1995-1996

 m. Clinical Research Task Force 1997-1998

 n. Long Term Planning Committee 1998-1999

 o. Ethics Committee 1999-2013

 p. Search Committee, Head for Biostatistics Division 1999-2000

 q. Awards Committee 2001-2005

 r. Search Committee, Head for Allergy and
Immunology Division, Department of Medicine 2001-2002

 s. Data Safety and Monitoring Committee 2002-2007

 t. Strategic Plan Implementation, Pediatric asthma
representative, Department of Pediatrics, 2007-2008

 u. Asthma Retreat, Co-Director 2006

 v. National Jewish Kauvar Symposium on Asthma, Director 2007

 w. Faculty Awards Committee, Chair 2008-2010

 x. Pediatric Pulmonary Division Search Committee, Chair 2009-2013

 y. Clinical Research Leadership Committee 2011-2013

B. University

 1. State University of New York at Buffalo

 a. Human Investigation Review Committee, l978-1982

 School of Pharmacy

 b. Geriatrics Committee, School of Medicine l980-198l

 2. University of Colorado School of Medicine

 a. House Staff Recruitment Evaluation 1985-1988

 b. Research Committee, Department of Pediatrics l986-1988

 c. Pediatric Residents Training Committee,
Department of Pediatrics 1988-1991

 d. Fellowship Review Committee 1992-1995

 e. Promotions Committee, Department of Pediatrics 1993-1997

 f. University Faculty Promotions Committee 1997-2000

 Co-chair, Promotions Committee 1999-2000

1. General Clinical Research Center,
Scientific Advisory Committee (SAC) 2001-2008
2. General Clinical Research Center
General Advisory Committee (GAC); Chair (2006-2008) 2003-2008
3. Participant and Clinical Interactions Resources (PCIR)

Oversight Committee for the Clinical and Translational

Sciences Institute 2008-2013

1. Resident Applicants Interviews 2014-present
2. Promotion (and Tenure 2017) Committee,

Department of Pediatrics 2015-present

1. Leadership Committee, Breathing Institute 2015-present
2. Research Operations Committee 2016-2017
3. Research Review Committee, Chair, Breathing Institute 2016-present
4. Research Operations Committee, Chair, Breathing Institute 2017-present
5. Research Prioritiziation Committee 2017-present
6. Scientific Steering Committee 2017-present
7. Search Committee, Chair, Emergency Medicine Section 2017-present

C. National

 1. American Academy of Allergy, Asthma and Immunology

 a. Committee on Drugs/Pharmacotherapy l982-2007

 b. Committee on Inhaled Steroids 1986-1990

 c. Postgraduate Education Committee (representative of the

 Asthma, Rhinitis and Respiratory Disease Section) 1989-1992

 d. Course Director, Asthma Course for the Asthma, Rhinitis

 and Respiratory Disease Section 1989-1993

 e. Secretary, Asthma, Rhinitis, and Respiratory Disease Section 1992-1993

 f. Chair-elect, Asthma, Rhinitis, and Respiratory Disease Section 1993-1995

 g. Training Program Directors Committee, Chair of Research

 Subcommittee 1993-1995

 h. Program Committee, Abstract Selection 1993-1996

 i. Chair, Asthma, Rhinitis, and Respiratory Disease Section 1995-1997

 j. Member, NAEPP Guidelines Dissemination

 Project Committee 1998-2000

1. Clinical Research Task Force, Joint Council of Allergy
and Immunology 2000-2007

l. Awards Committee 2002-2006

m. Office of School-Based Management, Director 2014-present

n. Grants Review Committee 2017-present

 2. American Academy of Pediatrics

 a. Section on Clinical Pharmacology, Committee member l984-1988

 b. Allergy and Immunology Section, member 1988-present

 c. Executive Committee, Allergy and Immunology Section 1992-1997

 d. Editor, Synopsis of literature for allergy and immunology,

 section publication 1993-1995

 e. Liaison, Committee on Drugs 1994-2000

3. Task force for the development of guidelines for non-bronchodilator anti-asthma drugs - co-chairman, section on special pharmacologic considerations, sponsored by the American Academy of Allergy and Immunology and the National Institute of Allergy and Infectious Diseases l985-1986

4. Task Force on Asthma Mortality, member Pharmacology Workshop
sponsored by the American Academy of Allergy and Immunology l986-1987

 5. United States Pharmacopeia - Pulmonary Disease Advisory Panel 1990-2000

6. Childhood Asthma Management Program - National Heart,
Lung and Blood Institute multicenter clinical trial.

 a. Steering Committee 1991-2013

 b. Director, Patient Education Center 1992-1999

 c. Publications and Presentations Committee 1996-2013

 Chair, Editorial Subcommittee

 d. Executive Committee 1997-2013

 e. Writing committee, main outcomes publication 1999-2000

 7. American Board of Allergy and Immunology 1991-1997

 a. Task Force on Honorarium/Insurance 1992

 b. Examination Proctor 1993-1997

 c. Recertification Examination Co-Chair 1994-1995

 d. Ad Hoc Examination Guidelines Committee 1995

 e. Ad Hoc Nominating Procedure Committee 1996

 f. Nominating Committee 1996

 g. Nominating Committee Chair 1997

 h. Conjoint Credentials Committee Chair 1997

 8. American College of Allergy and Immunology

 a. Member, Training Program Directors Advisory Committee 1993-1996

9. NHLBI Workshop on Asthma Outcome Measures,
Discussant on Treatment Measures 1992

10. NHLBI Workshop on Childhood and Adult Onset Asthma, Presenter on pharmacotherapy 1994

11. NHLBI Workshop on Early Intervention in Childhood Asthma, Presenter on pharmacologic intervention 1996

 12. Food and Drug Administration,

 a. Member of Pulmonary-Allergy Drugs

 Advisory Committee 1996-2000

 b. Member of Pediatrics Subcommittee,

 Infectious Disease Committee 1999-2002

 c. Member for the Oral and Nasally Inhaled Product
Subcommittee for Pharmaceutical Sciences 2000-2002

 d. Consultive and Ad hoc Advisor 2014-2018

 13. American Thoracic Society

 Ad-Hoc Committee on the Evaluation and Management of

 Refractory Asthma 1996-2000

 14. American College of Chest Physicians

 Co-Chair, Clinical Practice Guidelines for the

 “Use and Prevention of Complications from Inhaled

 Glucocorticoids in the Treatment of Asthma.” 1997-2002

 15. Pediatric Pharmacology Research Unit Network –
National Institutes of Child Health and Human Development 1999-2004

 a. Vice Chair, Protocol Review Subcommittee 1999-2001

 b. Chair, Pulmonary, Asthma and Allergy Working Group 1999-2003

 c. Member, task force on Special Populations 2000-2002

 d. Chair, Research Committee 2000-2001

 e. Member, Research Committee 2000-2003

 f. Vice Chair, Research Committee 2003

 16. Childhood Asthma and Education Research Network –
National Heart, Lung and Blood Institute 1999-2013

a. Lead Investigator, Characterizing Response to Leukotriene
Antagonist and Inhaled Corticosteroids in Childhood Asthma
(CLIC) study 1999-2003

b. Member, Presentations and publication committee 1999-2011

c. Member, Genetics Committee 1999-2011

d. Member, Conflict of Interest Policy Committee 2000-2001

e. Member, Quality Control Committee 2001-2002

f. Member, Pharmaceutical Contracts Committee 2003-2011

17. Participant in Workshop for Relative Potency of Inhaled
Corticosteroid Workshop, sponsored by Canada Health 2000

18. National Heart Lung and Blood Institute/National Asthma Education
and Prevention Program

 a. Consultant, Technical Advisory Group 2000-2001

 b. Member, Science Base Committee 2001-2007

 c. Member, Asthma and Pregnancy Guidelines Update 2003-2004

 d. Expert Panel-3, Asthma Guidelines 2005-2013

e. Special Advisor, Update of NAEPP Asthma Guidelines 2014-2015

f. Technical Expert Panel, NAEPP Asthma Guidelines 2016-2017

19. Task force for Development of Guidelines for Medications studies
in the Newborn – National Institutes of Child Health and Human Development/Food and Drug Administration 2003-2004

20. Inner City Asthma Consortium I and II - National Institutes of
Allergy and Infectious Diseases 2000-2015

 a. Chair, Protocol Development Committee 2002-2008

 b. Lead Investigator, Asthma Control Evaluation (ACE) study 2001-2008

 c. Lead Investigator, Preventive Omalizumab or Step-Up

 Therapy for Severe Fall Exacerbations (PROSE) Study 2008-2015

21. Asthma Clinical Research Network – National Heart, Lung
and Blood Institute 1993 - 2011

a. Lead Investigator, Measuring Response to Inhaled
Corticosteroids in Asthma (MICE) study 1993-1998

 b. Member, Genetics Committee 2001-2011

 c. Member, Medications Committee 2003-2011

 22. Denver Public School Asthma Program, Director

a. Executive Director, Colorado Cancer, Cardiovascular 2006-2008
and Pulmonary Disease Program and 2009-present

22. NICHD Workshop, “Emergency Research in Children:
Ethical, Regulatory and Clinical Challenges” 2006

23. NHLBI/NIAID Asthma Outcomes Task Force, Co-Chair,
Biomarkers Committee 2009-2012

 24. NHLBI AsthmaNet – asthma research network 2009 - present

 a. Publications and Presentations Committee, Chair 2009-present

 b. Long Range Planning Committee, Member 2010-2016

 c. Lead-Investigator, Individualized Asthma Therapy for

 Toddlers (INFANT) Study 2010-2016

 d. Lead Investigator, Pediatrics Section, Best drug response

 for African Americans with asthma (BARD) study 2012-present

 e. Priority Planning Committee, member 2014-2016

25. NICHD Vision Strategy Task Force – Co-Chair Diagnosis and
Therapeutics Committee 2010-2011

26. Global Initiative for Asthma, Scientific Advisory Committee 2013-2017

27. Global Initiative for Asthma, Board of Directors 2015-2017

28. NHLBI, PrecISE Network 2017-present

 a. Asthma Definitions Committee 2017

 b. MedicatiomSelection Committee non-T2 2017-present

 c. Protocol Development Committee 2018-present

 d. Publications and Presentations Committee, Chair 2018-present

D. Community activities

 1. American Lung Association, Asthma Camp Steering Committee 1988-1996

 Patient Education Director 1994-1996

 2. Mothers of Asthmatics, Advisory Board 1988-2001

 3. Colorado Clinical Guidelines Committee, Asthma 2005-2008

 4. Denver Public School Health Research Advisory Committee 2008-2017

 5. Asthma Nights for Denver Public Schools 2009-2015

 6. Colorado Asthma Coalition, consultant 2009-2017

 7. Denver Public School, Health Advisory Council 2011-2017

E. Pharmaceutical Industry Advisory Panel and Consultant

1. Advisory Board - Dura Pharmaceuticals 1993-1995

2. Ad hoc consultant 1995-2007- Glaxo/Allen & Hanburys,
Inc., Schering Pharmaceuticals, Fisons Pharmaceuticals, 3M
Pharmaceuticals, Marion Merrell Dow, Astra Inc., Forest
Pharmaceuticals, Muro Pharmaceuticals, Ross Products Division,
Abbott Laboratories, Amgen

3. Education coordinator

 a. Key Pharmaceuticals - symposium on theophylline update -
held in Denver, Colorado August 1994

 b. Rhône-Poulenc Rorer - symposium on "theophylline in the
management of asthma" held in Denver, Colorado February 1994

 c. Glaxo/Allen & Hanburys - organizing committee for
pharmaceutical representative preceptor program on asthma
 National Jewish Center, Denver, Colorado 1995- 1997

 d. Rhône-Poulenc Rorer – Co-Director for preceptorship
program on teaching patient education for pharmaceutical
representatives 1995-1996

 e. Zeneca Pharmaceuticals - Moderator for preceptorship
program for pharmaceutical representatives program on asthma 1996

4. Respiratory Drug Advisory Panel - Glaxo and Wellcome 1996-1999

5. Asthma Regional Advisory Board - Discovery International/Zeneca Pharmaceuticals 1996

6. Leaders in Choice Advisory Panel - Glaxo Wellcome 1996-1998

1. National Directives Respiratory Advisory Board – Merck 1997 – 1999
2. International Respiratory Advisory Board - 3M Pharmaceuticals 1998-1999
3. Pediatric Advisory Board, Chairman – Merck 1999- 2002
4. Ad hoc Consultant – Sepracor 1998-2002
5. Ad hoc Consultant – Schering, 2000-2001
6. Pediatric Asthma Advisory Board – Glaxo Smith Kline 2001-2004
7. Advisory Panel – Pulmicort Respules, Astra Zeneca 2000-2003
8. Respiratory Advisory Board – Aventis 2001-2007
9. Respiratory Advisory Board – Altana 2001 – 2007
10. Respiratory Advisory Board – Novartis/Genentech 2002 – 2008
11. Academic Allergy Specialist Advisory Board – Glaxo Smith Kline 2003-2004
12. Merck Scientific Advisory Board 2003 – 2010
Global Respiratory Advisory Board 2010 – 2015
13. Ad hoc consultant- Ross Laboratories 2003
14. Ad hoc consultant – Roche Pharmaceuticals, Session Chairman 2003
15. Advisory Panel – Symbicort Development– Astra Zeneca 2003 – 2007
16. Ad hoc consultant – Abbott Pharmaceuticals, Respiratory Division 2007 – 2009
17. Boehringer Ingelheim – consultant new drug development –
pediatric plan 2008-2009

Chair, pediatric tiotropium study 2010 – 2016

1. Schering – consultant new drug development 2009
2. Sepracor – consultant new drug development 2010
3. Glaxo Smith Kline, Chair Pediatric Steering Committee for the
FDA mandated Long Acting ß-agonist trial 2011 – 2016
4. Roche, Global Respiratory Advisory Board 2012-2017
5. Aerocrine/Circassia, Consultant Exhaled nitric oxide monitoring 2014-present
6. Glaxo Smith Kline, Food and Drug Administration Advisory Meeting Consultant 2015
7. Novartis, Chair, Advisory Committee meeting, new asthma medication and

TENOR II study 2015

1. Teva, Advisory Panel, new asthma medication 2016
2. Astra Zeneca, AIRS Forum Advisory Panel 2016-present
3. Aviragen, Advisory Panel, new antiviral medication 2017
4. GlaxoSmithKline, pediatric asthma panel 2017-present
5. GlaxoSmithKline, Global Advisory Panel, immunomodulatory 2017-present
6. Regeneron/Sanofi Advisory Committee, immunomodulatory 2017-present

F. International

1. International Advisory Board of Asthma UK Centre for Applied Asthma Research, London UK, Keynote lecture: Multicentre trials: the key to success in 2014; 2014-present

2. Global Initiative for Asthma 2013-2017

3. GlaxoSmnithKline, Global Pediatric Asthma Panel 2017-present

1. **Licensure and Board Certification**

 New York State Pharmacy Board February l973

 National Board of Medical Examiners July l976

 American Board of Pediatrics September l979

 Colorado State Board of Medical Examiners August l982

 American Board of Allergy and Immunology October 1987

1. **Inventions, Intellectual Property and Patens Held or Pending**

PATENTS HELD OR PENDING: Interferon-gamma for the treatment of severe asthma;
 use of peripheral blood mononuclear cell glucocorticoid receptors in assessing asthma
 severity

1. **Review and Referee Work**

A. Deputy Editor - Journal of Allergy and Clinical Immunology 1997-2018

B. Editorial Board

 Biology of the Neonate/Developmental Pharmacology 1987-1996

 Journal of Asthma 1988-1998

 Journal of Allergy and Clinical Immunology 1988-1993

 Pediatric Pulmonology 1989-1998

 Pediatric Asthma, Allergy and Immunology 1990-1996

 Yearbook of Allergy, Asthma and Clinical Immunology 1992-1997

 Pharmacotherapy 1993-2004

 Scientific Editor 2001-2004

 Annals of Allergy, Asthma and Immunology 1995-2000

 Bronchial Asthma: Index & Reviews 1996-1998

 Clinical Asthma Reviews 1996-1998

 Current Opinion in Allergy and Immunology 2015-2018

C. Ad Hoc Reviewer - in addition to editorial board activities

 American Journal of Respiratory and Critical Care Medicine; Chest; Clinical Drug Investigation; Current Therapeutic Research; Drug Safety; European Respiratory Journal; Journal of the American Academy of Pharmaceutical Sciences; Journal of the American Medical Association; Journal of Pediatric Gastroenterology and Nutrition; Journal of Pediatrics; Metabolism; Lancet; New England Journal of Medicine; Pediatric Allergy and Immunology; Pediatrics

D. National Institutes of Health Reviewer:

 Pharmacology (1992); Heart, Lung and Blood Institutes (1993); Maternal and Child Health (1993); Pharmacology (1993); Asthma Management in Minority Children Practical Insights for Clinicians, Researchers, and Public Health Planners, NHLBI, NIH Publication No. 95-3675 (1995); Consultant reviewer, Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma, NHLBI, NIH publication No. 97-4051 (1997); NIH/NHLBI ad hoc special reviewer (1999); NIH/NHLBI reviewer for Severe Asthma Research Group proposals (2001); NIH/NHLBI Program Project Grant Reviewer (2006, 2007, 2008); NIH/NHLBI Loan Repayment Program Grants (2008 - 2016); NIH/NHLBI Study Section Clinical Trials (2008 – 2013; Chair 2012-2013); NIH National Institute of Arthritis and Musculoskelatal Diseases, Pediatric Reported Outcomes study section (2015)

E. Section Author - UpToDate in Pulmonary Disease and Critical Care, sections on "Mechanisms of Steroid Action" and "Use of Glucocorticoids in Asthma Therapy" 1998-2002

F. Academic Advisory Board Pfizer Visiting Professorship Program in Allergic Diseases and Asthma, 2002 – 2005.

G. Asthma United Kingdom Center for Applied Research, Advisory Board (2014-present)

H. Food and Drug Administration - Food and Drug Administration Anaesthesia and Analgesia Panel (2015)

1. **Invited Extramural Lectures, Presentations and Visiting Professorships**

Local

1. Colorado Biosymposium on Respiratory Disease, 2009, University of Colorado Denver School of Medicine, lecture on “Asthma Progression: A new target for Therapeutic Intervention.”
2. Colorado School-Based Health Care Symposium, (1) 2010 Annual Meeting, workshop moderator and speaker, “The Denver Public School Asthma program: Collaborations to Enhance Communication” and (2) 2011 Annual Meeting, workshop on "New Directions in Asthma Management: What SBHCs Need to Know"? Denver, CO
3. Children’s Hospital of Denver, Pulmonary Conference,

2011, “Cotton Club”, Copper Mountain, lecture on “NIH Asthma Network Studies: An Update on Recent Studies”

2014 “Cotton Club”, Keystone, lecture on “New Therapies for Asthma”

2015 “Cotton Club”, Keystone, “Updating the NAEPP Asthma Guidelines: What and When?”

2016 – “Cotton Conference, Granby, CO, “Implications of reduced lung growth on long term asthma outcomes”

2018 – “Cotton Conference, “New Directions in Managing Childhood Asthma”; Lecture - Career Development “Fellow to Faculty Transition”

Regional

None

National

1. **American Society for Pharmacology and Experimental Therapeutics**

 1978 - Isoproterenol excretion and metabolism in the isolated perfused rat kidney.

 1979 - Prednisolone and prednisone metabolism and excretion in the isolated perfused rat kidney.

2. **American Academy of Allergy, Asthma and Immunology**

 1979 - Effect of diphenhydramine on prednisolone elimination kinetics.

 1980 - Intrasubject variation in sustained-release theophylline absorption.

 1981 - Effect of erythromycin base on theophylline elimination.

 1982 - Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy.

 1983 - Effect of erythromycin base on methylprednisolone kinetics.

 1984 - Intraindividual variation in absorption from a sustained release theophylline formulation during continuous therapy in asthmatic children.

 1985 - Sustained release theophylline absorption in young children; Evaluation of whole blood theophylline test requiring no instrument.

 1986 - Prednisolone and methylprednisolone elimination in children receiving carbamazepine and phenobarbital therapy.

 1987 - Interferon- reverses corticosteroid inhibition of oxygen radical release from human monocytes; 24-hour theophylline concentration profiles during therapy with a slow-release theophylline: Experience with 122 asthmatic children.

 1988 - Penetration of systemic corticosteroids into the lung: A difference between prednisolone and methylprednisolone; Application of corticosteroid pharmacokinetics to severe steroid-requiring asthmatics; Overestimation of endogenous cortisol in asthmatics receiving steroids using a commercial immunoassay; Are theophylline "levels" a reliable indicator of compliance?

 1989 - Patterns of theophylline absorption in adolescents: Comparison of two slow-release formulations; Effect of low-dose troleandomycin on methylprednisolone elimination; Methylprednisolone persists in the lung longer than prednisolone following single-dose administration.

 1990 - Plenary Session "Corticosteroid Therapy in Asthma - How to and What to Expect."

 1991 - Asthma Course Director - Speaker "New approaches to the treatment of asthma."

 1992 - Asthma Course Director and speaker at two workshops.

 1993 - Asthma Course Director and speaker at two workshops and one symposium session.

 1994 - Speaker at grand seminar on aerosol delivery systems; Minisymposium on glucocorticoids - "Effect of glucocorticoids on growth in children with asthma."; Asthma Consultant's course on difficult to control asthma - "Management of the difficult to control asthmatic."

 1995 - Plenary Session - "The future of anti-inflammatory therapy for asthma"; Workshop moderator and speaker - Childhood asthma"

 1996 - Symposium speaker - "Managing Inflammation in Asthma"

 1997 - Symposium speaker - "Short & long term safety of inhaled corticosteroid therapy"

 ARRD Symposium - "Therapeutic modulation of childhood asthma"

 Asthma Consultants Course - "Theophylline: Is there still a role?" (Pediatric viewpoint)

 1998 - Astra symposium, moderator and speaker, "Clinical significance of nebulized preparation" and "Budesonide pharmacokinetics"

 Regional, State and Local Allergy Societies, "Are all inhaled steroids the same?"

 Workshop speaker - "Mechanisms of steroid resistant asthma and implications for medical management"

 1999 – Pharmaceutical Symposia: “When is it appropriate to use inhaled steroids in the management of asthma in infants and children?

Grand Seminar: “Identifying the “preferred” inhaled steroid for children”

Minisymposium, “Challenges in designing individualized treatment programs for asthma management.” Asthma Consultants Course, Pro position - “Package inserts for inhaled corticosteroids should contain warning labels”

2000 - Grand Seminar, Risks of Poorly Controlled Asthma and Optimal use of Inhaled Corticosteroids. Moderator and lecture entitled “Poorly controlled asthma and permanent lung damage: Are your patients at risk?”

2001- Breakfast seminar – Lessons from the Childhood Asthma Management Program (CAMP); Workshop speaker “When should controller therapy be initiated for infants with recurrent wheezing/asthma?’; NHLBI Symposium “Measuring inhaled corticosteroid efficacy”

2002- Didactic Workshop “Adverse Impacts of Asthma Therapies” lecture on “Adverse impacts of inhaled corticosteroids: Children”

Dinner symposium “Epidemiology of Pediatric Asthma” lecture entitled “How do you identify the child who needs to start on controller therapy?

2003- Postgraduate Symposium on “Therapeutic Advances for Allergies and Asthma”, lecture entitled “Asthma therapy: How to measure a clinical response”.

Seminar, “Treating Severe Asthma in Children”

Symposium “Asthma Control and Disease Progression: Rationale for Targeted Asthma Therapy”; lecture entitled “The natural history of asthma: Modifying the disease”

Seminar, “Methodological Considerations in the Design and Implementation of Randomized Controlled Clinical Trials”

2004 – Course on Immunomodulation: From Bench to Marketplace; lecture entitled “Appropriate Endpoints for Asthma Trials”; Workshop Moderator “Designing Clinical Trials in Childhood Asthma,”; Seminar Discussion Leader “Treating Severe Asthma in Children”; NAEPP Expert Panel Report: Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment- Update 2004, lecture entitled “Evidence-based review of asthma medicines during pregnancy”; Symposium, “How variable is asthma?” moderator and speaker, lecture entitled “The Variable Nature of Asthma: What Are the Dynamics Within a Patient?” NHLBI Clinical Research Programs Symposium, CARE Network presentation, “Characterizing response to leukotriene receptor antagonist and inhaled corticosteroid”

2005 – NHLBI Clinical Research Program, lecture entitled “Monitoring Asthma: Insights from trial in children asthma ages 6-17 years on monitoring measures: Asthma outcomes, pulmonary function and biomarkers”; Clinical Research Workshop 1204: NIH Trials; Optimizing Response symposium, Elliot F. Ellis Lectureship, "Variability in response to asthma medications: Selecting the best medication for the patient."

2006 – Miami, FL,Course Difficult cases, discussion of asthma; Symposium on Advances in Non-Invasive Monitoring of Asthma in Children and adults, lecture entitled “Advantages and Limitations of eNO for Evaluation of Asthma Severity Progression and Treatment”: moderator for Pro/Con debate “Introduction: Mild persistent asthma requires maintenance therapy”; Oral abstract Session Presentation on Inflammation, “Biomarkers as Guides for the Management of Childhood Asthma” American Academy of Pediatrics Section on Allergy-Immunology, lecture entitled “Future trends in the management of childhood asthma: Are you ready?”; NHLBI Asthma clinical research networks, session moderator: “NHLBI research Networks Findings on predictors of response to therapy: genotype and phenotype in children and adults.”

2007 - San Diego, CA;Workshop – Journal of Allergy and Clinical Immunology Year in Review lecture on “Update on Asthma”; Symposium Medical Crossfire “Issues in the Management of Persistent Asthma: Looking Forward at Inhaled Corticosteroid Therapy”; Symposium “New NAEPP Guidelines for the Management of Asthma: Expert Panel Report 3”; Lecture on – “Management in Children”; NHLBI Symposium NHLBI Clinical Research Programs: Measuring Asthma Impairment and Risk to Determine Response to Therapy: What Are the Best Measures? lecture entitled “Are Biomarkers Effective in Assessing Impairment and Risk? Evidence From ACRN, CARE and CAMP”; Pro-Con debate, moderator, “LABA are the First Choice Add-on Agent”

2008 – Philadelphia, PA; Workshop lecture New Asthma Guidelines, discuss “Pediatric Implications”; Allied Health Seminar, lecture on “Impairment and Risk: How Do We Evaluate?” Symposium NHLBI Clinical Research Programs in Asthma: New Findings from Childhood Asthma Management Program (CAMP), Childhood Asthma Research and Education Network (CARE), and Asthma Clinical Research Network (ACRN), lecture on “CAMP Continuation Study Outcomes: Maximal Lung Growth and Early Lung Function Decline in Children with Asthma”

2009 - Washington, DC;Workshop lecture “JACI Year in Review-Asthma”; ADT Interest Section Forum, Pro/Con "All Conflicts of Interest in the Relationship of Industry and Academia Should be Avoided" – Con position; media session – “Breaking down barriers to improve asthma control”, Workshop lecture on “What Makes a Good Journal – Views from the Editorial Office Journal of Allergy and Immunology (JACI) Speaker”

2010 – New Orleans, LA, NHLBI Asthma Networks' Impact on Clinical Practice and Research: A Reflection on the Contributions of the Asthma Clinical Research Network and Childhood Asthma Research and Education Network lecture on “Advances in Understanding and Predicting Variable Responses to Asthma Treatment in Children “; EORD Forum, lecture on, “The Impact of Air Pollution on the Emergence of Allergic and Non-Allergic Diseases”

2011 – San Francisco, CA; Symposium – NIH Outcomes Task Force Report, Seminar- Biomarkers for Diagnosing and Managing Asthma

2012 - Orlando, FL Course, Biomarkers in Airway Diseases, Exhaled NO: Easy, but how useful? Poster session, Reducing Health Disparities For Asthma With a School Based Asthma Education Program, Symposium NHLBI CARE network findings – “Measuring outcomes in CARE Network Trials: Lessons Learned” [presented in my absence – due to family illness]

2013 – San Antonio, TX; Primary Discussion Leader: Exhaled NO: Time to Clear the Air!; Workshop – Panel Discussion: Reviewing and Publishing Workshop: Getting Involved in the JACI and JACI: In Practice; Workshop – Panel Discussion: How to Get Your Manuscript Published (Clayton, Leung, Schatz, Hans-Uwe Simon); Session, Exhaled NO: Time to Clear the Air!

2014 – San Diego, CA; Course lecture “Using biomarkers and genetics to personalize therapeutics for allergies and asthma”; Workshop lecture “The use of exhaled nitric oxide in pediatric asthma.”

2015 - Houston, Texas, Plenary session speaker: Utilization of Present Therapies Based Upon Biomarkers, Phenotypes and Endotypes; Symposium speaker: “Advances in Pediatric Basic Science, Clinical and Translational Asthma Research in the Past Seven Years” and “School-Centered Asthma Programs: The Building Bridges Program”; Workshop speaker: Journal of Allergy and Clinical Immunology “Year In Review – Asthma”

2016 – Los Angeles, CA, NHLBI Course: Incorporating New Methodology in Asthma Clinical Trials, lecture on, “Cross-age studies: Important decisions”; Seminar, Barriers to Asthma Management in Schools, Discussion Leader; Symposium moderator and lecture, “Overview of LABA Safety and Efficacy”; Panel Discussion, Update on Asthma Treatment: Evidence-Based Recommendations for 2016.

2017 – Atlanta, GA Symposium: NHLBI’s Clinical Asthma Research Network (AsthmaNet)’s Approach to Key Asthma Questions in Children and Adults lecture on “Metabolomics Analysis to Predict Treatment Response in Early Asthma”; Seminar: “What’s on the Horizon: Upcoming Strategies for Managing Childhood Asthma”; Abstract Presentation: Baseline Blood Eosinophils and Reduction of Asthma Exacerbations By Omalizumab in Children with Moderate-to Severe Allergic Asthma; Workshop: Allied Health: How to Make a School-Based Partnership Work in Your Community; lecture on “The School-Based Asthma Program: Your Role in Making it Work”

2018 – Orlando, FL March 2-5, Poster,Greater Treatment Benefit with Omalizumab in Children with Increased Asthma Severity: Exploratory Analyses from the Inner-City Anti-IgE Therapy for Asthma (ICATA) Study’; Poster, Real-Life Patterns of Asthma Controller Use Vary by Age, Time of Day and Season; Poster, Real-Life Patterns of Short-Acting Beta-Agonist Use in Persistent Asthmatics Vary by Age, Time of Day, and Season; Poster, An Analysis of Type 2 Biomarkers in TENOR II, Poster, The Composite Asthma Severity Index: A Tool for Assessing Impact of Omalizumab Trateament in Children with Moderate-to-Severe Persistent Allergic Asthma; Breakfast session “Not just for research anymore: Utilizing biomarkers to implement personalized medicine in the clinic”

2019 – San Francisco, CA, February 22-25, Symposium on Asthma Care in the Era of Precision Medicine, lecture on “Personalized Medicine at the Patient and Population Levels” [20 minutes; **Poster** Digital assessment of asthma controller and rescue medication use as children transition into adulthood; Poster: Assessing the sensitivity and specificity of self-reported short-acting beta agonist (SABA) inhaler use with electronic medication monitors (EMMs); Symposium moderator, Schools and Tools: How We Can Advance the Management of Asthma, Food Allergies and Anaphylaxis.

3. **American Society for Clinical Pharmacology and Therapeutics**

 1980 - Gentamicin serum concentration in premature neonates.

 1981 - Troleandomycin inhibition of methylprednisolone elimination in pediatric and adult patients.

 1982 - Pharmacokinetics of prednisolone in pediatric patients with inflammatory bowel disease.

 1985 - Theophylline bioavailability from sustained release delivery systems: Is one dose enough?

4. **Society for Pediatric Research/Pediatric Academic Societies**

 1980 - A reevaluation of gentamicin dosage regimen in small prematures; Quinidine elimination in pediatric patients.

 1985 - Sustained release theophylline: absorption in young children.

 1991 - Developmental pharmacology symposium: Drug mechanisms and applications in the treatment of airway disease.

 1998 - Plenary session speaker: New concepts in the pharmacologic management of childhood asthma

 2006 - Pediatric Academic Societies’ 2006 Annual meeting, San Francisco, CA, symposium entitled “New insights into the pathogenesis and treatment of asthma”, lecture entitled “Advances in drug treatment of asthma,” moderate abstract poster symposium “Asthma: Improving Care and Outcomes”

 2014 – “Personalized medicine for childhood asthma,” Vancouver, BC, Canada.

2016 - Symposium “Improving quality of care in children with allergic diseases in schools”, speaker on “Enhancing asthma care through school-centered programs”, Baltimore, MD.

5. **American College of Allergy, Asthma and Immunology**

 1987 - Critical assessment of troleandomycin in severe steroid-requiring asthmatic children.

 1988 - Comparison of bronchodilator properties of albuterol, atropine methylnitrate and the combination in severe asthmatic children.

 1990 - Workshop on the clinical pharmacology of medications used in the treatment of asthma.

 1991 - Plenary session symposium "Issues in immunomodulator therapy

 Point/counterpoint "Does methotrexate have a role in the treatment of asthma?"

 Workshop on the management of severe asthma

 1992 - Plenary session speaker “Adverse effects of topical glucocorticoids” and workshop on management of severe asthma.

 1993 - Workshop presentations on management of severe asthma and dosing strategies in childhood asthma.

 1994 - Workshop presentation on management of severe asthma; Plenary session - point/counterpoint discussion on first-line therapy in asthma; Goodman lecture/Plenary session: Steroids and viral infections in asthma

 1995 - Symposium of the Role of the Allergist in Controlling Inflammation in Asthma, lecture on "Monitoring inflammation and controlling asthma exacerbations"

 1996 - Plenary symposium, lecture entitled "Implications of polypharmacy in asthmatic patients," workshop on "Management of chronic asthma," Plenary Symposium lecture entitled "Optimizing Inhaled Glucocorticoid Therapy: Product Selection and Dosing Strategy"

 1997 - Pharmaceutical Symposium: Inhaled Drug Delivery and Compliance: A Closer Look, lecture entitled "Overcoming obstacles to compliance: The impact of steroid phobia and how safety concerns affect compliance"; Pharmaceutical Symposium on Critical Concepts in Respiratory Disease Management, lecture entitled "When apparent asthma is non-reversible"; Meet the Professor - "Inhaled corticosteroids"; Plenary Session on Asthma: New Approaches and Novel Therapies In Asthma, lecture entitled "Early Pharmacotherapy: Can it Cure Asthma?"; Workshop on Severe Asthma.

 1998 – Pharmaceutical symposium: “Development of a nebulized glucocorticoid for young kids: Clinical needs and challenges;” Pharmaceutical Dinner Symposium, "Old challenges and new opportunities for pharmacotherapy of the pediatric patient"; Meet the Professor breakfast, discussion on “Inhaled corticosteroids for asthma”; Pharmaceutical Dinner Symposium, "Consequences of untreated asthma: An Evidence-Based Approach," sponsor - Glaxo Wellcome "Inhaled corticosteroid therapy - Aren't they all alike?"; Pharmaceutical Symposium, "Asthma Therapy: What's different? What's New? and the Importance of Getting It to Where You Want" Moderator

1999 - Plenary session "Identifying the risk for persistent asthma in infants and young children."

2001 - Meet the Professor breakfast seminar, “New pharmacologic asthma therapies”;

moderator, symposium, New Destinations for Asthma Therapy, lecture on “Growth in understanding pediatric asthma” symposium, lecture on “Advances in Combination Therapy: Application to Pediatric Asthma.”

2002 - Symposium “Managing Asthma as a Variable Disease” lecture entitled “Optimizing asthma therapy to manage a variable disease.”; Symposium entitled “New Insights into Inhaled Corticosteroids” lecture on “ICS: Pharmacokinetics/Mechanisms of Action,”; World Allergy Organization Symposium entitled “Vancouver 2003 @ ACAAI: The Molecular basis of Allergic Inflammation”, lecture entitled “Inflammation, bronchial hyperreactivity and remodeling”.

2003 - Symposium on “Confident Selection of Controller Therapy for Asthma and Allergic Rhinitis”, lecture entitled“Use of Combination Therapy in Asthma”; Symposium on “Happy Sneezers to Chronic Wheezers: A Closer Look at Pediatric Asthma and Atopy”, lecture entitled “Implications for Therapeutic Selections”

2007 - Symposium, “Is ‘One Size Fits All’ The Ideal for Asthma therapy?”, lecture on “Are Inhaled Steroids the Best Drug for All Mild Persistent asthmatics?”; Meet the Professors Breakfast, A Review of the New Asthma Guidelines; Plenary session – What determines response to therapy in moderate to severe asthma? lecture on “What determines response to asthma therapy?”

2013 - Symposium entitled “COPD and Asthma: Exploring Immunopathophysiological Mechanisms”, lecture on “Severe asthma: Identifying mechanisms to inform therapy”; Meet the Professor session “Severe Asthma”

2014 – Atlanta, GA, Symposium: Root Cause of Allergy and Asthma, “acetaminophen”; Meet the Professor, “Tailoring Asthma Management – Step 2 to Step 4”

2017 – Boston, MA, Symposium Lecture, “Controller therapy: How to Choose the Correct Medication”; Meet the Professor session “Phenotype-based Approach for the Management of Preschool Episodic Wheezing and Asthma”

2018 – Seattle, WA, Presidential symposium, oral presentation, “Lessons learned from the pediatric studies in the NIH Asthma Networks”

6. **American College of Chest Physicians**

 1991 - Asthma Update Symposium "Treatment of acute asthma in children"

 Reactive Airway Diseases: 1991 Update "High dose inhaled steroids: Is it really a strong and safe therapeutic modality?"

 1992 - Postgraduate course: Asthma as an inflammatory disease, "Is there evidence for an anti-inflammatory effect with theophylline or beta-agonists?"

 1994 - Postgraduate course on childhood and adult asthma health care policies, lecture on "Pharmacology of asthma therapy."

 1997 - Panel discussion on New Choices in Pharmacologic Management of Asthma, lecture entitled "Difficult to control asthma: Rationale for new therapies,"

7. **American Academy of Pediatrics**

 1992 - Asthma Dialogue Session and Symposium on the Treatment of Asthma.

 1993 - Symposium for practitioners, Current Status of Asthma Therapy in Pediatrics, lecture on "Inhaled steroid controversies".

 1994 - Plenary session - "Management of the difficult to control asthmatic" (Spring meeting)

 Dialogue session - "Office management of asthma" (Fall meeting)

 1997 - Plenary Session - “Leukotriene antagonists in childhood asthma”

 1999 - Section of Allergy and Immunology symposium, "New and old available choices for inhaled steroids."

2002 – Section on Allergy and Immunology Symposium, “Cutting edge treatment for allergic disorders” and Symposium lecture on “Identifying the patient in need of intervention”

2003 – Symposium – “Pediatric Asthma: Impacting Health Care Delivery and Outcomes”, lecture entitled “Managing the Young Chronic Asthmatic and the Importance of Device, Delivery, and Drug Safety”

2004 – Dinner symposium program “Challenges of Wheezing and Asthma in children”, moderator and speaker – lecture on “Managing a Child asthmatic Like a Specialist”; Seminar, “Asthma therapy: New and Coming”; Plenary Session, “Asthma 2004: What Do the Studies Show Us?

2005 –

Symposium entitled: “Deciphering the Clues: Detailing the Environmental. Comorbid, and Lifestyle Factors that Influence the Course of Pediatric Asthma”. Lecture entitled “Breathing easier: New information on airway remodeling and the natural history of asthma”; Seminar, “Safe and Effective use of Inhaled Corticosteroids”

2010 - Selected Short Subjects “Asthma Disease Progression in Children: Can it be prevented?” and “Use of long acting bronchodilators in children: Safe or unsafe”

2017 - Pediatric Pulmonary Conference, Orlando, FL, Lectures on **“**Appropriate Use of Biologic Response Modifiers for Childhood Asthma; “Things to Consider in Selecting an Inhaled Corticosteroid; “Macrolide Antibiotics for Pediatric Respiratory Disease”

2017 - Section/Council Program, Section on Allergy and Immunology, “The safety of long-acting beta-agonists in Pediatrics: An Update”, Chicago, IL

2018 - Nov 6, Focused Topic, “New therapies in asthma treatment: What are biologics? Orlando, FL

8. **American Thoracic Society**

 1996 - Abstract session/Featured lecture - "Emerging issues in the management of childhood asthma" Evening symposia - "Comparative analysis of available inhaled glucocorticoids" Childhood Asthma Management Program NHLBI Symposia, "Baseline characteristics of the study population"

 1997 - Post-Graduate Course, "Managing difficult to control and steroid resistant asthma in children"; Annual Allergy Fellows Symposium, "Inhaled Corticosteroid Therapy"; Post-Graduate Course, Moscone Center, "Inhaled cortico-steroids: How to Tell When Enough is Enough"; Childhood Asthma Management Program NHLBI Symposia, "Environmental exposure and pulmonary function"; Postgraduate Seminar - "Improved targeting of inhaled steroids to the airways - Clinical implications in the treatment of asthma" - lecture entitled "The importance of the inhaled dose"

 1998- Allergy Fellows Symposium, Sutton Place Hotel, lecture entitled "Use of corticosteroids in early intervention"; Postgraduate Seminar entitled: Therapeutic Horizons in Asthma Management, lecture entitled "Therapeutic Targets in the Inflammatory Process"

 1999 - postgraduate course - Asthma Update: Airway inflammation and therapy issues, lecture entitled “Pros and cons of fixed combinations” in a section entitled Combination Therapy for Asthma, Panel discussion San Diego Convention Center

 2000 – Pharmaceutical Symposium - The Role of Additive Therapy in Adult and Pediatric Asthma – lecture entitled “Inhaled steroids: What is the optimal dose?”; Poster Discussion Co-Moderator, “Systemic Effects of Corticosteroids.”

2001 -NHLBI Childhood Asthma Management Program symposium, presentation on “Impact of Asthma Therapy on Lung Growth and Development”; Symposium, “Rationale for early intervention in childhood asthma”; NHLBI Asthma Clinical Research Network Symposium, “Measuring Inhaled Corticosteroid Efficacy”

 2002 - Meet the Professor Seminar**,** “Inhaled steroids and Growth”,American Thoracic Society /European Respiratory Society Symposium on “Approach to Tackling Severe Refractory Asthma,” lecture entitled “Severe Refractory Asthma in Children: Comparison to Adults”

 2003 - Symposium “Asthma Clinical Trials versus Real World Effectiveness: Comparing Apples to Oranges”, lecture entitled “Considering Therapeutic Choices in the Real World”; Symposium, “Mild Asthma: Should there be a concern? Lecture entitled “Mild asthma and the updated guidelines: The specialist’s role in educating the health care community”

2004 - Division of Lung Diseases, NHLBI Symposium CARE Network– lecture entitled “Factors determining response to ICS and LTRA in children with mild to moderate asthma: CLIC results”; Symposium entitled “Once-daily inhaled corticosteroids in the treatment of asthma: Weighing the risk-benefit relationship” lecture on “ The evidence for once-daily dosing of inhaled corticosteroids: A critical review of the literature”; Symposium on Bronchiolitis in Children: New Solutions, lecture entitled, "Impact of RSV disease on children"

2005 - symposium entitled “Moving Towards a New Age in Asthma Management”, lecture on "Enhancing ICS Therapy for Improved Patient Outcomes in Asthma."

2006 - NHLBI Symposium – Genotype and Phenotypic Predictors of Response to Asthma therapy: What do NIH Clinical Research Studies tell Us? Lecture on “Response in adults vs. children in ACRN and CARE studies”

2007 - Pulmonary and Allergy Fellows Program, lecture on “Asthma management and the New Guidelines”; Advances in Pharmacogenetics Postgraduate course, lecture on “Novel phenotypes for pharmacogenetics: Novel ways of detecting responders and non-responders”; Symposium, Pediatric Year in Review, lecture on –“Advances in Pediatric Asthma”; Pediatric Asthma Symposium, lecture on “Should we treat infantile asthma?”; National Institutes of Allergy and Infectious Diseases Symposium, Inner City Asthma Consortium, lecture entitled “Results of a randomized, double-blind, controlled trial of a biomarker (eNO) for guiding the treatment of childhood asthma.”

2008 - NHLBI Symposium"Childhood Asthma Management Program (CAMP) Continuation Study Outcomes:  Maximal Lung Growth and Early Lung Function Decline in Children with Asthma." Symposium lecture on “ Heterogeneity of asthma in children”; Symposium on Personalized Medicine: The Future of Asthma Care”, lecture on “Incorporating FeNo and other biomarkers into asthma management.”

2010 - New Orleans, Postgraduate Course,Bench to Bedside: The Art and Science of Translational Research, co-moderator and lecture on “Introductions, Educational Objectives, and Worldwide Environmental Factors Affecting Discovery and Development”**;** Thematic Poster session facilitator, Airway Function & Aerosols in Children, Adults and Mice.

2011 – Denver, CO; Postgraduate Course, Asthma and Allergic Diseases: State of the Art in Biology and Therapeutic Targets Course,lecture on“Defining Therapeutic Targets for Asthma”; NHLBI Symposium, lecture on “Lung development patterns in the NHLBI Childhood Asthma Management Program.”

2012 – San Francisco, CA Co-Moderator and speaker, Symposium “Variability of treatment response”, lecture “Differential response to asthma therapy in children”

2013 - Philadelphia, PA Symposium entitled “Beyond the EPR3/GINA guidelines: Incorporating the results of recent asthma trials into clinical care”; “Pediatric Asthma: What areas could be updated in the guidelines?” and “Anti-IgE: Where can it be useful in pediatric asthma?” Thematic Poster Session, " Asthma Mediators and Biomarkers", Lead Facilitator; Co-Chair mini-symposium *“ Early Life Risk Factors for Development of Asthma  ” moderator*; Poster Presentation Incidence Of Malignancy In Omalizumab And Non-Omalizumab Treated Patients With Moderate-To-Severe Asthma: The EXCELS Study”; NIAID ICAC Symposium “Inner City and Asthma: An Insight to the Disease”, lecture on “Does asthma treatment in the inner city need to be different?”

2015 – Denver, Colorado,Validation of Predictors for Fall Asthma Exacerbations in Inner City Children B27-VIRAL INFECTION AND PEDIATRIC ASTHMA  Poster Discussion Session; Reducing School Absenteeism Among Inner-City Children: Preliminary Results from the 2013-14 Building Bridges: Advancing Education by Improving Asthma Management in Inner-City Children Program B107-ASTHMA MANAGEMENT AND HEALTH EDUCATION Poster Discussion Session; Symposium entitled “ IMPLEMENTING COLLABORATIVE PROGRAMS TO SUPPORT STUDENTS WITH ASTHMA IN THE SCHOOL SETTING“, lecture entitled “ Lessons learned from a school-centered asthma program: Opportunities for dissemination and sustainability“

2016 - Joint ATS/ERS/JRS Symposium On Severe Asthma: A Global Perspective Session Type: lecture entitled  “9:22-Severe Asthma In The Pediatric Population

2017 – Washington, DC; Abstracts: A Feasibility Study of Daily Monitoring of Controller and Rescue Medication Use in a Pediatric Patient Population at High Risk of an Asthma Exacerbation; Reduction of Exacerbations by Baseline Indicators of Asthma Severity in Children Receiving Omalizumab;The Clinical Characteristics of Recent Asthma Exacerbators in the TENOR II Cohort; Lung Function Decline in the TENOR II Cohort; Racial Disparities in Asthma-Related Health Outcomes in Children with Severe or Difficult-to-Treat Asthma; Asthma Exacerbations and Lung Function Decline in a Pooled Analysis of Adolescents and Adults From Randomized Controlled Trials of Omalizumab; Building Bridges for Asthma Care: Reducing School Absence for Children with Health Disparities; Viva/PensieTinA-asthma® pooled lung function by allergic modelling; Safety of tiotropium in African American patients with asthma

2018 – San Diego, CA; Poster Greater Treatment Benefit with Omalizumab in Children with Increased Asthma Severity: Exploratory Analyses from the Preventative Omalizumab or Step-up Therapy for Fall Exacerbations (PROSE) Study RAPiD: Rapid Abstract Poster Discussion Session; Forced Expiratory Flow (FEF25-75%) as an Alternative Lung Function; Poster Measurement in Pediatric Patients; Thematic Poster Session; Natural History of TENOR I Patients More Than a Decade Later in TENOR II Based on GOLD Classification of Severity of Airflow Obstruction” thematic poster session; Assessment of Airway Inflammation Using Exhaled Nitric Oxide in Pediatric Asthma and Its Impact on Treatment Decisions Thematic Poster Session; Personal Exposure to Multiple Air Pollutants and Asthma Severity in an Urban Pediatric Asthma Panel RAPiD: Rapid Abstract Poster Discussion Session; Using Digital Technology to Identify Adherence Phenotypes May Identify Appropriate Time for Intervention, Poster discussion; Association between Objective Short-Acting Beta-Ag;onist Use and Self-Reported Asthma Control Test Scores among Adults with Asthma, Poster discussion

2019 – Dallas, TX – Moderator: Symposium Difficult to Treat Asthma, Posters presentations: Digitally Recorded Controller And Rescue Medication Use Vary By Age In Patients With Asthma**;** Real-life Patterns of Short-acting Beta-agonist Use In Patients With COPD Vary By Time Of Day And Season**;** Evaluating Adherence Data In The Clinical Setting: What Tools Should We Use To Describe Behavior?Breathing Counts: Addressing Barriers To Medication Use In High Risk Children With Asthma

1. National Academy of Sciences, 1999, Workshop on Rational Therapeutics for Infants and Children, presentation on “New directions in childhood asthma”.
2. Asthma ‘99: Theory to treatment” Conference, Honolulu, Hawaii, lecture on “Airway remodeling in the pediatric patient” and “Pharmacokinetic variables influencing clinical response to corticosteroids”.
3. NIAID/NIEHS Conference, June 17-19, 2001, Washington, DC, State of the Art Asthma Conference, *Current Strategies in Asthma Management from the Infant to Elderly*, sponsored by National Institute of Allergy and Infectious diseases (NIAID) and the National Institute of Environmental Health Sciences (NIEHS), lecture entitled “An Assessment of Efficacy of Current Treatment Modalities.”
4. World Asthma Meeting, Chicago, Ill – July 13-15, 2001 - Corticosteroids Breakout Session, “Long term inhaled corticosteroid therapy: Observations from the NHLBI Childhood Asthma Management Program (CAMP)”; NHLBI/NIAID Pediatric Asthma Program, summary of NHLBI CAMP study; Dinner Symposium, moderator; Emerging trends affecting the treatment of asthma.
5. Masters in Pediatric Pulmonology conference, University of Miami, Jan 20-21, 2002 – workshop “Childhood Asthma: Opportunities to make a difference” lecture on “Optimizing the use of inhaled corticosteroids for childhood asthma”.
6. NHLBI National Asthma Education and Prevention Program 2003 National Asthma Conference, Washington**,** D.C.,Jun 19, 2003 Symposium on "Therapeutic Issues: Assessing Risk and Avoiding Side Effects", lecture entitled “Potential side effects for children”; Working session: Therapeutic Issues: Making Difficult Decisions, moderated session and lecture entitled “Stepping treatment up and down”.
7. Lovelace Respiratory Research Institute (LRRI) Symposium, Santa Fe, NM, 2003, lecture entitled "Impact of early intervention on the natural history of asthma".
8. AAAAI Distinguished Lecture Series, November 2003, Pri-Med East Symposia, Boston, MA, lecture entitled “Revised asthma treatment guidelines: An update from the National Asthma Education and Prevention Program.”
9. Food and Drug Administration, Rockville, MD, Office of Generic Drugs, “Use of Exhaled Nitric Oxide for Measurements of Bioquivalence and Dose Response Relationship of Inhaled Corticosteroids, April 20, 2006.
10. Children’s Hospital of San Diego CME conference on Current Concepts in Pediatric Allergy and Otolaryngology: San Diego 2006, lecture entitled, “Individualization of asthma therapy: Who needs what and why?”; Case Presentations, Drug Controversies “Ask the Expert Faculty Panel”; Workshops, “The best objective measures in asthma: PFTs or do we NO?”; lecture on “Asthma Guidelines: Who is a mild asthmatic and how should they be managed?” “Case presentations: Controversies in the Guidelines “Ask the Expert Panel”.
11. NIH, NICHD Best Pharmaceuticals for Children Act Symposium,2006,Washington, DC lecture entitled “Information gaps in the treatment of asthma in pediatric outpatients”.
12. Rush Medical Center University, 2006, Chicago, lectures entitled " Current treatment options and future directions for the management of  pediatric asthma," "Early intervention in childhood asthma," and, "The use of long acting bronchodilators in the treatment of asthma."
13. Western Society of Asthma, Allergy and Immunology 2007 Maui, Hawaii, lecture on, “Early interventions in asthma: at what age and / or what level of intensity should ICS be started?” and “Monitoring the natural history of pediatric asthma.”
14. Los Angeles Asthma and Allergy Foundation Annual Meeting, Los Angeles, CA,CME conference, Keynote speaker, lecture on “Update on the New Asthma Guidelines.”
15. Oregon Allergy Society Meeting 2007, Portland, OR, lecture on “ The New NAEPP Guidelines” and “Refractory Asthma: Treatment Options”.
16. American College of Clinical Pharmacy 2007 Annual Meeting, Denver, CO, Symposium: Incorporating Surrogate Markers into Research Investigations, lectureentitled, "Surrogate Markers and Surrogate Endpoints in Clinical Research."
17. California Society for Allergy, Asthma and Immunology, 2008, Huntington Beach, CA, lectures on “Severe asthma in children” and “Application of biomarkers in the management of asthma” .
18. Colorado Asian Health Education and Promotion Multicultural Symposium on “Healthy Living for Our Families”, presentation entitled “The Denver Public School Asthma Program: Accomplishments and Future Plans”.
19. Nemacolin Conference on Childhood Asthma, 2008, Pittsburgh, PA, lecture on “Individualizing asthma therapy: Application of biomarkers”.
20. Los Angeles Society for Pediatrics Conference, 2008, Anaheim, CA, lecture on “Advances in childhood asthma” Use of inhaled corticosteroids for managing childhood asthma” and “Management of severe childhood asthma”.
21. Johns Hopkins Department of Pediatrics Grand Rounds, 2009, Baltimore, MD;lecture entitled ”Individualizing asthma therapy: Directing new insights to improve asthma control”.
22. Western Society for Allergy, Asthma and Immunology 2010, Lanai, Hawaii,lectures on“Early intervention and its effect on the course of allergic disease”and“Evaluation and treatment of the wheezing infant”.
23. National Institutes of Health, NHLBI/NIAID Asthma Outcomes Task Force Workshop 2010 – presentation on Biomarkers Committee Report.
24. Colorado Section of the American Academy of Pediatrics Chapter, “Pediatric Asthma 2011: Recent Advances”.
25. Allergy, Asthma and Immunology Foundation of Northern California, invited by Dr. Michael Martin, lecture on “Controversial issues in the management of childhood asthma: Working toward resolution”, San Francisco, CA.
26. William Pearson Lectureship, Seattle, 2011, Washington State Allergy, Asthma and Immunology Society: Personalizing asthma therapy to achieve asthma control; Grand Rounds, Seattle Children’s Hospital, Grand Rounds: "Managing Asthma with Onset in Young Children".
27. Florida Allergy Asthma Annual Meeting, Amelia Island, FL2011 **-** lecture on “Systemic effects of inhaled corticosteroids”.
28. NICHD Workshop on Diagnostics and Therapeutics, 2011, Washington, DC, plenary presentation on “Improving methods to diagnose and manage childhood disease” and breakout session co-moderator, Break-out session summary
29. National Asthma Education and Prevention Program meeting, 2011, Updating the asthma guidelines”.
30. NIEHS/EPA Sponsored Children’s Environmental Health Centers Meeting, Bethesda MDlecture on “Personalizing asthma therapy: Assessing the environment”.
31. Allergy, Asthma, Immunology Society of Georgia, Lake Lanier, GA, 2012 lecture entitled "NHLBI CAMP study: The natural history of childhood asthma".
32. Webinar Patient Centered Outcomes Research Institute meeting and Webinar, 2013, Advisory Panel on “Severe Asthma in African American and Hispanic/Latinos”, presentation on “Asthma Research: Treatment of Children,” Washington, DC.
33. Nationwide Children’s Hospital, 2015, lecture, "Personalized medicine for asthma: The train has left the station!", Columbus, Ohio
34. Asthma Research Summit California Department of Public Health, Los Angeles, CA 2015 lecture on “Heterogeneity of asthma phenotypes and endotypes” and “Developing a ‘Circle of Support’ in the Community for Children with Severe Asthma”
35. American Academy of Allergy, Asthma and Immunology, School Centered Asthma Summit meeting 2015, “Building Bridges: A Model school-centered asthma program”, Washington, DC
36. Pharmacotherapy of asthma, NICHD 2016 Webinar
37. Patient Centered Outcomes Research meeting 2016, Houston, TX, panel discussion for Journal Editors.
38. Pediatric Pharmacy Advocacy Group, Atlanta, GA, 2016, speaker, “Steroid Pharmacology – Following the Yellow Brick Road”, Atlanta
39. California Allergy, speaker, Asthma and Immunology Society mtg,2016, San Francisco, CA, lectures on **“**Community engagement: lessons from a school-centered asthma program”andPersonalized Medicine for Asthma Management
40. American Academy of Allergy, Asthma and Immunology Asthma Course: The Life Spectrum of Asthma, Chicago; moderator for Case Discussion Workshop
41. American Academy of Pediatrics, Pediatric Pulmonary Conference, Orlando, FL, Lectures on “Appropriate Use of Biologic Response Modifiers for Childhood Asthma; “Things to Consider in Selecting an Inhaled Corticosteroid; “Macrolide Antibiotics for Pediatric Respiratory Disease”
42. NICHD Webinar, 2017, “Study Design, Biomarkers and Endpoints in Asthma Medication Evaluation”
43. Los Angeles Society of Allergy, 2017, Asthma and Clinical Immunology Meeting, lecture on “Updates in childhood asthma management”
44. Nemacolin Annual International Asthma Conference, 2017, Pittsburgh, PA. Personalized Medicine for Asthma Mini-Symposium, lecture on “Will personalized medicine approaches be useful in mild/moderate asthma?”
45. NICHD lecture series 2018, lecture on “Pharmacotherapy of Asthma”
46. Global MindED conference, Denver, CO, 2018, panel discussion on “Chronic disease management: From sick care to health care”
47. Eastern Allergy Conference, Palm Beach, FL, 2019 “Biomarkers in Severe Asthma”; June 2 “Controversies in asthma management: ICS dose escalation to prevent exacerbations and oral corticosteroids for wheezing infants”
48. University of California Irvice, Orange County, CA, 2019, Grand Rounds entitled “Improving Asthma Management by Focusing on the Risk Domain”

**International**

1. **World Conference on Clinical Pharmacology and Therapeutics** 1980 - Quinidine elimination in pediatric patients.

2. **European Respiratory Society**

1. Fisons symposium on Nedocromil in Childhood Asthma, lecture on "Safety and
 efficacy of long term therapy in childhood asthma"
2. Allergy and Immunology Section Symposium on "New Actions of
 Glucocorticoids", lecture on "Steroid resistant asthma"

3.  **Allergy and Immunology Society of Mexico Annual Meeting**

 1994 - Inhaled steroids: Helpful of Harmful?

 Management of the difficult to control asthmatic

 Roundtable on controversies in immunotherapy

 2003 - National Congress of Pediatric Allergy and Clinical Immunology, lectures on “Pharmacogenetics: Applications for childhood asthma” and “Early intervention in childhood asthma”

4. **European Respiratory Society**

 1994 - Fisons symposium on Nedocromil in Childhood Asthma, lecture on "Safety and efficacy of long term therapy in childhood asthma"

1. - Allergy and Immunology Section Symposium on "New Actions of Glucocorticoids", lecture on "Steroid resistant asthma"

2014 - Symposium: Delivering care in Chronic Airway Diseases for Every Patient: Opportunities, Obstacles and Challenges - “If you had to choose only one controller medicine for your asthma patient, what would it be?”

2016 - Symposium Deep phenotyping to improve treatment outcomes in pediatric asthma, speaker,lecture on“Application of biomarkers and patient characteristics to personalize asthma treatment for children

2018 - Paris, France, Presentations: Pediatric Year in Review, lecture, “Year in Review, What’s New in Pediatric Asthma?” Evening Symposium Early management of asthma to prevent adverse outcomes – different management strategies depending on age group

5. **Allergy and Immunology Society of Mexico Annual Meeting**

 1994 - Inhaled steroids: Helpful of Harmful?

 Management of the difficult to control asthmatic

 Roundtable on controversies in immunotherapy

2003 - National Congress of Pediatric Allergy and Clinical Immunology, lectures on “Pharmacogenetics: Applications for childhood asthma” and “Early intervention in childhood asthma”

6. **World Asthma Conference,** Barcelona, Spain, 1998 Interactive session: Controversies: Inhaled steroids: How much, how soon, how long? presentation entitled: “long-term high-dose is dangerous-Con position**”**

 Major Symposia on Lifetime Therapy, "Difficult to treat asthma”

1. XVI World Congress on Asthma Buenos Aires, Argentina, 1999 -lectures entitled: 1.) "Safety and efficacy of new HFA-BDP delivery system." 2.) "Leukotriene assessment and modifier therapy in childhood asthma" 3.) "Severe persistent and steroid resistant asthma" and 4.) "Management of severe asthma in children"
2. Japanese Respiratory Society, Hiroshima, Japan,2001symposium on “Safety of inhaled corticosteroids” lecture title “Optimizing the benefits of inhaled steroids for the treatment of childhood asthma.”
3. British Society for Allergy and Clinical Immunology, Harrogate, North Yorkshire, Dec 3, 2002, Symposium on "Mechanisms of glucocorticoid action and resistance", lecture entitled "Strategies for management of glucocorticoid resistance in asthma".
4. World Allergy Organization Congress,

Vancouver, BC, Canada, Sep 8-9, 2003, Seminar, “Inhaled Corticosteroids” Symposium entitled “Pediatric Asthma – Issues and Answers” (sponsored by ACAAI), lecture entitled “Airway remodeling – Does it Occur in Children?”

Bangkok, Thailand, Dec 2007, Symposium – Pediatric Asthma – lecture entitled “What do PEAK, PACT, CAMP, etc tell us?”; Symposium – Asthma treatment – lecture entitled “Comparison of inhaled Corticosteroids – Is there a “best” steroid?”

Buenos Aires, Argentina, Dec 6-11, 2009, Co-Moderator and Speaker for Pediatric Asthma Symposium, lectures on “Inhaled corticosteroids in children: benefits and limitations” and “use of biomarkers to personalize asthma therapy”.

Cancun, Mexico, 2011, Seminar, Treatment of the Asthmatic Patient Under 5: NIH asthma network studies; NIAID and NHLBI: Standardizing Outcomes in Asthma Clinical Research, lecture on “Biomarkers as Outcome Measures in Asthma Clinical Research”; moderator, abstract presentations – “Inhaled corticosteroids for asthma”; Symposium on Asthma in Children: Treatment, lecture on “Step Care”

Rio de Janiero, Brazil 2014Chair session on Pediatric Allergy: Upper and Lower Airway;Update in Pediatric Asthma, lecture on “Are intermittent inhaled steroids an effective option to treat asthma in children?”**;** Chair Poster session on Asthma Diagnosis and Treatment

1. World Asthma Meeting, Bangkok, Thailand,February 2004, Plenary session on “Different Asthma Phenotypes”– speaker lecture on “Childhood Asthma, “ moderator, Concurrent Session on “Childhood Asthma,”
2. Asthma Begins in Children Meeting, Vienna, Austria, April 2005, lecture entitled “Mild Asthma – The Next Frontier”
3. Firestone Respiratory Institute Meeting, Hamilton, Ontario,October 2005, Deciding Therapy Session, lecture entitled “Individualizing Asthma Therapy”
4. Japanese Society of Pediatric Allergology and Clinical Immunology Annual Meeting Fukui, Japan, November 2005, lecture entitled, Frontier of the treatment for infant asthma in the U.S.
5. Hong Kong Pediatric Respirology Society, Hong Kong, China, October 2006, lecture on "Application of Biomarkers for the Management of Pediatric Asthma" and lecture on "Current and Future Management of Pediatric Asthma"
6. Prince of Wales Hospital, Hong Kong, China, October 2006, Chinese University of Hong Kong, lecture on “Early intervention in childhood asthma”
7. Japanese Society of Allergy, 2006, Tokyo, Japan, lecture entitled, “Early intervention in childhood asthma”
8. Exacerbations in Asthma and COPD Conference 2007,San Juan, Puerto Rico,lecture on “Issues in clinical trial strategies in asthma exacerbations”
9. World Allergy Congress, Co-moderator and speaker at Pediatric Asthma Symposium, lectures on “Inhaled corticosteroids in children: benefits and limitations” and “use of biomarkers to personalize asthma therapy”, Buenos Aires, Argentina
10. World Congress of Asthma mtg, Quebec. Break-Out Session, Pediatric Asthma, lecture on “Current and future management of asthma in children”; Break-Out session – Pharmacologic treatment of Asthma, lecture on, “Monoclonal Antibodies”; Break-out Session, Severe Asthma in Children, lecture on “Asthma exacerbations in children”; AAAAI Spectrum of Asthma Symposium, lecture on, “Treatment: What Have We Learned from the Networks?
11. World Allergy International Scientific Conference 2014, Rio de Janiero, BrazilChair session on Pediatric Allergy: Upper and Lower Airway;Update in Pediatric Asthma, lecture on “Are intermittent inhaled steroids an effective option to treat asthma in children?”**;** Chair Poster session on Asthma Diagnosis and Treatment.
12. King’s College John Price Pediatric Respiratory Conference, 2017, London, UKlectures; Key note lecture “A Step-Care Approach to Personalized Medicine for Asthma: Lifespan considerations”, “Closing the Gaps of Communication in Asthma Care for Children”, “Antibiotics for early infant wheezing disorders Pro-Con debate”
13. Chilean Respiratory Society meeting, 2017 **Puerto Varas, Chile** "Managing emerging asthma in young children” “A Step-Care Approach to Personalized Medicine for Asthma: Lifespan Considerations” “Facilitating communication among health care providers to manage severe asthma” “Asthma Care in the Next 10 years: Where Do We Go From Here?
14. International Congress on Pediatric Pulmonology, **Toledo, Spain,** symposium “Choosing the right controller therapy in paediatric patients with asthma”, moderator and speaker, Important steps in choosing a controller medication; poster presentations: Efficacy of tiotropium add-on therapy in children and adolescents who experienced episodes of asthma worsening during four Phase III studies; FEV1 improvements with tiotropium & long-acting beta2-agonists added to inhaled corticosteroid therapy are similar in paediatric patients with asthma; Effect of tiotropium Respimat® on seasonal asthma worsening in paediatric patient; Plenary session, lecture entitled “Steroid refractory inflammatory phenotypes in wheeze and asthma”**;** Workshop on global aspects of pediatric asthma, moderator and **l**ecture entitled “Asthma training and education in the USA”
15. Sophia Children’s Hospital, **Rotterdam, Netherlands** – visiting professor: lectures entitled - “Enhancing community engagement through a school-centered asthma program”; Pediatric Grand Rounds, “Improving Asthma Management by Reducing Risk”
16. Pulmonary Conference 2018, **Taormino, Italy**, session on New Challenges in Pediatric Pulmonology, lecture entitled “Therapeutic challenges in pediatric asthma”.
17. Asthma UK meeting 2019, **London,** Plenary session lecture on “Technology, asthma and the future”
18. King’s College John Price Pediatric Respiratory Conference 2019, **London, UK,**  lectures on **“**Personalized Medicine**”; “**Asthma Across the Lifespan: Focusing on the Risk Domain**”; “**Applying Technology to Asthma Care.”
19. **Teaching Record**

Medical Students

Annual lectures (two to three per year) since 1982 in the Treatment of Asthma for the Department of Pharmacology University of Colorado Health Sciences Center School of Medicine Course Number 6000

Graduate Students

Lectures in the graduate medical School Department of Pharmacology Course Number 7620 from 1992 – 2002 (two to three lectures per year) on immunology, immunomodulators and biologic response modifiers.

House Officers

None

Key Administrative Position

Course Director: Director of Fellowship Training, Department of Pediatrics, Allergy and Immunology Program, University of Colorado Health Sciences Center and National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado (1989-1995); 2003 - initiated lecture series in the principles of clinical research for Department of Pediatrics Allergy and immunology fellows.

Training Program Director, University of Colorado Allergy and Immunology Program – Pediatrics (2011-2013); also Chair of Training Program Education Committee (2011-2013) and member of the Clinical Competency Committee (2013)

Postdoctoral Fellows

Primarily clinical research training for fellows in our Department of Pediatrics Allergy and Immunology Training Program: Robert Rogers, M.D. (1983), James Haltom, M.D. (1984), Maryanne Bartoszek (Scott), M.D. (1986), Bruce D. Ball, M.D. (1988-89), Pakit Vichyanond, M.D. (1989), Richard Ando, M.D. (1990), Leon Greos, M.D. (1991), Amanda Dove, M.D. (1992), Jaime Alvarez, M.D. (1992), Jeffrey Kam, M.D. (1994), Jeffrey Leflein, M.D. (1995), Sai Nimmigadda, M.D. (1995-6), Michael Clayton, M.D. (1995), Beth Macomber (2004), Christopher Mjaanes (2004), Richard Henderson (2006), Grace Tamesis (2008), Tracy Kruzick (2008), Jonathan Malka (2010), Summer Monforte (2012), Chris Cleveland (2013).

Pediatric Pulmonary section: Heather [Hoch] De Keyser (2014), Deborah Liptzin (2014), Mfonobong Udoko (2020)

Emeregency Medicine Section: Nidhya Navanandan (2019)

1. **Grant Support**

A. Current funding:

1. National Heart, Lung and Blood Institute, 1UG1HL139123, Precision Interventions for Severe and/or exacerbation Prone Asthma (PrecISE), Co-Principal Investigators: Michael Wechsler, MD [Medicine] and Stanley J. Szefler, MD [Pediatrics], 9/30/17 - 9/29/23; $350,000 per year plus patient care costs.

2. Colorado Cancer, Cardiovascular and Pulmonary Disease Grant, 19 FHLA 108325, Colorado Comprehensive School-Centered Asthma Program (AsthmaCOMP), Principal Investigator: Stanley J. Szefler, MD, 7/1/18-6/30/21. Total grant: $2,600,398; Year 3 $869,137.

3. Propeller Health, Data Integration and Community Enhancement Center: Electronic Medication Monitoring, 7-1-19 t0 6-30-19, total gfrant $150,000.

4. National Heart, Lung and Blood Institute, 1UG3HL151297-01A1, Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR), “Reducing Asthma Attacks in Disadvantaged School Children with Asthma, 9-10-2020 through 8-31-2023 $2.7 million, Year 1: $610,000 direct costs.

B. Past funding:

1. National Institutes of Allergy and Infectious Diseases. Allergy Center Grant (AI-14198) "Multidisciplinary study of asthma." Principal investigator: Elliott Middleton, M.D. and Stanley J. Szefler, M.D., 9/17/79-8/31/82. Total direct costs $59,089.
2. Muro Pharmaceuticals, Inc., "Bioavailability assessment of a liquid prednisone preparation," Principal investigator: Stanley J. Szefler, M.D., 9/1/80-6/30/81. Total direct costs $11,551.
3. Fisons Corporation, "Evaluation of theophylline absorption from two controlled-release formulations," Principal investigator: Stanley J. Szefler, M.D., 4/1/81-3/31/82. Total direct costs $21,431.
4. Western New York Chapter of the American Heart Association, "Quinidine elimination in pediatric patients," Principal investigator: Danny D. Shen, Ph.D. and co-investigator Stanley J. Szefler, M.D., 9/1/80-8/31/82. Total direct costs $19,500.
5. National Institutes of Health, Heart, Lung and Blood Institute (RO1-HL-30513), "Corticosteroid pharmacologic action and disposition," Principal investigator: Stanley J. Szefler, M.D., 9/1/81-11/30/85. Total direct costs $302,000.
6. Searle Pharmaceutical Inc., "Investigation of intrasubject variability in theophylline absorption from sustained-release preparations," Principal investigator: Stanley J. Szefler, M.D., 11/1/83-10/31/84. Total direct costs $53,106.
7. Muro Pharmaceutical Inc., "Bioavailability assessment of an oral liquid prednisolone preparation," Principal investigator: Stanley J. Szefler, M.D., 6/1/84-8/31/84. Total direct costs $9,983.
8. Syntex Medical Diagnostics, "Theophylline levels determined by the Quant-Stick method," Principal investigator: Stanley J. Szefler, M.D., 7/1/84-8/31/84. Total direct costs $8,000.
9. William H. Rorer, Inc., "Investigation of theophylline absorption from sustained-release formulations in young children," Principal investigator: Stanley J. Szefler, M.D., 6/1/84-3/31/85. Total direct costs $26,922.
10. Merck, Sharp and Dohme, "Comparison of efficacy and side effects of enprofylline, Theo-Dur and placebo in patients with mild to moderate asthma," Principal investigator: Harold Nelson, M.D. and co-investigator Stanley J. Szefler, M.D., 3/1/87-7/1/87. Total direct costs $41,000.
11. Food and Drug Administration, FD-R-000278-01, "Efficacy of troleandomycin in severe asthmatic children," Principal investigator: Stanley J. Szefler, M.D., 9/30/87-9/29/90, Annual direct costs $110,000.
12. Program Project Grant "Inflammation, airway reactivity and asthma," NIH-POL-HL-36577-02, Principal investigator: Richard Martin and co-investigator Stanley J. Szefler, M.D., for project "Nocturnal asthma and airways inflammation," 7/1/86-6/30/91, Annual direct costs $93,906.
13. William H. Rorer Pharmaceuticals, "Comparative evaluation of two sustained-release theophylline products in severe asthmatic children," Principal investigators: Stanley J. Szefler, M.D. and Malcolm Hill, Pharm. D., 7/1/87-6/30/88. Annual direct costs $30,061
14. Biomedical research support grant, National Jewish, "Corticosteroid concentrations in rabbit lung: Analysis of bronchoalveolar lavage fluid," Principal investigator: Malcolm Hill, Pharm. D. and co-investigator Stanley J. Szefler, M.D., 2/1/87-1/31/88. Direct costs $10,192.
15. Wallace Laboratories, "Placebo-controlled study of effectiveness and safety of azelastine in asthmatic patients," Principal investigator: Harold Nelson, M.D. and co-investigator Stanley J. Szefler, M.D., 8/1/87-2/28/89. Total direct costs $115,000.
16. Syntex Laboratories, "Performance assessment of the Accu-Level Theophylline II monitoring technique," Principal investigator: Stanley J. Szefler, M.D., 1/1/88-3/30/88. Total direct costs $5,000.
17. American College of Allergists, Fellowship training fund, "Clinical assessment of efficacy of troleandomycin in severe steroid-requiring asthmatic children," 7/1/87-6/30/88. Total direct costs $5,000 fellowship support for Bruce D. Ball, M.D.
18. Schering-Plough Corporation, "Short and long-term behavior change in asthmatic children taking theophylline," Principal investigator: Stanley J. Szefler, M.D., 9/1/87-8/30/89. Total direct costs $110,860.
19. American College of Allergists, Fellowship research training fund, "Do macrolide antibiotics inhibit cell infiltration into to the lung?" 7/1/88-6/30/89. Total direct costs $4,000 fellowship support for Leon Greos, M.D.
20. 3M/Riker Laboratories, "Single dose duration of action comparative study of pirbuterol, albuterol and placebo aerosols." Principal investigator: Malcolm Hill, Pharm. D. and Co-investigator Stanley J. Szefler, M.D. 9/1/88-1/30/89. Total direct costs $32,000.
21. W.H. Rorer, "Adrenal function in adult asthmatics during chronic treatment with aerosolized triamcinolone acetonide." Principal investigator - Stanley J. Szefler, M.D. 7/1/88-8/30/89. Total direct costs $64,000.
22. NIH-T32 HL 07670-01, "Academic Training in Pediatric Pulmonary Diseases." Gary Larsen, M.D. Principal investigator, S. J. Szefler, M.D. Co-investigator. 7/1/88-6/30/93. Annual direct costs $112,808, Total direct costs $760,452.
23. Program Project Grant "Inflammation, airway reactivity and asthma, NIH-2-P01-HL 36577-06. Co-Principal investigators: Donald Leung, M.D., Ph.D. and Stanley J. Szefler, M.D., for project "Steroid-resistant asthma" 7/1/91-6/30/96. Annual direct costs, $124,000.
24. Fisons Pharmaceuticals, A randomized double-blind multicenter group comparative study of the absolute efficacy and safety of nedocromil sodium 0.5% nebulizer solution TID in the treatment of children 2-4 years of age with bronchial asthma. Principal Investigator: Stanley J. Szefler, M.D. 9/1/91-12/1/92, $50,000.
25. Besselar, Inc. Randomized placebo-controlled study to determine the efficacy of budesonide in glucocorticoid treated asthma. Principal Investigator Stanley J. Szefler, M.D., 9/1/91 to 11/30/93, $120,000.
26. National Heart, Lung and Blood Institute, N01-HR-16048, Childhood Asthma Management Program. Principal Investigator: Stanley J. Szefler, M.D., 9/30/91 to 9/29/99. Total direct cost $6,413,517; annual cost $889,575.
27. National Heart, Lung and Blood Institute, HL51834, Asthma Clinical Research Network, Co-Principal Investigators - Richard Martin, M.D. and Stanley J. Szefler, M.D., 9/30/93-8/31/98, total direct cost $2,5000,000, annual direct cost $625,000; renewed for 9/1/98 to 8/31/2003.
28. Astra/Draco, "A study of 3 dose levels once a day of budesonide nebulizer suspension and placebo in asthmatic children age 8 and under. (Drug Study) Principal Investigator: Stanley J Szefler, MD. Dates and cost of entire project: 8/1/94-7/31/95, $76,745. Cost of current year: Same.
29. Merck Research Laboratories, "A multiple, double-blind, randomized, parallel-group study comparing MK-0476 to placebo in 6 - 14 year old patients with chronic asthma" Dates and cost of entire project: 7/1/95 - 10/30/96, $42,000.
30. 3M Pharmaceuticals, Inc., "Global clinical trial with inhaled HFA-134 beclomethasone dipropionate in childhood asthma," Principal Investigator: Stanley J. Szefler, M.D., Dates and cost of entire project: 9/96 - 12/97, $89,000.
31. Astra, Inc., "Initiating inhaled budesonide in asthmatic patients with recent onset of asthma," Global clinical trial, Principal Investigator: Stanley J. Szefler, M.D., Dates and cost of entire project: 9/96 - 8/2003, $140,000.
32. Glaxo Wellcome, Inc. - “Early intervention in childhood asthma,” National Jewish protocol sponsored by Glaxo Wellcome - multicenter trial, Principal Investigators: Erwin Gelfand, M.D. and Stanley J. Szefler, M.D., Dates and cost of entire project: 9/96 - 12/98, $1,200,000.
33. National Heart, Lung and Blood Institute, HL51834, Asthma Clinical Research Network, Co-Principal Investigator - Richard Martin, M.D.; Co-investigator Stanley J. Szefler, M.D., 9/30/98-8/31/03, total direct cost $2,5000,000, annual direct cost $625,000.
34. National Institute of Child Health and Human Development, 1 U01 HD37237, Pediatric Pharmacology Research Unit Network, Principal Investigator: Stanley J. Szefler, M.D. Dates and cost of project: Year 1 1/1/1999-12/31/2000; $267,508; entire project 1/1/1999-12/31/2003: $1,355,175.
35. National Heart, Lung and Blood Institute, N01-HR-16048, Childhood Asthma Management Program Continuation Study. Principal Investigator: Stanley J. Szefler, M.D., 9/30/99 to 4/30/04. Total direct cost $2,000,00; annual cost $400,000.
36. National Heart, Lung, and Blood Institute, Childhood Asthma Research and Education Network. 1U10 HL64288, Year 1: 9/30/99 - 9/29/00, $600,000; Principal Investigator Denver site, entire project 9/30/99 - 9/29/04 $3,500,000.
37. National Institute of Child Health and Human Development, 1 U01 HD37237-04S1, Pediatric Pharmacology Research Unit Network Directors Funds Award, Principal Investigator: Stanley J. Szefler, M.D. Dates and cost of project: 9/30/2002-12/31/2003; $122,143.
38. National Institutes of Allergy and Infectious Diseases, Inner City Asthma Consortium, N01-AI-25496, Associate Principal Investigator for consortium; Principal Investigator Denver site, entire project 9/30/02-12/31/09; Year 1 – 158,000 core funds plus additional study budget funds; total 6 year project funding approximately $6,000,000 pending project development timeline.
39. National Heart, Lung and Blood Institute, N01-HR-16048, Childhood Asthma Management Program Continuation Study/Phase 2. Principal Investigator: Stanley J. Szefler, M.D., 5/1/04 to 9/30/08. Year cost 132,627; total award $809,822.
40. Ross Pharmaceuticals, Evaluation of a nutritional formula for asthma intervention in children, 6/1/04-12/31/05. Principal Investigator, S. J. Szefler, Total award, $1,100,000.
41. Colorado Cancer, Cardiovascular and Pulmonary Disease Grants. “Reducing School Absence due to Asthma Exacerbations in the Denver Public School System, 1/1/06 – 6/31/06 $267,000; with continuation from 7/1/06 to 6/31/08 for total of $1,200,000.
42. NIH/NHLBI, Proteomics Program in Lung Disease. Frank Accurso, MD, PI, 10/01/05 – 09/30/09 $930,057.
43. Glaxo Smith Kline “Reducing health disparities for asthma with an evidence-based school program ["OAS study"]”, Principal Investigator: Stanley J. Szefler, MD, September 1, 2008 to August 31, 2009. Total grant: $150,000.
44. National Heart, Lung and Blood Institute, R21HL087811, Progression of Airway Obstruction in Childhood Asthma. Principal Investigator: Stanley J. Szefler, MD, 9/1/08-6/30/11. Year cost $234,000; total award 429,000.
45. National Heart, Lung and Blood Institute, HL51834, Asthma Clinical Research Network, Co-Principal Investigator - Richard Martin, M.D.; Co-Investigator Stanley J. Szefler, M.D., 9/30/03-8/31/11, total direct cost $2,5000,000, annual direct cost $625,000.
46. National Heart, Lung, and Blood Institute, Childhood Asthma Research and Education Network. 1U10 HL64288, Year 1: 9/30/04 - 9/29/05, $815,000; Principal Investigator Denver site, entire project 9/30/04 - 9/29/11 $4,327,075.
47. Colorado Cancer, Cardiovascular and Pulmonary Disease Grant #06-FLA-00845, Principal Investigator: Stanley J. Szefler, MD, 7/1/09-9/30/12. Total grant: $1,100,000.
48. National Heart, Lung and Blood Institute, 2U01-HL-075416, Childhood Asthma Management Program Continuation Study/Phase 3. Principal Investigator: Stanley J. Szefler, M.D., 10/1/07 to 9/30/11. Year cost 150,684; total award $631,000.
49. Inner City Asthma Consortium (ICAC) II N01-AI-90052 and N01 AI025496. Principal Investigator: William Busse, MD [Madison, WI; Co-investigator: Stanley J. Szefler, MD, 9/29/09-9/30/14, funding determined based on protocols. [renewed for 10/1/14-3/30/15]
50. National Institute of Environmental Health Sciences/Environmental Protection Agency. 1 P01 ES018181, Childhood Environment and Health Center Grant (CEHC). Principal Investigator: David Schwartz, Co-Director: Stanley Szefler, MD, 9/30/09 - 9/29/14, total funding: $6,000,000.
51. Glaxo Smith Kline, Building Bridges for Asthma Program. Principal Investigator: Stanley J. Szefler, MD, 1/1/12-12/31/16, total $3,000,000.
52. Colorado Cancer, Cardiovascular and Pulmonary Disease Grant #13-FLA-48556, Step Up Asthma program for the Denver Public Schools, Principal Investigator: Stanley J. Szefler, MD, 10/1/12-6/30/15. Total grant: $1,253,128. [renewed for 7/1/15-6-30-18; Year 1 $795,000.
53. Roche Clinical Trial, lebrikizumab in adolescents with asthma, 12/1/14-present, total, approximately $90,000.
54. Colorado Cancer, Cardiovascular and Pulmonary Disease Grant #17 FHLA 93211 and 18 FHLA 96089 , Breathing Counts, Principal Investigator: Heather Hoch, MD, 10/1/16-6/30/18. Total grant: $700,000.
55. National Heart, Lung and Blood Institute, 1U10HL098075, Asthma Research Network (AsthmaNet), Co\_Principal Investigators: Michael Wechsler, MD [Medicine] and Stanley J. Szefler, MD [Pediatrics], 9/30/09 - 9/29/18 with NCE. Total funding: $5,782,376.
56. National Heart, Lung and Blood Institute, 1 UG1 HL139123, Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE). Co-Principal Investigators: Michael Wechsler, MD and Stanley J. Szefler, MD. 9-1-17-8-31-23, Direct Costs: Year 1 #$240,000 plus patient care costs per year.
57. Colorado Cancer, Cardiovascular and Pulmonary Disease Program, Colorado Department of Public Health and Environment, AsthmaCOMP, 7-1-18 to 6-30-21, total funding: $917,000 per year.
58. **Bibliography: CU Profiles** [**https://profiles.ucdenver.edu/display/3353673**](https://profiles.ucdenver.edu/display/3353673)

A. Publications in refereed journals:

1. **Szefler SJ**, Jusko WJ. Decreased volume of distribution of digoxin in a patient with renal failure. Res Comm Chem Pathol Pharmacol 6:l095-l098, l973.
2. Jusko WJ, **Szefler SJ**, Goldfarb AL. Pharmacokinetic design of digoxin dosage regimens in relation to renal function. J Clin Pharmacol l4:525-535, l974.
3. **Szefler SJ**, Koup JR, Giacoia GP. Paradoxical behavior of serum digoxin concentrations in an anuric neonate. J Pediatr 9l:487-489, l977.
4. **Szefler SJ**, Acara M. Isoproterenol excretion and metabolism in the isolated perfused rat kidney. J Pharmacol Exp Ther 2l0:295-300, l979.
5. **Szefler SJ**, Wynn RJ, Clarke DF, Buckwald S, Shen D, Schentag JJ. Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates. J Pediatr 97:3l2-3l5, l980.
6. **Szefler SJ**, Rose JQ, Ellis EF, Spector SL, Green A, Jusko WJ. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol 66:447-455, l980.
7. Rocci ML, **Szefler SJ**, Acara M, Jusko WJ. Prednisolone metabolism and excretion in the isolated perfused rat kidney. Drug Metab and Dispos 9:l77-l82, l98l.
8. Lee TP, **Szefler SJ**, Ellis EF. Beta-adrenergic receptors of human polymorphonuclear leukocytes. Res Comm Chem Pathol Pharmacol 3l:453-462, l98l.
9. Zarowitz BJM, **Szefler SJ**, Lasezkay GM. Effect of erythromycin base on theophylline kinetics. Clin Pharmacol Ther 29:60l-605, l98l.
10. Dederich RA, **Szefler SJ**, Green ER. Intrasubject variation in sustained-release theophylline absorption. J Allergy Clin Immunol 67: 465-47l, l98l.
11. **Szefler SJ**, Ellis EF, Brenner M, Rose JQ, Spector SL, Yurchak A, Andrews F, Jusko WJ. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. J Allergy Clin Immunol 69:455-462, l982.
12. **Szefler SJ**, Brenner M, Jusko WJ, Spector SL, Flesher KA, Ellis EF. Dose- and time-related effect of troleandomycin on methylprednisolone elimination. Clin Pharmacol Therap 32:l66-l7l, l982.
13. **Szefler SJ**, Pieroni DR, Gingell RL, Shen DD. Rapid elimination of quinidine in pediatric patients. Pediatr 70:370-375, l982.
14. Georgitis J, Flesher K, **Szefler SJ**. Bioavailability assessment of a liquid prednisone preparation. J Allergy Clin Immunol 70:243-247, l982.
15. Zarowitz BJM, Wynn RJ, Buckwald S, **Szefler SJ**. High gentamicin trough concentrations in neonates of less than 28 weeks gestational age. Dev Pharmacol Ther 5:68-75, l982
16. Milsap RL, George DE, **Szefler SJ** Murray KA, Lebenthal E, Jusko WJ. Effect of inflammatory bowel disease on absorption and disposition of prednisolone. Dig Dis Sci 28:l6l-l68, l983.
17. Boekenoogen SJ, **Szefler SJ**, Jusko WJ. Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab 56:702-709, l983.
18. Faden H, Neidermeyer L, **Szefler SJ**, Eddy E. Chloramphenicol use among hospitalized children. Hosp Form l8:43l-434, l983.
19. LaForce CF, **Szefler SJ**, Miller MF, Ebling W, Brenner M. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol 72: 34-39, l983.
20. Ebling WF, **Szefler SJ**, Jusko WJ. Analysis of cortisol, methylprednisolone, and methylprednisolone hemisuccinate: Absence of effects of troleandomycin on ester hydrolysis. J Chromatogr Biomed Appl 305:27l-280, l984.
21. **Szefler SJ**, Rogers RJ, Strunk RC. Drug abuse and the asthmatic patient: A case report. J Allergy Clin Immunol 74:20l-204, l984.
22. Georgitis JW, **Szefler SJ**, Baswell B, Shen DD. Use of pharmacokinetic profile in evaluating patients with repeatedly low theophylline concentrations. Ann Allergy 53:23l-235, l984.
23. Pollack GM, Baswell B, **Szefler SJ**, Shen DD. Comparison of inter-and intra-subject variation in oral absorption of theophylline from sustained-release products. Int J Pharm 2l:3-l6, l984.
24. Rogers RJ, Kalisker A, Wiener MB, **Szefler SJ**. Inconsistent absorption from a sustained-release theophylline preparation during continuous therapy in asthmatic children. J Pediatr l06:496-50l, l985.
25. Ebling WF, **Szefler SJ**, Jusko WJ. Methylprednisolone disposition in rabbits: Analysis, prodrug conversion, reversible metabolism, and comparison to man. Drug Metab Dispos 13:296-304, l985.
26. Haltom JR, **Szefler SJ**. Theophylline absorption in young asthmatic children receiving sustained-release formulations. J Pediatr 107:805-810, l985.
27. Suez D, **Szefler SJ**. Excessive accumulation of mucus in children with asthma: A potential role for erythromycin? A Case Discussion. J Allergy Clin Immunol 77:330-334, l986.
28. Vaughn LM, Weinberger MM, Milavetz G, Tillson S, Ellis EF, Jenne J, **Szefler SJ**, Wiener MB, Conboy C, Shaughnessy T, Carrico J. Multicenter evaluation of disposable visual measuring device to assay theophylline from capillary blood sample. Lancet i:l84-l86, l986.
29. **Szefler SJ**, Ebling WF, Georgitis JW, Jusko WJ. Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. Eur J Clin Pharmac 30:323-329, l986.
30. Ebling WF, Milsap RL, **Szefler SJ**, Jusko WJ. 6 Methylprednisolone and 6-methylprednisone plasma protein binding in man and rabbit. J Pharm Sci 75:760-763, l986.
31. **Szefler SJ**, Edwards CK, Haslett C, Zahniser NR, Miller JA, Henson PM. Effects of cell isolation procedures and radioligand selection on the characterization of human leukocyte -adrenergic receptors. Bioch Pharmacol 36:1589-1597, 1987.
32. Bartoszek M, Brenner AM, **Szefler SJ**. Prednisolone and methylprednisolone kinetics in asthmatic children receiving anticonvulsant therapy. Clin Pharmacol Ther 42:424-432, 1987.
33. Rogers RJ, Wiener MB, Hill MR, **Szefler SJ**. Theophylline absorption from two sustained-release products: Implications for therapeutic drug monitoring. Amer Rev Respir Dis 136:1168-1173, 1987.
34. Ebling WF, Rich SA, **Szefler SJ**, Jusko WJ. Troleandomycin effects on methylprednisolone and methylprednisone interconversion and disposition in the rabbit. Eur J Drug Metab Pharmacokin 12:49-57, 1987.
35. Hill MR, Haltom J, **Szefler SJ**. Consistency of theophylline absorption from a sustained-release formulation in asthmatic children. Pharmacotherapy 8:277-283, 1988.
36. **Szefler SJ**, Norton C, Ball BD, Gross JM, Aida Y, Pabst MJ. IFN- and LPS overcome glucocorticoid inhibition of priming for superoxide release in human monocytes: Evidence that secretion of IL-1 and tumor necrosis factor- is not essential for monocyte priming. J Immunol 142:3985-3992, 1989.
37. Kossoy AF, Hill MR, Lin FL, **Szefler SJ**. Are theophylline "levels" a reliable indicator of compliance? J Allergy Clin Immunol 84:60-65, 1989.
38. Vichyanond P, Irvin CG, Larsen GL, **Szefler SJ**, Hill MR. Penetration of corticosteroids into the lung: Evidence for a difference between methylprednisolone and prednisolone. J Allergy Clin Immunol 84:867-873, 1989.
39. Ball BD, Hill MR, Brenner M, Sanks R, **Szefler SJ**. Effect of low-dose troleandomycin on glucocorticoid kinetics and airway hyperresponsiveness in severely asthmatic children. Annals of Allergy 65:37-45, 1990.
40. Vichyanond P, Sladek W, Sur S, Hill MR, **Szefler SJ**, Nelson HS. Efficacy of atropine methylnitrate alone and in combination with albuterol in children with asthma. Chest 98:637-642, 1990.
41. Hill MR, **Szefler SJ**, Ball BD, Bartoszek M, Brenner M. Monitoring glucocorticoid therapy: A pharmacokinetic approach. Clin Pharmacol Ther 48:390-398, 1990.
42. **Szefler SJ**, Ando R, Cicutto LC, Surs W, Hill MR, Martin RJ. Plasma histamine, epinephrine, cortisol and leukocyte ß-adrenergic receptors in nocturnal asthma. Clin Pharmacol Ther 49:59-68, 1991.
43. Erzurum SC, Leff JA, Cochran JE, Ackerson LM, **Szefler SJ**, Martin RJ, Cott GR. Lack of benefit from methotrexate in severe steroid dependent asthmatics. A double-blind, placebo-controlled study. Ann Int Med 114:353-360, 1991.
44. Martin RJ, Cicutto LC, Smith HR, Ballard RD, **Szefler SJ.** Airways inflammation in nocturnal asthma. Am Rev Respir Dis 143:351-357, 1991.
45. Greos LS, Vichyanond P, Bloedow DC, Irvin CG, Larsen GL, **Szefler SJ**, Hill MR. Methylprednisolone achieves greater concentrations in the lung than prednisolone: A pharmacokinetic analysis. Am Rev Respir Dis 144:586-592, 1991.
46. Glynn-Barnhart AM, Erzurum SC, Leff JA, Martin RJ, Cochran JE, Cott GR, **Szefler SJ**. Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. J Allergy Clin Immunol 88:180-186, 1991.
47. Corrigan CJ, Brown P, Barnes NC, **Szefler SJ,** Tsai J-J, Freu AJ, Crompton GK, Kay AB. Glucocorticoid resistance in chronic asthma: Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics and inhibition of peripheral blood T-cell proliferation by glucocorticoid *in vitro*. Am Rev Respir Dis 144:1016-1025, 1991.
48. Dove AM, **Szefler SJ**, Hill MR, Jusko WJ, Larsen GL, Accurso FJ. Altered prednisolone pharmacokinetics in patients with cystic fibrosis. J Pediatr 120:789-794, 1992.
49. Alvarez J, Surs W, Leung DYM, Iklé D, Gelfand EW, **Szefler SJ**. Steroid resistant asthma: Immunologic and pharmacologic features. J Allergy Clin Immunol 89:714-721, 1992.
50. Bender BG, Lerner JA, Iklé D, Comer C, **Szefler SJ** Psychological change associated with theophylline treatment of asthmatic children: A six month study. Pediatr Pulmonol 11:233-242, 1992.
51. **Szefler SJ**, Kamada AK, Hughes DJ, Brenner AM, Gelfand EW. Alternative treatment for asthma: Assessing the need. J Asthma 29:91-97, 1992.
52. Kamada AK, Hill MR, Brenner AM, **Szefler SJ**. Effect of low-dose troleandomycin on theophylline clearance: Implications for therapeutic drug monitoring. Pharmacotherapy 12:98-102, 1992.
53. Multicenter study (**Szefler SJ** - study participant). Adrenal function in adult asthmatics during chronic daily treatment with 800, 1200 and 1600 g Azmacort. Chest 101:1250-1256, 1992.
54. Zaragoza RH, **Szefler SJ**, Bratton DL. Brief Report: Therapeutic manipulations in severe nocturnal asthma: A nonconventional approach in a severe high-risk asthmatic. J Asthma 29:281-287, 1992.
55. Glynn-Barnhart AM, Erzurum SC, Leff JA, Martin RJ, Cochran JE, Cott GR, **Szefler SJ**: Pharmacokinetics of low-dose methotrexate in adult asthmatics. Pharmacotherapy 12(5):383-390, 1992.
56. Kamada AK, Leung DYM, Gleason MC, Hill MR, **Szefler SJ**. High-dose systemic glucocorticoid therapy in the treatment of asthma: A case of resistance and patterns of response. J Allergy Clin Immunol 90:685-687, 1992.
57. Kamada AK, Hill MR, Iklé DN, Brenner AM, **Szefler SJ**. Efficacy and safety of troleandomycin therapy in severe, steroid-requiring asthmatic children. J Allergy Clin Immunol 91:873-882, 1993.
58. Kam JC, **Szefler SJ**, Surs W, Sher ER, Leung DYM. Combination IL-2 and IL-4 reduces glucocorticoid receptor binding affinity and T cell response to glucocorticoids. J Immunol 151:3460-3466, 1993. PMID 8376786
59. Sher ER, Leung DYM, Surs W, Kam JC, Zieg, G, Kamada AK, **Szefler SJ**. Steroid resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest. 93:33-39, 1994. PMID 8282803
60. Spahn JD, Kamada AK, **Szefler SJ**, Leung DYM. Difficult to control asthma: identification of conditions contributing to poor response to glucocorticoid therapy. Am J Asthma Allergy Pediatricians 7:87-92, 1994. No PMID available.
61. Kamada AK, Spahn JD, Surs W, Brown E, Leung DYM, **Szefler SJ**. Coexistence of glucocorticoid receptor and pharmacokinetic abnormalities: Factors that contribute to a poor response to treatment with glucocorticoids in children with asthma. J Pediatr 124:984-986, 1994. PMID 8201491
62. Leung DYM, Martin RJ, **Szefler SJ**, Sher ER, Ying S, Kay AB, Hamid Q. Dysregulation of interleukin 4, interleukin 5, and interferon- in steroid-resistant asthma. J Exp Med 181:33-40, 1995 PMID 7807013 PMCID PMC2191836
63. Leflein J, Brown E, Hill M, Kelley HW, Nelson HS, **Szefler SJ**. Delivery of glucocorticoids via jet nebulization: Aerosol characteristics and output. J Allergy Clin Immunol 95:944-949, 1995. PMID 7751514
64. Spahn JD, Leung DYM, Surs W, Harbeck RJ, Nimmagadda S, **Szefler SJ**. Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. Am J Respir Crit Care Med 151:1709-1714, 1995. PMID 7767511
65. Pincus DJ, **Szefler SJ**, Ackerson LM, Martin RJ. Chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy. J Allergy Clin Immunol 95:1172-1178, 1995. PMID 7797785
66. Clayton MH, Leung DYM, Surs W, **Szefler SJ**. Altered glucocorticoid receptor binding in atopic dermatitis. J Allergy Clin Immunol 96;421-423, 1995. PMID 7560645
67. Spahn JD, **Szefler SJ**, Surs W, Doherty DE, Leung DYM. A novel action of interleukin-13: Induction of diminished monocyte glucocorticoid receptor binding affinity. J Immunol 157:2654-2659, 1996. PMID 8805670
68. Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, Lazarus SC, Lemanske RF, Martin RJ, Peters SP, Sorkness C, **Szefler SJ** for the National Heart, Lung and Blood Institute’s Asthma Clinical Research. Comparison of regularly scheduled with as needed use of albuterol in mild asthma. N Engl J Med 335:841-847, 1996. PMID 8778601
69. Spahn JD, Landwehr LP, Nimmigadda S, Surs W, Leung DYM, **Szefler SJ**. Effects of glucocorticoids on lymphocyte activation in steroid-sensitive and steroid-resistant asthmatics. J Allergy Clin Immunol 98:1073-1079, 1996. PMID 8977508
70. Fish JE, Peters SP, Chambers CV, McGeady SJ, Epstein KR, Boushey HA, Cherniack RM, Chinchilli VM, Drazen JM, Fahy JV, Hurd SS, Israel E, Lazarus SC, Lemanske RF, Martin RJ, Mauger EA, Sorkness C, **Szefler SJ**. An evaluation of colchicine as an alternative to inhaled corticosteroids in moderate asthma. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Am J Respir Crit Care Med 1997;156:1165-1171. PMID 9351617
71. Nimmagadda SR, **Szefler, SJ**, Spahn JD, Surs W, Leung, DYM. Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics. Am J Respir Crit Care Med 155:87-93, 1997. PMID 9001294
72. Kamada AK, Wiener MB, Scott MB, Selner JC, **Szefler SJ**. A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. Pharmacotherapy, 17:353-356, 1997. PMID 9085328
73. Martin RJ, Wanger JS, Irvin CG, Bartelson BB, Cherniack RM, Asthma Clinical Research Network (ACRN) (**Szefler SJ** - investigator). Methacholine challenge testing: safety of low starting FEV1. Chest 112:53-56, 1997. PMID 9228357
74. Wenzel SE, **Szefler SJ**, Leung DYM, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma: persistent inflammation despite high dose glucocorticoids. Am J Respir Crit Care Med 1997;156:737-43. PMID 9309987
75. Lanz MJ, Leung DYM, Harbeck R, **Szefler SJ**, White CW. Use of exhaled nitric oxide to monitor ongoing inflammation in children with asthma. Pediatr Pulmonol 24:305-311, 1997. No PMID available
76. Leung DYM, Hamid Q, Vottero A, **Szefler SJ**, Surs W, Minshall E, Chrousos GP, Klemm D. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor . J Exp Med 186:1567-74, 1997. PMID 9348314 PMCID PMC2199113
77. Redd CE, Offord KP, Nelson HS, Li JT, Tinkelman DG and the American Academy of Allergy, Asthma and Immunology Beclomethasone Dipropionate-Theophylline Study Group **(Szefler SJ - Planning and Organizing Committee)**. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. J Allergy Clin Immunol 1998;101:14-23. PMID 9449495
78. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, Becker A for the Pediatric Montelukast Study Group (**Szefler SJ - investigator**). Montelukast for chronic asthma in 6- to 14-year old children. JAMA 1998;279:1181-1186. PMID 9555757
79. Chan MTS, Leung DYM, **Szefler SJ**, Spahn JD. Patterns of steroid response in difficult-to-control asthma: clinical characteristics of steroid resistant asthma. J Allergy Clin Immunol 1998:101:594-601. PMID 9600494
80. Nimmagadda SR, Spahn JD, Nelson HS, Jenkins J, **Szefler SJ**, Leung DY. Fluticasone propionate results in improved glucocorticoid receptor binding affinity and reduced oral glucocorticoid requirements in severe asthma. Ann Allergy Asthma Immunol 1998;81:35-40. PMID 9690571
81. Shapiro G, Bronsky EA, LaForce CF, Mendelson L, Pearlman D, Schwartz RH, **Szefler SJ.** The dose-related efficacy of budesonide Tubuhaler® in the treatment of children with moderate to severe glucocorticosteroid-dependent asthma. J Pediatr 1998;132:976-982. PMID 9627589
82. Chu HW, Halliday JL, Martin RJ, Leung DY, **Szefler SJ**, Wenzel SE. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am J Respir Crit Care Med 1998;158(6):1936-1944. PMID 9847289
83. **Szefler SJ**, Oliver S, Bender B, Nelson HS, Culkin C, Taggart V. Design and implementation of a patient education center for the childhood asthma management program. Ann Allergy Asthma Immunol 1998, 81:571-581. PMID: 9892029
84. Childhood Asthma Management Program Research Group (**Szefler SJ** - Writing committee). The Childhood Asthma Management Program (CAMP): Design, rationale, and methods. Controlled Clinical Trials 1999;20:91-120. PMID 10027502
85. Spahn JD, Leung DYM, Chan MTS, **Szefler SJ**, Gelfand EW. Mechanisms of glucocorticoid reduction in asthmatics treated with intravenous immunoglobulin. J Allergy Clin Immunol 1999;103:421-426. PMID 10069875
86. Zeiger RS, Dawson C, Weiss S, for the Childhood Asthma Management Program (CAMP) Research Group (**Szefler SJ**, Denver site Director). Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP). J Allergy Clin Immunol 1999:103:376-387. PMID 10069869
87. Martin RJ, Pak J, Kunselman SJ, Cherniack RJ, and the Asthma Clinical Research Network (ACRN) (**Szefler SJ** – co-investigator). Assessment of the AirWatch lung function monitoring system. J Allergy Clin Immunol 1999:103;535-536. PMID 10069893
88. Childhood Asthma Management Program Research Group (**Szefler SJ**, Denver site Director). Recruitment of participants in the Childhood Asthma Management Program (CAMP). I. Description of Methods. J Asthma 1999:36(3):217-237. PMID 10350219
89. Wamboldt FS, Spahn JD, Klinnert MD, Wamboldt MZ, Gavin LA, **Szefler SJ,** Leung DYM. Clinical outcomes of steroid-insensitive asthma. Ann Allergy Asthma Immunol 1999;83:55-60. PMID 10437817
90. Wamboldt FS, Bender BG, O’Connor SL, Gavin LA, Wamboldt MZ, Milgrom H, **Szefler SJ,** Iklé D, Rand C. Reliability of the model MC-311 MDI Chronolog. J Allergy Clin Immunol 1999;104:53-57. PMID 10400839
91. Hamid QA, Wenzel SE, Hauk PJ, Tsicopoulos A, Wallaert B, Lafitte J-J, Chrousos GP, **Szefler SJ**, Leung DYM. Increased glucocorticoid receptor  in airway cells of glucocorticoid insensitive asthma. Am J Respir Crit Care Med 1999;159:1600-1604. PMID 10228133
92. **Szefler SJ,** Boushey HA, Pearlman DS, Togias A, Liddle R, Furlong A, Shah T, Knobil K. Time to onset of effect of fluticasone propionate in patients with asthma. J Allergy Clin Immunol 1999;103-780-788. PMID 10329810
93. Hauk PJ, Wenzel SE, Trumble AE, **Szefler SJ,** Leung DYM. Increased T-cell receptor vbeta8+ T cells in bronchoalveolar lavage fluid of subjects with poorly controlled asthma: a potential role for microbial superantigens. J Allergy Clin Immunol 1999;104:37-45. PMID 10400837
94. Fost DA, Leung DYM, Martin RJ, Brown EE, **Szefler SJ** and Spahn JD. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. J Allergy Clin Immunol 1999;103:1031-1035. PMID 10359882
95. Kemp J, Skoner DP, **Szefler SJ**, Walton-Bowen K, Cruz-Rivera M, Smith JA. Once-daily budesonide inhalation suspension for the treatment of asthma in infants and young children. Ann Allergy Asthma Immunol 1999;83:231-239. PMID 10507269
96. Nelson HS, **Szefler SJ**, Jacobs J, Huss K, Shapiro G, Sternberg AL, for the Childhood Asthma Management Program Research Group. The relationships among environmental allergen sensitization, allergen exposure, pulmonary function, and bronchial hyperresponsiveness in the Childhood Asthma Management Program. J Allergy Clin Immunol 1999; 104:775-85. PMID: 10518821
97. Skoner DP, **Szefler SJ**, Welch M, Walton-Bowel K, Cruz-Rivera M, Smith JA. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. J Clin Allergy Immunol 2000;105(2):259-68. PMID 10669845
98. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, LeManske Jr RF, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, **Szefler SJ**, Weiss ST, Yandava CN. The effect of polymorphisms of the 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000;162(1):75-80. PMID 109032223
99. Weiss ST, Van Natta ML, Zeiger RS for the Childhood Asthma Management Program Research Group (**Szefler SJ** - PI/Denver Site). Relationship between increased airway responsiveness and asthma severity in the Childhood Asthma Management Program. Am J Respir Crit Care Med 2000;162:50-56. PMID 10903219
100. The Childhood Asthma Management Program Research Group (**Szefler SJ**). Long term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343(16):1054-63. PMID: 11027739
101. Bender B, Wamboldt FS, O'Connor SL, Rand C, **Szefler SJ**, Milgrom H, Wamboldt MZ. Measurement of children's asthma medication adherence by self-report, mother report, canister weight, and Doser CT. Ann Allergy Asthma Immunol 2000;85(5):416-21. PMID 11101187
102. Vanden Burgt JA, Busse WW, Martin RJ, **Szefler SJ**, Donnel D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000;160(6):1209-1226. PMID 11112914
103. Wamboldt MZ, Bihun JT, **Szefler SJ**, Hewitt J. Perception of induced bronchoconstriction in a community sample of adolescents. J Allergy Clin Immunol 2000;160(6):1102-1107. PMID 11112893
104. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, Lemanske RF, Jr., Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, **Szefler SJ**, Weiss ST, Yandava CN. Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 2001;124(1-3):183-186. PMID 11306963
105. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Jr., Sorkness CA, Kraft M, Fish JE, Peters SP, Craig T, Drazen JM, Ford JG, Israel E, Martin RJ, Mauger EA, Nachman SA, Spahn JD, **Szefler SJ**. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial. JAMA 2001;285(20):2583-2593. PMID 11368732
106. Lemanske RF, Jr., Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, Drazen JM, Chinchilli VM, Craig T, Fish JE, Ford JG, Israel E, Kraft M, Martin RJ, Nachman SA, Peters SP, Spahn JD, **Szefler SJ**. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: A randomized controlled trial. JAMA 2001;285(20):2594-2603. PMID 11368733
107. Leone FT, Mauger EA, Peters SP, Chinchilli VM, Fish JE, Boushey HA, Cherniack RM, Drazen JM, Fahy JV, Ford J, Israel E, Lazarus SC, Lemanske RF, Martin RJ, McGeady SJ, Sorkness C, **Szefler SJ**. The utility of peak flow, symptom scores, and beta-agonist use as outcome measures in asthma clinical research. Chest 2001;119(4):1027-1033. PMID 11296165
108. Fahy JV, Boushey HA, Lazarus SC, Mauger EA, Cherniack RM, Chinchilli VM, Craig TJ, Drazen JM, Ford JG, Fish JE, Israel E, Kraft M, Lemanske RF, Martin RJ, McLean D, Peters SP, Sorkness C, **Szefler SJ**, for the National Heart, Lung and Blood Institute’s Asthma Clinical Research Network. Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. Am J Respir Crit Care Med 2001;163:1470–1475. PMID 11371420
109. Spahn JD, Fost DA, Covar R, Martin RJ, Brown EE **Szefler SJ** Leung DYM. Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 2001, 87:501–505. PMID 11770698
110. **Szefler SJ**, Richard J. Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, Craig TJ, Dolovich M, Eng P, Drazen JM, Fagan JK, Fahy JV, Fish JE, Ford JG, Elliot Israel E, Kiley J, Kraft M, Lazarus SC, Lemanske RF, Mauger E., Peters SP, Sorkness CA, for the Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002, 109:410-418. PMID: 11897984
111. Leflein JG, **Szefler SJ**, Murphy KR, Fitzpatrick S, Cruz-Rivera M, Walton-Bowen K, Smith JA, Casty FE. Nebulized budesonide inhalation suspension compared to cromolyn sodium nebulizer solution in young children: results of a randomized outcomes trial. Pediatr. 2002, 109:866-872. PMID: 11986448
112. Martin RJ, **Szefler SJ**, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, Cherniak RM, Craig TJ, Drazen JM, Fagan JK, Fahy JV, Fish JE, Ford JG, Israel E, Kunselman SJ, Lazarus SC, Lemanski RF, Peters SP, and Sorkness CA for the Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002, 165:1377-1383. PMID: 12016099
113. Pedersen S, Warner J, Wahn U, Staab D, LeBourgeois M, VanEssen-Zadvliet E, Arora S, and **Szefler, SJ**. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics. 2002, 109:e92. PMID: 12042586
114. Wamboldt FS, Ho J, Milgrom H, Wamboldt MZ, Sanders B, **Szefler SJ**, and Bender BG. Prevalence and correlates of household exposures to tobacco smoke and pets in children with asthma. J Pediatrics. 2002 141:109-115. PMID 12091860
115. Strunk RC, Sternberg AL, Bacharier LB, **Szefler SJ** for the Childhood Asthma Management Program Research Group. Nocturnal awakening caused by asthma in children with mild-to-moderate asthma in the Childhood Asthma Management Program. J Allergy Clin Immunol, 2002, 110:395-403. PMID: 12209085
116. S**zefler SJ**, Warner JO, Staab D, Wahn U, Le Bourgeois M, van Essen-Zandvliet EEM, Arora S, Pedersen S on behalf of the Pediatric Study Group. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: a six-month, open-label, randomized trial. J Allergy Clin Immunol, 2002;110:45-50. PMID: 12110818
117. Wamboldt FS, Ho J, Milgrom H, Wamboldt MZ, Sanders B, **Szefler SJ**, Bender BG. Prevalence and correlates of household exposures to tobacco smoke and pets in children with asthma. J Allergy Clin Immunol, 2002;141:109-115. PMID: 12091860
118. Kelly HW, Strunk RC, Donithan M, Bloomberg GR, McWilliams BC, **Szefler SJ**. Growth and bone density in children with mild-moderate asthma: a cross sectional study in children entering the Childhood Asthma Management Program (CAMP), J Pediatrics, 2003;142:286-291. PMID: 12640377
119. Ruff ME, **Szefler SJ**, Meltzer EO, Berger WE. Erratum: ‘Efficacy and safety of extrafine beclomethasone dipropionate aerosol therapy in children with asthma: a 12-week placebo-controlled trial.’ Pediatric Asthma Allergy Immunol, 2003; 16:1-13. No PMID available.
120. Covar RA, **Szefler SJ**, Martin RJ, Sundstrom DA, Silkoff PE, Murphy J, Young DA, Spahn JD. Relations between exhaled nitric oxide and measures of disease activity among children with mild to moderate asthma. J. Pediatrics, 2003; 142:469-475. PMID: 12756375
121. Jenkins HA, Cool C, **Szefler S**, Covar R, Brugman S, Gelfand EW, and Spahn JD. Histopathology of severe childhood asthma: a case series. Chest, 2003; 124:32-41. PMID: 12853499
122. Kraft M, Martin RJ, Lazarus SC, Fahy JV, Boushey HA, Lemanske RF, **Szefler SJ**. on behalf of the NHLBI Asthma Clinical Research Network. Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids. Chest 2003;124:42-50. PMID: 12853500
123. Bender BG, Ellison MC, Gleason M, Murphy JR, Sundstrom DA, and **Szefler SJ**. Minimizing attrition in a long-term clinical trial of pediatric asthma. Ann Allergy Asthma Immunol 2003;91:168-176. PMID: 12952111
124. Leone FT, Fish JE, **Szefler SJ** and West SL. Systemic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma. Collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest, 2003;124:2329-2340. PMID: 14665517
125. Jenkins HA, Cherniack R, **Szefler SJ**, Covar R, Gelfand EW, and Spahn JD. A comparison of the clinical characteristics of children and adults with severe asthma. Chest, 2003;124:1318-1324. PMID: 14555561
126. Strunk RC, **Szefler SJ**, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, Hodgdon K, Morgan W, Sorkness CA, Lemanske RF for the Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 2003;112:883-892. PMID: 14610474
127. Guilbert TW, Morgan WJ, Krawiec M, Lemanske RF, Sorkness C, **Szefler SJ**, Larsen G, Spahn JD, Zeiger RS, Heldt G, Strunk RC, Bacharier LB, Bloomberg GR, Chinchilli VM, Boehmer SJ, Mauger EA, Mauger DT, Taussig LM, Martinez FD. The prevention of early asthma in kids study: design, rationale and methods for the Childhood Asthma Research and Education network. Controlled Clin Trials, 2004;25:286-310. PMID: 10027502
128. **Szefler SJ**, Lyzell E, Fitzpatrick S, Cruz-Rivera M. Safety profile of budesonide inhalation suspension in the pediatric population: worldwide experience. Ann Allergy Asthma Immunol 2004;93:83-90. PMID: 15281476
129. Covar RA, Spahn JD, Murphy JR, **Szefler SJ** for the Childhood Asthma Management Program Research Group. Progression of asthma measured by lung function in the Childhood Asthma Management Program. Am J Respir Crit Care Med, 2004:170:235-241. PMID: 15028558
130. Covar RA, Spahn JD, Martin RJ, Silkoff PE, Sundstrom DA, Murphy J, **Szefler SJ**. Safety and application of induced sputum analysis in childhood asthma. J Allergy Clin Immunol, 2004:114:575-582. PMID: 15356559
131. O’Connor SL, Bender BG, Gavin-Devitt LA, Wambolt MZ, Milgrom H, **Szefler SJ**, Rand C, Wamboldt FS. Measuring adherence with the Doser CT in children with asthma. J of Asthma, 2004;41:663-670. PMID 15584316
132. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniak R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF, Liggett SB, Martin RJ, Mitra N, Peters SP, Silverman E, Sorkness CA, **Szefler SJ**, Wechsler ME, Weiss ST, Drazaen JM for the National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet 2004;364:1505-1512. PMID: 15500895
133. Guilbert TW, Morgan WJ, Zeiger RS, Bacharier LB, Boehmer SJ, Krawiec M, Larsen G, Lemanske RF, Liu A, Mauger DT, Sorkness C, **Szefler SJ**, Strunk RC, Taussig LM and Martinez FD. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. J Allergy Clin Immunol 2004;114:1282-1287. PMID: 15577824
134. Colice GL, Stampone P, Leung DYM, **Szefler SJ**. Oral corticosteroids in poorly controlled asthma. J Allergy Clin Immunol, 2004; 115:200-201. PMID: 15637569
135. Busse WW, Cloutier M, Dombrowski M, Nelson HS, Reed M, Schatz M, Scialli AR, Stoloff S, **Szefler SJ**, Fulwood R, Kiley JP, Morosco GJ, Schmidt DK, Taggart VS, Wilson T, Bratten S, Louthian P, Boushey HA, Buist S, Clark NM, Kelly HW, Lemanske RF, Martinez FD, Shapiro G, Stoloff S (NHLBI Working Group). Quick Reference NAEPP Expert Panel Report. Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment – 2004 Update. J Allergy Clin Immunol 2005;115:34-46. PMID 15637545
136. **Szefler SJ**, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Zeiger RS, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Clin Allergy Immunol 2005, 115:233-242. PMID: 15696076
137. Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Boushey HA, Chinchilli VM, Craig TJ, Dimango E, Kraft M, Leone F, Lemanske RF, Martin RJ, Pesola GR, Peters SP, Sorkness CA, **Szefler SJ**, Israel E for the NHLBI Asthma Clinical Research Network. Sputum eosinophils predict asthma control following discontinuation of inhaled corticosteroids. J Allergy Clin Immunol, 2005; 115:720-727. PMID: 15805990
138. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, Chinchilli VM, Craig TJ, Dimango EA, Deykin A, Fagan JK, Fish JE, Ford JG, Kraft M, Lemanske RF, Leone FT, Martin RJ, Mauger EA, Pesola GR, Peters SP, Rollings NJ, **Szefler SJ**, Wechsler ME, Israel E, for the National Heart, Lung and Blood Institute’s Asthma Clinical Research Network. Daily vs. as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005; 352:1519-1528. PMID: 15829533
139. Covar RA, Cool C, **Szefler SJ**. Case Study: Progression of asthma in childhood. J Allergy Clin Immunol 2005, 115:700-707. PMID: 15805987
140. Whelan G, Blumer JL, Martin RJ, **Szefler SJ** on behalf of the Asthma Clinical Research network and the Pediatric Pharmacology Research Unit Network. Fluticasone propionate plasma concentration and systemic effect: Effect of delivery device and duration of administration. J Allergy Clin Immunol 2005, 116:525-530. PMID: 16159619
141. Chinchilli VM, Phillips BR, Mauger DT and **Szefler SJ** for the Childhood Asthma Research and Education (CARE) Network of the National Heart Lung and Blood Institute. A general class of correlation coefficients for the 2x2 crossover design. Biometrical Journal, 2005, 47:1-10. PMID: 16385905
142. **Szefler SJ**, Rohatagi S, Williams J, Lloyd M, Kundu S and Banerji D. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005, 128:1104-1114. PMID 16162694
143. Zeiger RS, **Szefler SJ**, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Larsen GL, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkenss CA, and Taussig LM for the Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Response profiles to fluticasone and montelukast in mild to moderate persistent childhood asthma. J Allergy Clin Immunol, 2006; 117:45-52. PMID: 16287583
144. Wechsler ME, Lehman E, Lazarus SC, Lemanske RF, Boushey HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ, DiMango E, Kraft M, Leone F, Martin RJ, Peters SP, **Szefler SJ**, Liu W, and Israel E for the National Heart, Lung and Blood Institute’s Asthma Clinical Research Network. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med, 2006; 173:519-526. PMID: 16322642 PMC2662935
145. Walsh MC, **Szefler SJ**, Davis J, Allen M, Van Marter L, Abman S, Blackmon L, Jobe A. The newborn drug development initiative workshop I: summary proceedings from the bronchopulmonary dysplasia group. Supplement to Pediatrics: Newborn Drug Development Initiative: Improving Neonatal Therapeutics. Pediatrics, 2006; 117:52-56. No PMID available.
146. Tantisira KG, Fuhlbrigge AL, Tonascia J, Van Natta M, Zeiger RS, Strunk RC, **Szefler SJ**, Weiss ST for the Childhood Asthma Management Program Research Group. Bronchodilation and bronchoconstriction: predictors on future lung function in childhood asthma. J Allergy Clin Immunol, 2006; 117:1264-1271. PMID: 16750985
147. Baumel MJ, DuBuske L, Szefler SJ, Rosenwasser L, Nash DB. National guidelines for a novel therapy: update on clinical trials and experience using consensus panel recommendations for incorporation omalizumab into asthma management. Pharmacy and Therapeutics 2006; 31:276-282. No PMID available.
148. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, **Szefler SJ**, Bacharier LB, Lemanske, RF Jr., Strunk RC, Allen DB, Bloomberg GR, Heldt G, Krawiec M, Larsen G, Liu AH, Chinchilli VM, Sorkness CA, Taussig LM, Martinez FD. Two Year Inhaled Corticosteroid Treatment on Subsequent Asthma in High-Risk Toddlers. N Engl J Med, 2006, 354:1985-1997. PMID: 16687711
149. Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, DiMango E, Fahy JV, Kraft M, Leone F, Lazarus SC, Lemanske RF, Martin RJ, Pesola GR, Peters SP, Sorkness CA, **Szefler SJ**, and Israel E for the National Heart, Lung and Blood Institute’s Asthma Clinical Research Network. Combination therapy with a long-acting β-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med 2006, 175:228-234. PMID 16973987 PMCID PMC1899264
150. Strunk RC, Weiss ST, Yates KP, Tonascia J, Zeiger RS and **Szefler SJ** for the CAMP group. Mild to moderate asthma affects lung growth in children and adolescents. J Allergy Clin Immunology, 2006; 118:1040-7. PMID: 17088127
151. Martin RJ, **Szefler SJ**, King TS, Kraft M, Boushey HA, Chinchilli VM, Craig TJ, DiMango EA, Deykin A, Fahy JV, Israel E, Lazarus SC, Lemanske RF, Leone FT, Pesola GR, Peters SP, Sorkness CA, Szwejbka LA and Wechsler ME for the National Heart, Lung and Blood Institute’s Asthma Clinical Research Center. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunology 2007;119:73-80. PMID: 17208587 PMCID: PMC2872157
152. Sorkness CA, Lemanske RF, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, Strunk RC, **Szefler SJ**, Zeiger RS, Bacharier LB, Bloomberg GR, Covar RA, Guilbert TW, Heldt G, Larsen GL, Mellon MH, Morgan WJ, Moss MH, Spahn JD and Taussig LM for the Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. J Allergy Clin Immunology 2007;119;64-72. PMID: 17140647
153. Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, DiMango E, Fahy JV, Kraft M, Leone F, Lazarus SC, Lemanske RF, Martin RJ, Pesola GR, Peters SP, Sorkness CA, **Szefler SJ**, and Israel E for the National Heart, Lung and Blood Institute’s Asthma Clinical Research Network. Combination therapy with a long-acting β-Agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med, 2007;175:228-234. PMID: 16973987 PMC1899264
154. Lazarus SC, Chinchilli VM., Rollings NJ, Boushey HA, Cherniack R, Craig TJ, Deykin A, DiMango E, Fish JE, Ford JG, Israel E, Kiley J, Kraft M, Lemanske RF, Leone F, Martin RJ, Pesola GR, Peters SP, Sorkness CA, **Szefler SJ**, Wechsler ME, Fahy JV for the National Heart Lung and Blood Institute’s Asthma Clinical Research Network. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med, 2007; 175:783-790. PMID: 17204725 PMC 1899291
155. Chipps BE, **Szefler SJ**, Simons ER, Haselkorn T, Minks RF, Deniz Y, Lee JH for the TENOR Study Group. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunology 2007; 119:1156-1163. PMID: 17397912
156. Bisgaard H and **Szefler SJ**. Prevalence of Asthma-Like Symptoms in Young Children. Pediatric Pulmonology, 2007;42:723-728. PMID 17598172
157. **Szefler SJ**, Baker JW, Uryniak T, Goldman M, Silkoff PE. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol 2007;120:1043-50. PMID: 17983871
158. Wamboldt FS, Balkissoon RC, Rankin AE, **Szefler SJ**, Hammond SK, Glasgow RE, Dickinson WP. Correlates of household smoking bans in low income families of children with and without asthma. Fam Proc 2008; 47:81-94. PMID:18411831
159. Neville KA, **Szefler SJ**, Abdel-Rahman SM, Lahu G, Zech K, Herzog R, Bethke TD, Gleason M. and Kearns GL. Single-Dose Pharmacokinetics of Roflumilast in Children and Adolescents. J Clin Pharm 2008;48:978-985. PMID: 18508947
160. Sykes A, Seemungal T, Sears M, Manino D, Bartlett NW, Walton RP, Martinez F, O’Donnell D, Nair P, Caramori G, **Szefler SJ**, Gauvrea G, O’Byrne P, Edwards MR, Taylor DR, Busse WW, Lazarus S, Rennard SI, Johnston SL. Review of the first International Congress on Exacerbations of Airway Disease (ICEAD): Acute exacerbations of asthma. Thorax, 2008; 63:758-60. No PMID available.
161. Seemungal T, Sykes A, Sears M, Manino D, Bartlett NW, Walton RP, Martinez F, O’Donnell D, Nair P, Caramori G, **Szefler SJ**, Gauvrea G, O’Byrne P, Edwards MR, Taylor DR, Busse WW, Lazarus S, Rennard SI, Johnston SL. Review of the first International Congress on Exacerbations of Airway Disease (ICEAD): Recent Advances in Exacerbations of COPD. Thorax, 2008; 63:850-2. No PMID available.
162. Taylor DR, Bateman E, Boulet L-P, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HAM, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stolof SW, **Szefler SJ**, Sullivan SD, Thomas MD, Wenzel SE and Reddel HK. A new perspective on concepts of asthma severity and control. Eur Respir J, 2008; 32:545-554. PMID: 18757695
163. **Szefler SJ**, Mitchell H, Sorkness CA, Gergen PJ, O’Connor GT, Morgan WJ, Katan M, Pongracic JA, Teach SJ, Bloomberg GR, Eggleston PA, Gruchalla RS, Kercsmar CM, Liu AH, Wildfire JJ, Curry MD, Busse WW. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomized controlled trial. Lancet 2008, 372:1065-1072. PMID: 18805335 PMCID PMC2610850.
164. Strunk RC, Bacharier LB, Phillips BR, **Szefler SJ**, Zeiger RS, Chinchilli VM, Martinez FD, Lemanske RF, Taussig LM, Mauger DT, Morgan WJ, Sorkness CA, Paul IM, Guilbert T, Krawiec M, Covar R, Larsen GL for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate to severe childhood asthma study. J Allergy Clin Immunology 2008;122:1138-1144. PMID:18951618 PMC2737448
165. Bacharier LB, Guilbert TW, Zeiger RS, Strunk RC, Morgan WJ, Lemanske RF, Moss M, **Szefler SJ**, Krawiec M, Boehmer S, Mauger D, Taussig LM, Martinez FD for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Episodic Use of an Inhaled Corticosteroid or Leukotriene Receptor Antagonist in Preschool Children with Moderate-to-Severe Intermittent Wheezing J Allergy Clin Immunology 2008;122:1127-1135. PMID: 18973936 PMC2753208 NIHMS124337
166. Sharma S, Litonjuo AA. Tantisara KG, Fuhlbrigge AL, **Szefler SJ**, Strunk RC, Zeiger RS, Murphy AJ, Weiss ST and the Childhood Asthma research Program Research Group. Clinical predictors and outcomes of consistent bronchodilator response in the Childhood Asthma Management Program. J Allergy Clin Immunol 2008;122:921-928. PMID: 18848350 PMC2947830 NIHMS232435
167. Covar RA, **Szefler SJ**, Zeiger RS, Sorkness CA, Moss M, Mauger DT, Boehmer SJ, Strunk, RC, Martinez FD, Taussig LM for the Childhood Asthma Research and Education Network. Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children. J Allergy Clin Immunol 2008; 122:741-747. PMID: 19014765. PMC3024439 NIHMS: 124336
168. Walter MJ, Castro M, Kunselman SJ, Chinchilli VM, Reno M, Ramkumar TP, Avila PC, Boushey HA, Ameredes BT, Bleecker ER, Calhoun WJ, Cherniack RM, Craig TJ, Denlinger LC,, Israel E, Fahy JV, Jarjour NN, Kraft M< Lazarus SC, Lemanske RF, Martin RJ, Peters SP, Ramsdell JW, Sorkness CA, Sutherland ER, **Szefler SJ**, Wasserman SI, Wechsler ME and the National Heart, Lung and Blood Institute’s Asthma Clinical Research Network. Predicting worsening asthma control following the common cold. Eur Respir J 2008; 32:1548-1554. PMID 18768579 PMCID PMC2592508
169. Knuffman JE, Sorkness CA, Lemanske RF, Mauger DT, Boehmer SJ, Martinez FD, Bacharier LB, Strunk RC, **Szefler SJ**, Zeiger RS, Taussig LM for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. J Allergy Clin Immunology 2009; 123:411-6. PMID: 19121860 PMC2662352 NIHMS95195
170. Strunk RC, Sternberg AL, **Szefler SJ**, Zeiger RS, Bender BG, Tonascia J on behalf of the Childhood Asthma Management Program (CAMP) Research Group. Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J Pediatr 2009; 154:682-687. PMID: 19167726. PMCID: PMC2942076
171. Reddel HK, Taylor DR, Bateman ED, Boulet L-P, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HAM, Lazarus SC, Levy ML, O’Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, **Szefler SJ**, Thomas MD, Wenzel SE on behalf of the American Thoracic Society/European Respiratory Society Task Force on Asthma. Asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180:59-99. PMID:19535666
172. Larsen GL, Morgan W, Heldt GP, Mauger DT, Boehmer SJ, Chinchilli VM, Lemanske RF, Martinez F, Strunk RC, Szefler SJ, Zeiger RS, Taussig LM, Bacharier LB, Guilbert TW, Redford S, Sorkness CA for the Childhood Asthma Research and education Network of the National Heart, Lung and Blood Institute. Impulse oscillometry versus spirometery in a long-term study of controller therapy for pediatric asthma. J Allergy Clin Immunol, 2009; 123:861-7. PMID: 19070356 PMCID: PMC4291457
173. Bacharier LB, Guilbert TW, Zeiger RS, Strunk RC, Morgan WJ, Lemanske RF, Moss M, **Szefler SJ**, Krawiec M, Boehmer S, Mauger D, Taussig LM, Martinez FD for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma. J Allergy Clin Immunol, 2009, 123:1077-82. PMID: 19230959 PMCID PMC2909590
174. Rogers AJ, Tantisira KG, Fuhlbrigge AL, Litonjua AA, Lasky-Su JA, **Szefler SJ**, Strunk R, Zeiger RS, and Weiss ST for the Childhood Asthma Management Program (CAMP) Research Group. Predictors of poor response during asthma therapy differ with definition of outcome. Pharmacogenomics, 2009:10:1231-1242. PMID: 19663668 PMCID PMC2746392
175. Long AA, Fish JE, Rahmaoui A, Miller MK, Bradley MS, Taki HN, Demeo AN, Tilles SA, **Szefler SJ.** Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma & Immunol, 2009;103:212-219. PMID: 19788018
176. Gruchalla RS, Sampson HA, Matsui E, David G, Gergen PJ, Calatroni A, Brown M, Liu AH, Bloomberg GR, Chmiel JF, Kumar R, Lamm C, Smartt E, Sorkness CA, Steinbach SF, Stone KD, **Szefler SJ**, and Busse WW. Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: role of predictors in the setting of high adherence. J Allergy Clin Immunology, 2009 124:213-221. PMID: 19615730 PMC2757267 NIHMS133047
177. Kruzick T, Covar RA, Gleason M, Cicutto L, White M, Shocks D, **Szefler SJ**. Does access to care equal asthma control in school-age children? J Allergy Clin Immunol, 2009;124:381-383. PMID: 19596141
178. Haselkorn T, Fish JE, Zeiger RS, Szefler SJ, Miller DP, Chipps BE, Simons ER, Weiss ST, Wenzel SE, Borish L, Bleecker ER for the TENOR Study Group. Consistently very poorly controlled asthma by the impairment domain of the EPR-3 guidelines increases risk for future severe asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatments regimens study. J Allergy Clin Immunol, 2009;124:895-902. PMID: 19811812
179. Haselkorn T, Zeiger RS, Chipps BE, Mink DR, **Szefler SJ**, Simons FER, Massanari M, Fish JE. Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma. J Allergy Clin Immunology 2009;124:921-927. PMID:19895984
180. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L, Fahy JV, Jarjour N, Kazani S, Kim S, Kraft M, Lazarus SC, Lemanske RF, Markezich A, Martin RJ, Permaul P, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, **Szefler SJ**, Walter MJ, Wasserman S, Israel E for the National Heart, Lung and Blood Institute’s Asthma Clinical Research Network. Effect of β2-adrenergic receptor polymorphism on response to long acting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomized, placebo-controlled, crossover trial. Lancet 2009;374:1754-64. PMID:19932356 PMCID: PMC2914569.
181. Kattan M, Kumar R, Bloomberg GR, Mitchell HE, Calatroni A, Gergen PJ, Kercsmar CM, Visness CM, Matsui EC, Steinbach SF, **Szefler SJ**, Sorkness CA, Morgan WJ, Teach SJ, Gan VN. Asthma control, adiposity and adipokines among inner city adolescents. J Allergy Clin Immunol, 2010;125:584-92. PMID 20226295 PMCID PMC3596816
182. Lemanske R, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, **Szefler SJ**, Zeiger RS, Bacharier LB, Covar RA, Guilbert TW, Larsen G, Mellon MH Morgan WJ, Moss MH, Spahn JD, Taussig LM for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Step-up therapy for children with uncontrolled asthma while receiving inhaled corticosteroids. N Engl J Med 2010;362:975-985. PMID: 20197425. PMCID PMC2989902J
183. Haselkorn T, **Szefler SJ**, Simons ER, Zeiger RS, Mink DR, Chipps BE, Borish L, Wong DA for the TENOR Study Group. Allergy, total serum IgE and airflow in children and adolescents in TENOR. Pediatric Allergy and Immunology 2010;21:1157-1165. PMID 20444153
184. Covar R, Gleason M, Macomber B, Stewart L, Szefler P, Engelhardt K, Murphy J, Liu A, Wood S, DeMichele S, Gelfand EW, **Szefler SJ**. Impact of a Novel Nutritional Formula on Asthma Control and Biomarkers of Allergic Airway Inflammation in Children. Clin Experimental Allergy 2010, 40:1163-1174. PMID 20545703
185. Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E, Boushey HA, Calhoun WJ, Castro M, Cherniack RM, Chinchilli VM, Craig TJ, Denlinger L, DiMango EA, Fahy JV, Israel E, Jarjour N, Kraft M, Lazarus SC, Lemanske RB, Peters SP, Ransdell J, Smith RA, Sorkness CA, **Szefler SJ**, Walter MJ, Wasserman SI, Wechsler ME, Chu HW, Martin RJ for the National Heart, Lung and Blood Institute’s Asthma Clinical Research Network. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immnol 2010, 126:747-53. PMID 20920764 PMCID PMC2950827
186. Simon MR, Chinchilli VM, Phillips BR, Sorkness CA, Lemanske RF, **Szefler SJ**, Taussig L, Bacharier LB, Morgan W for the Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung and Blood Institute. Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children. J Allergy Clin Immunology 2010; 126:527-34. PMID 20638110 PMCID PMC2933964
187. Rabinovitch N, Graber NJ, Chinchilli VM, Sorkness CA, Zeiger RS, Strunk RC, Bacharier LB, Martinez FD, Szefler SJ for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. J Allergy Clin Immunol 2010;126:545-551.e1-4. PMID 20816189 PMCID PMC2935914
188. Covar RA, Strunk R, Zeiger RS, Wilson L, Liu AH, Weiss S, Tonascia J, Spahn JD, **Szefler SJ** for the Childhood Asthma Management Program Research Group. Predictors of remitting, periodic and persistent childhood asthma. J Allergy Clin Immunology 2010, 125:359-66 e3. PMID: 20159245 PMCID: PMC2844768
189. Murphy A, Chu JH, Zu M, Carey VJ, Lazarus R, Liu A, **Szefler SJ**, Strunk R, DeMuth K, Castro M, Hansel NN, Diette GB, Vonakis BM, Adkinson NF, Klanderman BJ, Senter-Sylvia J, Ziniti J, Lange C, Pastinen T, Raby BA. Mapping of numerous disease-associated expression polymorphisms in primary peripheral blood CD4+ lymphocytes. Hum Mol Genet 2010; 19:4745-4757. PMID 20833654 PMCID: PMC2972694.
190. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Ameredes WT, Boushey HA, Calhoun WJ, Castro M, Cherniack M, Denlinger L, Engle LL, DiMango EA, Fahy JV, Israel E, Jarjour N, Kraft MC, Lazarus SC, Lemanske RF, Martin RJ, Meyers DA, Ramsdell J, Sorkness CA, Sutherland ER, **Szefler SJ**, Wasserman SI, Wechsler ME, Chinchilli VM, Bleecker ER for the National Heart, Lung and Blood Institute’s Asthma Clinical Research Network. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010, 363:1715-26. PMID 20979471 PMCID PMC3011177.
191. Wang L, Hollenbeak C, Mauger D, Zeiger RS, Paul I, Sorkness CA, Lemanske RF, Martinez FD, Strunk RC, **Szefler SJ**, Taussig LM for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Cost-effectiveness analysis of fluticasone vs. montelukast in children with mild moderate persistent asthma in the pediatric asthma controller trial (PACT). J Allergy Cin Immunol, 2011; 127:161-6. PMID 21211651 PMC3061816 NIHMS258088
192. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF, Mauger DT, Strunk RC, **Szefler SJ**, Zeiger RS, Bacharier LB, Bade E, Covar RA, Freidman NJ, Guilbert TW, Heidarian-Raissy H, Kelly HW, Malka-Raise J, Mellon MH, Sorkness CA, Taussig L. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomized, double-blind, placebo-controlled trial. Lancet 2011; 377:650-657. PMID 21324520
193. Busse WW, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, Chmiel JF, Steinbach SF, Calatroni A, Togias A, Thompson KM, **Szefler SJ**, Sorkness CA. An omalizumab (anti-IgE) randomized trial for asthma in inner-city children. N Engl J Med 2011; 364:1005-1015. PMID 21410369 PMC3093964
194. Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, Lange C, Lazarus R, Sylvia J, Klanderman B, Duan QL, Qiu W, Hirota T, Martinez F, Mauger D, Sorkness C, **Szefler SJ**, Lazarus SC, Lemanske RF, Peters SP, Lima JJ, Nakamura Y, Tamari M, Weiss, ST. Genome-wide association of GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011;365:1173-1183. PMID 21991891 PMC3667396
195. **Szefler SJ**, Zeiger RS, Haselkorn T, Mink DR, Kamath TV, Fish JE, Chipps BD. Economic burden of impairment in children with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2011;107:110-119. PMID 21802018
196. Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF, Strunk RC, Covar R, **Szefler SJ**, Boehmer S, Jackson DJ, Sorkness CA, Gern JE, Kelly HW, Friedman NJ, Mellon MH, Schatz M, Morgan WJ, Chinchilli VM, Raissy HH, Bade E, Malka-Rais J, Beigelman A, Taussig LM for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011;365:1990-2001. PMID 22111718 PMC3247621
197. Wu R, Tong C, Wang Z, Mauger D, Tantisira K, **Szefler SJ**, Chinchilli VM, Israel E. A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics. Drug Discovery Today, 2011;16:884-890. PMID 21920452 NIHMS328022 PMC4029408
198. Krishnan JA, Bender BG, Wamboldt FS, **Szefler SJ**, Adkinson NF Jr, Zeiger RS, Wise RA, Bilderback AL, Rand CS; Adherence Ancillary Study Group. Adherence to inhaled corticosteroids: An ancillary study of the Childhood Asthma Management Program clinical trial. J Allergy Clin Immunol 2012;129:112-8. PMID: 22104610 PMC3350797 NIHMS335791
199. Guilbert TW, Mauger DT, Allen DB, Zeiger RS, Lemanske RF, **Szefler SJ**, Strunk RC, Bacharier LB, Covar R, Sorkness CA, Taussig LM, Martinez FD for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Growth of preschool children at high risk for asthma two years after discontinuation of fluticasone. J Allergy Clin Immunol, 2011;128:956-63 e7. PMID 21820163 PMC3224818
200. Sharma S, Murphy A, Howrylak J, Himes B, Cho M, Chu JH, Hunninghake G, Fuhlbrigge A, Klandermann B, Ziniti J, Senter-Sylvia J, Liu A, **Szefler SJ**, Strunk R, Castro M, Hansel NN, Diette GB, Vonakis BM, Adkinson NF, Carey VJ, Raby BA. The impact of race in epidemiologic studies of gene expression. Genetic Epidemiology 2011;35:93-101. PMID 21254216 PMC3718033
201. Wildfire JJ, Gergen PJ, Sorkness CA, Mitchell HE, Calatroni A, Kattan M, **Szefler SJ**, Teach SJ, Bloomberg GR, Wood RA, Liu AH, Pongracic JA, Chmiel JF, Conroy K, Rivera-Sanchez Y, Morgan WJ, Busse WW. Development and validation of the composite asthma severity index – an outcome measure for use in children and adolescents. J Allergy Clin Immunol, 2012;129:694-701. PMID 22244599 PMC3294274
202. Zeiger RS, Yegin A, Simons FER, Haselkorn T, Rasouliyan L, **Szefler SJ**, Chipps BE for the TENOR Study Group. Evaluation of the National Heart, Lung and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations. Ann Allergy Asthma Immunol 2012;108:81-87. PMID 22289725
203. **Szefler SJ,** Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, Hunt JF, Kita H, Liu AH, Penettieri RA, Schleimer RP, Minnicozzi M. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012;129;S9-23. PMID 22386512 PMC3390196 NIHMS387444
204. Tantisira KG, Damask A, **Szefler SJ**, Schuemann B, Markezich A, Su J, Klanderman B, Sylvia J, Wu R, Martinez F, Boushey HA, Chinchilli VM, Mauger D, Weiss ST, Israel E for the SHARP Investigators. Genome-wide association identifies the T Gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med 2012;185:1286-1291. PMID 22538805 PMC3381232
205. Chipps BE. Zeiger RS, Borish L, Wenzel SE, Yegin A, Hayden ML, Miller DP, Bleecker ER, Simons FER, **Szefler SJ**, Weiss ST, Hasselkorn T. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 2012, 130:332-42. PMID 22694932 PMC3622643
206. Himes BE, Jiang X, Hu R, Chen Wu A, Lasky-Su JA, Klanderman BJ, … **Szefler SJ** co-author, et al. Genome-wide association analysis in asthma subjects identifies SPATS2L as a novel bronchodilator response gene. PLoS Genetics, 2012;8:e1002824-34. PMID 22792082 PMC3390407
207. Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleeker ER, Castro M, Cherniack RM, Chinchilli VM, Craig T, Denlinger L, DiMango EA, Engle LL, Fahy JV, Grant JA, Israel E, Jarjour N, Kazani SD, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF, Lugogo N, Martin RJ, Meyers DA, Moore WC, Pascual R, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, **Szefler SJ**, Wasserman SI, Walter MJ, Wechsler ME, Boushey HA. Comparison of Physician-Based, Biomarker-Based, and Symptom-Based Strategies for Adjustment of Inhaled Corticosteroid Therapy in Adults with Asthma: The Basalt Randomized Trial. JAMA, 2012;308:987-997. PMID 22968888 PMC3697088
208. Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gern J, Lemanske R …. (**Szefler SJ** co-author) et al. International consensus on (ICON) pediatric asthma. Allergy, 2012;67:976-97. PMID22702533 PMC4442800
209. Chipps BE, Zeiger RS, Dorenbaum A, Borish L, Wenzel SE, Miller DP, Hayden ML, Bleecker ER, Simons ER, **Szefler SJ**, Weiss ST, Haselkorn T for the TENOR Study Group. Assessment of asthma control and asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) Observational Cohort. Current Resp Care Reports 2012;1:259-69. PMID 23136642 PMC3485530
210. **Szefler SJ**, Carlsson LG, Uryniak T, Baker JW. Budesonide inhalation suspension versus montelukast in children aged 2 to 4 years with mild to persistent asthma. J Allergy Clin Immunol: In Practice 2013;1:58-64. PMID 24229823
211. Denlinger LC, Manthei DM, Seibold MA, Ahn K, Bleecker E, Boushey HA, Calhoun WJ, Castro M, Chinchilli VM, Fahy JV, Hawkins GA, Icitovic N, Israel E, Jarjour NN, King T, Kraft M, Lazarus SC, Lehman E, Martin RJ, Meyers DA, Peters SP, Sheerar D, Shi L, Sutherland ER, **Szefler SJ**, Wechsler ME, Sorkness CA, Lemanske RF and the NHLBI Asthma Clinical Research Network Investigators. P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy. Am J Respir Crit Care Med 2013;187:28-33. PMID 23144325 PMC3570642
212. Himes BE, Sheppard K, Berndt A, Leme AS, Myers RA, Gignoux CR, Levin AM, Gauderman WJ, Yang JJ, Mathias RA, Romieu I, Torgerson DG, Roth LA, Huntsman S, Eng C, Klanderman B, Ziniti J, Senter-Sylvia J, **Szefler SJ**, Lemanske RF, Zeiger RS, Strunk RC, Martinez FD, Boushey H, Chinchilli VM, Israel E, Mauger D, Koppelman GH, Postma DS, Nieuwenhuis MAE, Vonk JM, Lima JJ, Irvin CG, Peters SP, Kubo M, Tamari M, Nakamura Y, Litonjua AA, Tantisira KG, Raby BA, Bleecker ER, Meyers DA, London SJ, Barnes KC, Gilliland FD, Williams LK, Burchard EG, Nicolae DL, Ober C, DeMeo DL, Silverman EK, Paigen B, Churchill G, Shapiro SD, Weiss ST. Integration of mouse and human genome-wide association data identifies KCNIP4 as an asthma gene. PLOS Onem 2013;8:e56179. PMID 23457522 PMC3572953
213. Sorkness CA, Wildfire JJ, Gergen PJ, Calatroni A, Mitchell HE, Busse WW, O’Connor GT, Pongracic JA, Ross K, Gill M, Kattan M, Morgan WJ, Teach SJ, Liu AH, **Szefler SJ**. Reassessment of omalzumab dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol: In Practice 2013;163-71. PMID 24565455 PMC4254887
214. **Szefler SJ**. Budesonide inhalation suspension versus montelukast in children aged 2-4 years with mild persistent asthma. J Allergy Clin Immunol in Practice 2013;1:58-64. PMID 24229823.
215. Li X, Hawkins GA, Ampleford EJ, Moore WC, Li H, Hastie AT, Howard TD, Boushey HA, Busse WW, Calhoun WJ, Castro M, Erzurum SC, Israel E, Lemanske RF, **Szefler SJ**, Wasserman SI, Wenzel SE, Peters SP, Meyers DA, Bleecker ER. Genome-wide association study identifies Th1 pathway genes associated with lung function in asthma. J Allergy Clin Immunol 2013:132:313-20. PMID 23541324 PMC3746327
216. Himes BE, Qiu W, Klanderman B, Ziniti J, Senter-Sylvia J, **Szefler SJ**, Lemanske RF, Zeiger RS, Strunk RC, Martinez FD, Boushey H, Chinchilli VM, Israel E Mauger D, Koppelman GH, Nieuwenhuis MAE, Postma DS, Vonk JM, Rafaels N, Hansel NN, Barnes K, Raby B, Tantisira KG, Weiss ST. *ITGB5* and *AGFG1* Variants are Associated with Airway Responsiveness in Asthma Subjects. BMC Med Genet 2013;14:86-96. PMID 23984888 PMC3765944
217. Tamesis GP, Covar RA, Strand M, Liu AH, **Szefler SJ**, Klinnert MD. Predictors for asthma at age 7 years for low-income children enrolled in the Childhood Asthma Prevention Study. J Pediatr 2013;162:536-42. PMID 23036483 PMC3582795
218. Peters SP, Bleecker ER, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, Boushey HA, Calhoun WJ, Castro M, Cherniack RM, Craig T, Denlinger LC, Engle LL, DiMango EA, Israel E, Kraft M, Lazarus SC, Lemanske RF, Lugogo N, Martin RJ, Meyers DA, Ramsdell J, Sorkness CA, Sutherland ER, Wasserman SI, Walter MJ, Wechsler ME, Chinchilli VM, and **Szefler SJ** for the National Heart, Lung and Blood Institute’s Asthma Clinical Research Network. Predictors of response to tiotropium versus salmeterol in asthmatic adults. J Allergy Clin Immunol 2013;132:1068-74. PMID 24084072 PMC3826080
219. Szefler SJ, Chmiel JF, Fitzpatrick AM, Giacoia G, Green TP, Jackson DJ, Nielsen HC, Phipatanakul W, Raissy HH. Asthma across the ages: Knowledge gaps in childhood asthma. J Allergy Clin Immunol 2014;133:3-13 PMID 24290281 PMC3925634
220. Rabinovitch N, Mauger DT, Reisdorph N, Covar R, Malka J, Lemanske RF, Guilbert TW, Zeiger RS, Bachiar LB, Szefler SJ. Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma. J Allergy Clin Immunol 2014;133:350-6. PMID 24084071 PMC3960329
221. Chang TS, Lemanske RF, Mauger D, Fitzpatrick A, Sorkness CA, **Szefler SJ**, Gangnon RE, Page CD, Jackson DJ on behalf of the Childhood Asthma Research and Education (CARE) Network Investigators. Childhood asthma clusters and response to therapy in clinical trials. J Allergy Clin Immunol 2014;133:363-9. PMID 24139497 PMC3960405
222. Park HW, Dahlin A, Tse S, Duan QL, Schuemann B, Martinez FD, Peters SP, **Szefler SJ**, Lima JJ, Kubo M, Tamari M, Tantisira KG. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J Allergy Clin Immunol 2014;133-664-9. PMID 24486069 PMC4112383
223. Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, Iribarren C, Chenn H, Carrigan G, Rosen K, **Szefler SJ**. Incidence of malignancy in omalizumab-treated and non-omalizumab-treated patients with moderate-to-severe asthma. J Allergy Clin Immunol 2014;134:560-567. PMID 24679845
224. Meltzer LJ, Ullrich M, **Szefler SJ**. Sleep duration, sleep hygiene and insomnia in adolescents with asthma. J Allergy Clin Immunol In Practice 2014;2:562-9. PMID:25213049 PMC4163200
225. Beigelman A, Zeiger RS, Mauger D, Strunk RC, Jackson DJ, Martinez FD, Morgan WJ, Covar R, **Szefler SJ**, Taussig LM, Bacharier LB for the Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung and Blood Institute. The association between vitamin D status and the rate of exacerbations requiring oral corticosteroids in preschool children with recurrent wheezing. J Allergy Clin Immunol 2014; 133:1489-92e3. PMID24698320 PMC4086617
226. Malka J, Mauger DT, Covar R, Rabinovitch N, Lemanske RF, Spahn JD, Strunk RC, Zeiger RS, Morgan WJ, **Szefler SJ**. Eczema and race as combined determinants for differential response to step-up asthma therapy. J Allergy Clin Immunol 2014; 134:483-5. PMID24835502 PMC4119870.
227. Yang I, Pedersen B, Liu A, O’Connor G, Teach S, Kattan M, Misiak R, Gruchalla R, Steinbach S, **Szefler SJ**, Gill M, Calatroni A, David G, Hennessy C, Davidson E, von Mutius E, Ege M, Genuneit E, Braun-Fahrlander C, Shabalin A, Gergen P, Togias A, Busse W, Schwartz D. DNA methylation changes and childhood asthma in the inner city. J Allergy Clin Immunol 2015;136:69-80. PMID:25769910 PMC4494877
228. Gerald JK, Gerald LB, Vasquez MM, Morgan WJ, Boehmer SJ, Lemanske RF, Mauger DT, Strunk RC, **Szefler SJ**, Zeiger RS, Bacharier LB, Bade E, Covar RA, Guilbert TW, Heidarian-Raissy H, Kelly HW, Malka-Rais J, Sorkness CA, Taussig L, Chinchilli VM, Martinez FD. Markers of differential response to inhaled corticosteroid treatment among children with mild persistent asthma. J Allergy Clin Immunol: In Practice 2015;3:540-546. PMID:25783161 PMC4500671
229. Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Li CL, Hamelmann E, Engle M, **Szefler SJ**. A randomized dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids. Respiratory Research 2015; 16:20. PMID:25851298 PMC4331449
230. Teach SJ, Gergen PJ, **Szefler SJ**, Mitchell HE, Calatroni A, Wildfire J, Bloomberg G, Kercsmar C, Liu A, Makhija M, Matsui E, Morgan W, O’Connor G, Busse WW. Seasonal risk factors for asthma exacerbations among inner city children. J Allergy Clinical Immunol 2015;135:1465-73. PMID 25794658 PMC4461505
231. Israel E, Lasky-Su J, Markezich A, Damask A, **Szefler SJ**, Schuemann B, Klanderman B, Sylvia J, Kazani S, Wu R, Martinez F, Boushey HA, Chinchilli VM, Mauger D, Weiss ST, Tantisita KG for the SHARP investigators. Genome-wide association study of short acting β2-agonists: A novel genome wide significant locus on chromosome 2 near *ASB3.* Am J Respir Crit Care Med 2015;191:530-537. PMID 25562107 PMC4384768
232. Pijnenburg MW, Baraldi E, Brand PLP, Carlson KH, Eber E, Frischer T, Hedlin G, Kulkarni N, Lex C, Makela MJ, Mantzourani E, Moeller A, Pavord I, Piacentini G, Price D, Rottier BL, Saglani S, Sly PD, **Szefler SJ**, Tonia T, Turner S, Wooler E, Lodrup Carlsen KC. ERS Task Force Statement: Monitoring of asthma in children. Eur Respir J 2015;45:906-25. PMID: 25745042
233. Zemanick ET, Wagner BD, Robertson CE, Stevens MJ, **Szefler SJ**, Accurso FJ, Sagel SD, Harris JK. Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods. Ann Am Thorac Soc 2015;12:221-9. PMID: 25474078 PMC4342834
234. Wang Y, Tong C, Wang Z, Wang Z, Mauger D, Tantisira KG, Israel E, **Szefler SJ**, Chinchilli VM, Boushey HA, Lazarus SC, Lemanske RF, Wu R. Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma. Pharmacogenomics J 2015; 15:422-29. PMID 25601762
235. Meltzer LJ, Faino A, **Szefler SJ**, Strand M, Gelfand EW, Beebe DW. Experimentally manipulated sleep duration in adolescents with asthma: feasibility and preliminary findings. Pediatric Pulmonology 2015;50:1360-1367. PMID 25872769
236. Dunn RM, Lehman E, Chinchilli VM, Martin RJ, Boushey HA, Israel E, Kraft M, Lazarus SC, Lemanske RF, Lugogo NL, Peters SP, Sorkness CA, **Szefler SJ**, Wechsler ME on behalf of the NHLBI Asthma Clinical Research Network. Impact of age and gender on response to asthma therapy. Am J Respir Crit Care Med 2015;192:551-558. PMID 26068329 PMC 4595693
237. Hamelmann E, Bateman ED, Vogelberg C, **Szefler SJ**, Vandewalker M, Moroni-Zentgraf P, Avis M, Unseld A, Engel M, Boner AL. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J Allergy Clin Immunol 2016;138:441-50. PMID 26960245
238. Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, Jackson DJ, Baxi SN, Benson M, Burnham CAD, Cabana M, Castro M, Chmiel JF, Covar R, Daines M, Gaffin JM, Gentile DA, Holguin F, Israel E, Kelly W, Lazarus SC, Lemanske RF, Ly N, Meade K, Morgan W, Moy J, Olin T, Peters SP, Phipatanakul W, Pongracic JA, Raissy HH, Ross K, Sheehan WJ, Sorkness C, **Szefler SJ**, Teague WG, Thyne S, Martinez FD for the National Heart, Lung and Blood Institute’s AsthmaNet. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA 2015;314:2034-2044. PMID 26575060 PMC4757487
239. Reddel H, Bateman E, Becker A, Boulet LP, Cruz A, Drazen J, Haahtela T, Hurd S, Inoue H, deJongste J, Lemanske R, Levy M, O’Byrne P, Paggiaro P, Pedersen S, Pizzichini E, Soto-Quiros M, **Szefler SJ**, Wong G, Fitzgerald M. A summary of the new GINA strategy: a roadmad to asthma control. Eur Respir J 2015;46:622-39. PMID 26206872 PMC4554554
240. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ, Calatroni A, Wildfire JJ, Gergen PJ, Cohen RT, Pongracic JA, Kercsmar CM, Hershey GK, Gruchalla RS, Liu AH, Zoratti EM, Kattan M, Grindle KA, Gern JE, Busse WW, **Szefler SJ**. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015; 136:1476-85. PMID 26518090 PMC4679705
241. Bender BG, Krishnan JA, Chambers DA, Cloutier MM, Riekert KA, Rand CS, Schatz M, Thomson CC, Wilson SR, Apter A, Carson SS, Geroge M, Gerald JK, Gerald LB, Goss CH, Okelo SO, Mularski RA, Nguyen HQ, Patal MR, **Szefler SJ**, Weiss C, Wilsn KC, Freemer MM. American Thoracic Society – National Heart, Lung and Blood Institute Implementation Research Workshop Report. Ann Am Thorac Soc 2015l12:S213-21. PMID 26653201
242. **Szefler SJ**. Examining causes of the urban (inner city) asthma epidemic: implementing new management strategies. Allergy Asthma Proc 2016;37:4-8. PMID 26831839
243. Cicutto L, Shocks D, Gleason M, Haas-Howard C, White M, **Szefler SJ**. Creating district readiness for implementing evidence-based school-centered asthma programs: Denver Public Schools as a case study. NASN School Nurse 2016;31:112-8. PMID 26822131
244. McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, Wise RA, **Szefler SJ**, Sharma S, Kho AT, Cho MH, Croteau-Chonka DC, Castaldi PJ, Jain G, Sanyal A, Zhan Y, Lajoie BR, Dekker J, Stamatoyannopoulos J, Covar RA, Zeiger RS, Adkinson NF, Williams PV, Kelly HW, Grasemann H, Vonk JM, Koppelman GH, Postma DS, Raby BA, Houston I, Lu Q, Fuhlbrigge AL, Tantisira KG, Silverman EK, Tonascia J, Weiss ST, and Strunk RC for the CAMP Research Group. Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med 2016;374:1842-52. PMID 27168434
245. Liu AH, Anderson III WC, Dutmr CM, Searing DA, **Szefler SJ**. Advances in asthma 2015: across the lifespan. J Allergy Clin Immunol 2016;138:397-404.
246. Hamelmann E, Bateman ED, Vogelberg C, **Szefler SJ**, Vandewalker M, Moroni-Zentgraf P, Avis M, Unseld A, Engel M, Boner AL. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J Allergy Clin Immunol 2016;138:441-50. PMID 26960245
247. Lemanske RF, Kakumanu S, Shanovich K, Antos N, Cloutier MM, Mazyck D, Phipatanakul W, Schantz S, Szefler SJ, Vandlik R, Williams P. Creation and implementation of SAMPRO™: a school-based asthma management program. J Allergy Clin Immunol 2016;138;711-23. PMID 27596707
248. Liptzin DR, Gleason MC, Cicutto LC, Cleveland CL, Shocks DJ, White MK, Faino AV, **Szefler SJ**. Developing, implementing, and evaluating a school-centered asthma program: Step Up Asthma Program. J Allergy Clin Immunol: In Practice 2016;4:972-9. PMID 27283054
249. Sheehan WJ, Mauger DT, Paul IM, Moy JN, Boehmer SJ, **Szefler SJ**, Fitzzpatrick AM, Jackson DJ, Bacharier LB, Cabana MD, Covar R, Holguin F, Lemanske RF, Martinez FD, Pongracic JA, Beigelman A, Baxi SN, Benson M, Blake K, Chmiel JF, Daines CL, Daines MO, Gaffin JM, Gentile DA, Gower WA, Israel E, Vardhan Kumar H, Lang JE, Lazarus SC, Lima JJ, Ly N, Marbin J, Morgan WJ, Myers R, Olin JT, Peters SP, Raissy HH, Robison RG, Ross K, Sorkness CA, Thyne SM, Wechsler ME, Phipatanakul W for the NIH/NHLBI AsthmaNet. Acetaminophen versus ibuprofen in young children with mild persistent asthma. N Engl J Med 2016;375:619-30. PMID:27532828
250. Stempel DA, **Szefler SJ**, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, Mitchell H, Kral KM, Raphiou IH, Prillaman BA, Buaron KS, Yun Kirby S, Pascoe SJ for the VESTRI Investigators. Safety of adding salmeterol to fluticasone propionate in asthmatic children. N Engl J Med 2016;375:840-9. PMID: 27579634
251. McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, VanNatta ML, Wise RA, **Szefler SJ**, Sharma S, Kho AT, Cho MH, Croteau-Chonka DC, Castaldi PJ, Jain G, Sanyal A, Zhan Y, Lajoie BR, Dekker J, Stamatoyannopoulos J, Covar RA, Zeiger RS, Adkinson NF, Williams PV, Kelly HW, Grasemann H, Vonk JM, Koppelman GH, Postma DS, Raby BA, Houston I, Lu Q, Fuhlbrigge AL, Tantisira KG, Silverman EK, Tonascia J, Weiss ST, Strunk RC for the CAMP Research Group. Genetics and genomics of longitudinal lung function patterns in individuals with asthma. Am J Resp Crit Care Med 2016:194:1465-1474. PMID: 27367781
252. Fitzpatrick AM, Jackson DJ, Mauger DT, Boehmer SJ, Phipatanakul W, Sheehand WJ, Moy JN, Paul IM, Bacharier LB, Cabana MD, Covar R,Holguin F, Lemanske RF, Martinez FD, Pongracic JA, Beigelman A, Baxi SN, Benson M, Blake K, Chmiel J, Daines CL, Daines MO, Gaffin JM, Gentile DA, Gower WA, Israel E, Kumar HV, Lang JE, Lazarus SC, Lima JJ, Ly N, Marbin J, Morgan W, Myers RE, Olin JT, Peters SP, Raissy HH, Robison RG, Ross K, Sorkness CA, Thyne SM, **Szefler SJ** for the NIH/NHLBI AsthmaNET. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol 2016;138:1608-18. PMID: 27777180
253. Yang I, Pedersen BS, Liu AH, O’Connor GT, Pillai D, Kattan M, Misiak RT, Gruchalla R, **Szefler SJ,** Khurana Hershey GK, Kercsmar C, Richards A, Stevens AD, Kolakowski CA, Makhija M, Sorkness CA, Krouse RZ, Visness C, Davidson EJ, Hennessy CE, Martin RJ, Togias A, Busse WW, and Schwartz DA. The nasal methylome and childhood atopic asthma. J Allergy Clin Immunol 2017;139:1478-88. PMID: 27745942
254. Iribarren C, Rahmaoui A, Long AA, **Szefler SJ**, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study for moderate-to-severe asthma. J Allergy Clin Immunol 2017;139:1489-95. PMID: 27639934

1. Chipps BE, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler SJ, Kattan M, Kianifard F, et al. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. J Allergy Clin Immunol, 2017:139:1431-1444. PMID: 28477722.
2. Hoch HE, Calatroni A, West JB, Liu AH, Gergen PJ, Gruchalla RS, Khurana Hershey K, Kercsmar CM, Kim H, Lamm C, Makhija M, Mitchell H, Teach SJ, Wildfire JJ, Busse WW, **Szefler SJ**. Can we predict fall asthma exacerbations ? Validation of the seasonal asthma exacerbation index. J Allergy Clin Immunol 2017; J Allergy Clin Immunol. 2017;140:1130-7. PMID: 28238748
3. **Szefler SJ**, Murphy K, Harper T, Boner A, Laki I, Engel M, El Azzi G, Moroni-Zewntgraf P, Finnigan H, Hamelmann E. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol 2017;140:1277-87. PMID: 28189771.
4. Nyenhuis SM, Krishnan JA, Berry A, Calhoun WJ. Chinchilli VM, Engle L, Grossman N, Holguin F, Israel E, Kittles RA, Kraft M, Lazarus SC, Lehman EB, Mauger DT, Moy JN, Peters SP, Phipatanakul W, Smith LJ, Sumino K, **Szefler SJ,** Wechsler ME, Wenzel S, White SR, Ackerman SJ. Race may contribute to differences in airway inflammation in asthma. J Allergy Clin Immunol 2017;140:257-265. PMID: 28069248
5. Esquivel A, Busse WW, Calatroni A, Togias AG, Esquivel A, Busse WW, Calatroni A, Togias AG, Grindle KG, Bochkov YA, Gruchalla RS, Kattan M, Kercsmar CM, Khurana Hershey G, Kim H, Lebeau P, Liu AH, **Szefler** SJ, Teach SJ, West JB, Wildfire J, Pongracic JA, Gern JE. [Effects of Omalizumab on Rhinovirus Infections, Illnesses and Exacerbations of Asthma.](https://www.ncbi.nlm.nih.gov/pubmed/28608756) Am J Respir Crit Care Med. 2017;196:985-992.PMID:28608756
6. Snieder H, Nickels S, Gleason, M, McFarlane A, **Szefler S**, Allison M. Stakeholder perspectives on optimizing communication in a school-centered asthma program. J School Health 2017; 2017;87:941-948.
7. Lang JE, Fitzpatrick AM, Mauger DT, Guilbert TW, Jackson DJ, Lemanske RF, Martinez FD, Strunk RC, Zeiger RS, Phiapatanakul W, Bacharier L, Pongracic JA, Holguin F, Cabana MD, Covar RA, Raissy HH, Tang M, **Szefler SJ** for the National Institutes of Health/National Heart, Lung and Blood Institute AsthmaNet. Overweight/Obesity Status on Asthma Severity in preschool children with worse asthma but robust improvement on and response to inhaled corticosteroids. J Allergy Clin Immunol 2018; 141:1459-67. PMID:29273557
8. Chipps BE, Haselkorn T, Paknis B, Ortiz B, Bleecker ER, Kianifard F, Foreman AJ, **Szefler** SJ, Zeiger RS; Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens Study Group. [More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II.](https://www.ncbi.nlm.nih.gov/pubmed/28797732) J Allergy Clin Immunol. 2017 2018;141:1590-7. PMID:28797732
9. Vrijlandt EJLE, El Azzi G, Vandewalker M, Rupp N, Harper T, Graham L, **Szefler** SJ, Moroni-Zentgraf P, Sharma A, Vulcu SD, Sigmund R, Chawes B, Engel M, Bisgaard H. [Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/29361462) Lancet Respir Med. 2018 6(2):127-137. doi: 10.1016/S2213-2600(18)30012-2. Epub 2018 Jan 18. PMID: 29361462
10. Hoch H, Kempe A, Brinton J, **Szefler S**. Feasibility of medication monitoring adherence in high risk asthmatic children. J Asthma 2018;11:1-3.  PMID:29641374
11. Morris CR, Mauger DT, Suh JH, Phipatanakul W, Sheehan WJ, Moy JN, Paul IM, **Szefler** SJ, Jackson DJ, Fitzpatrick AM; National Institutes of Health/National Heart, Lung, and Blood Institute AsthmaNet. Glutathione and arginine levels: Predictors for acetaminophen-associated asthma exacerbations. J Allergy Clin Immunol. 2018;142:308-311. doi: 10.1016/j.jaci.2018.01.045. PMID:29518418
12. **Szefler SJ\***, Cloutier MM\* (Co-Lead authors), Villarreal M, Hollenbach JP, Gleason M, Haas-Howard, C, Vinick C, Calatroni A, Cicutto L, White M, Williams S, McGinn M, Langton C, Shocks D, Mitchell H, Stempel D. Building Bridges for asthma acare: Reducing school absence for inner city children with health disaprities. J Allergy Clin Immunol, 2019; 143:746-54. PMID: 30055181
13. Hollenbach JP, Villarreal M, Simoneau T, Langton C, Mitchell H, Flores G, Cloutier MM **Szefler SJ**. Inaccuracy of asthma-related self-reported healthcare utilization data compared to Medicoad Claims. J Asthma, 2019;56(9):947-950. doi: 10.1080/02770903.2018.1502302. [Epub 2018] PMID:30091938
14. Guilbert T, Zeiger RS, Haselkorn T, Iqbal A, Alvarez C, Mink DR, Chipps BE, Szefler SJ. Racial disparities in asthma-related outcomes in children with severe/difficult-to-treat asthma. J Allergy Clin Immunol In Practice 2019;7:568-77 PMID:30172020
15. Fielding S, Pijnenburg M, de Jongste JC, Pike KC, Roberts G, Petsky H, Chang AB, Fritsch M, Frischer T, Szefler S, Gergen P, Vermeulen F, Vael R, Turner S. [Change in FEV1 and FeNO measurements as predictors of future asthma outcomes in children.](https://www.ncbi.nlm.nih.gov/pubmed/30359613) Chest. 2019;155:331-341. PMID:30359613
16. Cicutto L, Gleason M, Haas-Howard C, White M, Hollenbach JP, Williams S, McGinn M, Villarreal M, Mitchell H, Cloutier MM, Vinick C, Langton C, Shocks DJ, Stempel DA, **Szefler** SJ. [Building Bridges for Asthma Care Program: A School-Centered Program Connecting Schools, Families, and Community Health-Care Providers.](https://www.ncbi.nlm.nih.gov/pubmed/30336726) J Sch Nurs. 2020 36:168-180. doi: 10.1177/1059840518805824. [Epub ahead of print] PMID:30336726
17. Fitzpatrick AM, Bacharier LB, Guilbert TW, Jackson DJ, **Szefler** SJ, Beigelman A, Cabana MD, Covar R, Holguin F, Lemanske RF Jr, Martinez FD, Morgan W, Phipatanakul W, Pongracic JA, Zeiger RS, Mauger DT; NIH/NHLBI AsthmaNet [Phenotypes of Recurrent Wheezing in Preschool Children: Identification by Latent Class Analysis and Utility in Prediction of Future Exacerbation.](https://www.ncbi.nlm.nih.gov/pubmed/30267890) J Allergy Clin Immunol Pract. 2019;7:915-924. PMID: 30267890
18. **Szefler** SJ, Hoch HE, Tuffli M, Gondalia R, Barrett MA, Van Sickle D, Stempel DA. [Quantifying beta-agonist utilization: Occasions or puffs?](https://www.ncbi.nlm.nih.gov/pubmed/30218718) J Allergy Clin Immunol Pract. 2019;7:1088-1090. doi: 10.1016/j.jaip.2018.08.037 PMID:30218718
19. Merchant R, **Szefler** SJ, Bender BG, Tuffli M, Barrett MA, Gondalia R, Kaye L, Van Sickle D, Stempel DA. [Impact of a digital health intervention on asthma resource utilization.](https://www.ncbi.nlm.nih.gov/pubmed/30524644) World Allergy Organ J. 2018 Dec 3;11(1):28. doi: 10.1186/s40413-018-0209-0. eCollection 2018. PMID: 30524644
20. Kercsmar CM, Sorkness CA, Calatroni A, Gergen PJ, Bloomberg GR, Gruchalla RS, Kattan M, Liu AH, O'Connor GT, Pongracic JA, **Szefler** SJ, Teach SJ, Wildfire JJ, Wood RA, Zoratti EM, Busse WW; NIAID-sponsored Inner-City Asthma Consortium. [A computerized decision support tool to implement asthma guidelines for children and adolescents.](https://www.ncbi.nlm.nih.gov/pubmed/30529451) J Allergy Clin Immunol. 2018 Dec 5. pii: S0091-6749(18)31724-X. doi: 10.1016/j.jaci.2018.10.060. [Epub ahead of print] PMID:30529451
21. Guilbert TW, Bacharier LB, Mauger DT, Phipatanakul W, **Szefler** SJ, Boehmer S, Beigelman A, Fitzpatrick AM, Jackson DJ, Baxi SN, Benson M, Burnham CD, Cabana MD, Castro M, Chmiel JF, Covar R, Daines M, Gaffin JM, Gentile DA, Holguin F, Israel E, Kelly HW, Lazarus SC, Lemanske RF Jr, Ly N, Meade K, Morgan W, Moy J, Olin JT, Peters SP, Pongracic JA, Raissy HH, Ross K, Sheehan WJ, Sorkness C, Teague WG, Thyne S, Martinez FD; National Heart, Lung, and Blood Institute’s AsthmaNet. [Challenges in Assessing the Efficacy of Systemic Corticosteroids for Severe Wheezing Episodes in Preschool Children.](https://www.ncbi.nlm.nih.gov/pubmed/30660645) J Allergy Clin Immunol. 2019 May;143(5):1934-1937.e4. doi: 10.1016/j.jaci.2018.10.071. PMID:30660645
22. Tyler A, Cotter JM, Moss A, Topoz I, Dempsey A, Reese J, **Szefler** S, Hoch H. [Outcomes for Pediatric Asthmatic Inpatients After Implementation of an Emergency Department Dexamethasone Treatment Protocol.](https://www.ncbi.nlm.nih.gov/pubmed/30670462) Hosp Pediatr. 2019 Feb;9(2):92-99. Doi:10.1542/hpeds.2018-0099. PMID:30670462
23. Messinger AI, Bui N, Wagner BD, **Szefler** SJ, Vu T, Deterding RR. [Novel pediatric-automated respiratory score using physiologic data and machine learning in asthma.](https://www.ncbi.nlm.nih.gov/pubmed/31006993) Pediatr Pulmonol. 2019 Apr 21. doi: 10.1002/ppul.24342. [Epub ahead of print] PMID: 31006993
24. Bennett TD, Callahan TJ, Feinstein JA, Ghosh D, Lakhani SA, Spaeder MC, **Szefler** SJ, Kahn MG. [Data Science for Child Health.](https://www.ncbi.nlm.nih.gov/pubmed/30686480) J Pediatr. 2019 May;208:12-22. Jan 24. pii: S0022-3476(18)31815-8. doi: 10.1016/j.jpeds.2018.12.041. PMID:30686480
25. Anderson WC 3rd, Gondalia R, Hoch HE, Kaye L, **Szefler** SJ, Stempel DA. [Screening for inhalation technique errors with electronic medication monitors.](https://www.ncbi.nlm.nih.gov/pubmed/30776523) J Allergy Clin Immunol Pract. 2019 Feb 15. pii: S2213-2198(19)30170-9. doi: 10.1016/j.jaip.2019.02.006. PMID:30776523
26. **Szefler** SJ, Vogelberg C, Bernstein JA, Goldstein S, Mansfield L, Zaremba-Pechmann L, Engel M, Hamelmann E. [Tiotropium Is Efficacious in 6- to 17-Year-Olds with Asthma, Independent of T2 Phenotype.](https://www.ncbi.nlm.nih.gov/pubmed/30922990) .J Allergy Clin Immunol Pract. 2019;7:2286-95 doi: 10.1016/j.jaip.2019.03.019. PMID:30922990
27. **Szefler** SJ, Raphiou I, Zeiger RS, Stempel D, Kral K, Pascoe S. [Seasonal variation in asthma exacerbations in the AUSTRI and VESTRI studies.](https://www.ncbi.nlm.nih.gov/pubmed/31086795) ERJ Open Res. 2019 Apr 26;5(2). pii: 00153-2018. doi: 10.1183/23120541.00153-2018. eCollection 2019 Apr.PMID:31086795
28. Vogelberg C, **Szefler** SJ, Vrijlandt EJLE, Boner AL, Engel M, Azzi GE, Vulcu SD, Moroni-Zentgraf PM, Eickmeier O, Hamelmann EH. [Tiotropium add-on therapy is safe and reduces seasonal worsenings in paediatric asthma patients.](https://www.ncbi.nlm.nih.gov/pubmed/31097514) Eur Respir J. 2019 Jun 13;53(6)6. pii: 1801824. doi: 10.1183/13993003.01824-2018. [Epub ahead of print] PMID:31097514
29. Lazarus SC, Krishnan JA, King TS, Lang JE, Blake KV, Covar R, Lugogo N, Wenzel S, Chinchilli VM, Mauger DT, Dyer AM, Boushey HA, Fahy JV, Woodruff PG, Bacharier LB, Cabana MD, Cardet JC, Castro M, Chmiel J, Denlinger L, DiMango E, Fitzpatrick AM, Gentile D, Hastie A, Holguin F, Israel E, Jackson D, Kraft M, LaForce C, Lemanske RF Jr, Martinez FD, Moore W, Morgan WJ, Moy JN, Myers R, Peters SP, Phipatanakul W, Pongracic JA, Que L, Ross K, Smith L, **Szefler** SJ, Wechsler ME, Sorkness CA; National Heart, Lung, and Blood Institute AsthmaNet. [Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level.](https://www.ncbi.nlm.nih.gov/pubmed/31112384) N Engl J Med. 2019 May 23;380(21):2009-2019. doi: 10.1056/NEJMoa1814917. Epub 2019 May 19. PMID:31112384
30. Cotter J, Tyler A, Reese J, Ziniel S, Federico M, Anderson W, Kupfer O, **Szefler** S, Kerby G, Hoch H. [Steroid Variability in Pediatric Inpatient Asthmatics: Survey on Provider Preferences of Dexamethasone versus Prednisone.](https://www.ncbi.nlm.nih.gov/pubmed/31113252) J Asthma. 2019 12:1-7. doi: 10.1080/02770903.2019.1622713. [Epub ahead of print] PMID:31113252
31. Barnes PJ, **Szefler** SJ, Reddel HK, Chipps BE. [Symptoms and perception of airway obstruction in asthma: clinical implications for use of reliever medications.](https://www.ncbi.nlm.nih.gov/pubmed/31330221) J Allergy Clin Immunol. 2019;244:1180-1186 doi: 10.1016/j.jaci.2019.06.040. [Epub ahead of print] PMID: 31330221
32. Graham LM, Kerstjens HAM, Vogelberg C, Hamelmann E, **Szefler** SJ, Pisternick-Ruf W, Engel M, El Azzi G, Unseld A, Foggs MB. [Safety of tiotropium Respimat® in black or African-American patients with symptomatic asthma.](https://www.ncbi.nlm.nih.gov/pubmed/31302579) Respir Med. 2019 Aug;155:58-60. doi: 10.1016/j.rmed.2019.07.002. [Epub ahead of print] PMID: 31302579
33. Wechsler ME, **Szefler SJ**, Ortega VE, Pongracic JA, Chinchilli V, Lima JJ, Krishnan JA, Kunselman SJ, Mauger D, Bleecker ER, Bacharier LB, Beigelman A, Benson M, Blake KV, Cabana MD, Cardet JC, Castro M, Chmiel JF, Covar R, Denlinger L, DiMango E, Fitzpatrick AM, Gentile D, Grossman N, Holguin F, Jackson DJ, Kumar H, Kraft M, LaForce CF, Lang J, Lazarus SC, Lemanske RF Jr, Long D, Lugogo N, Martinez F, Meyers DA, Moore WC, Moy J, Naureckas E, Olin JT, Peters SP, Phipatanakul W, Que L, Raissy H, Robison RG, Ross K, Sheehan W, Smith LJ, Solway J, Sorkness CA, Sullivan-Vedder L, Wenzel S, White S, Israel E; NHLBI AsthmaNet. [Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma.](https://www.ncbi.nlm.nih.gov/pubmed/31553835) N Engl J Med. 2019 Sep 26;381(13):1227-1239. doi: 10.1056/NEJMoa1905560. PMID: 31553835
34. Fitzpatrick AM, **Szefler** SJ, Mauger DT, Phillips BR, Denlinger LC, Moore WC, Sorkness RL, Wenzel SE, Gergen PJ, Bleecker ER, Castro M, Erzurum SC, Fahy JV, Gaston BM, Israel E, Levy BD, Meyers DA, Teague WG, Bacharier LB, Ly NP, Phipatanakul W, Ross KR, Zein J, Jarjour NN. [Development and Initial Validation of the Asthma Severity Scoring System (ASSESS).](https://www.ncbi.nlm.nih.gov/pubmed/31604088) J Allergy Clin Immunol. 2019;145:127-139. doi: 10.1016/j.jaci.2019.09.018. PMID:31604088
35. Anderson WC 3rd, Gondalia R, Hoch HE, Kaye L, Barrett M, Szefler SJ, Stempel DA. [Assessing asthma control: comparison of electronic-recorded short-acting beta-agonist rescue use and self-reported use utilizing the asthma control test.](https://www.ncbi.nlm.nih.gov/pubmed/31668103) J Asthma. 2019;9:1-5. doi: 10.1080/02770903.2019.1687715. [Epub ahead of print] PMID: 31668103
36. Hamelmann E, von Mutius E, Bush A, Szefler SJ. [Addressing the risk domain in the long-term management of pediatric asthma.](https://www.ncbi.nlm.nih.gov/pubmed/31732983) Pediatr Allergy Immunol. 2020;31:233-242. PMID: 31732983
37. Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID, **Szefler** SJ, Woodruff PG, de Giorgio-Miller A, Trudo F, Fageras M, Ambrose CS. [An Expert Consensus Framework for Asthma Remission as a Treatment Goal.](https://www.ncbi.nlm.nih.gov/pubmed/31866436) J Allergy Clin Immunol 2020;145:757-765. doi: 10.1016/j.jaci.2019.12.006. PMID: 31866436
38. Fielding S, Pijnenburg M, de Jongste J, Pike K, Roberts G, Petsky H, Chang AB, Fritsch M, Frischer T, Szefler S, Gergen P, Vermeulen F, Vael R, Turner S. [What is a clinically meaningful change in exhaled nitric oxide for children with asthma?](https://www.ncbi.nlm.nih.gov/pubmed/31909561) Pediatr Pulmonol. 2020;55:599-606. doi: 10.1002/ppul.24630. PMID:31909561
39. **Szefler** SJ. [Update on the NAEPP asthma guidelines: The wait is over, or is it?](https://www.ncbi.nlm.nih.gov/pubmed/32004522) J Allergy Clin Immunol. 2020 Jan 28. pii: S0091-6749(20)30114-7. doi: 10.1016/j.jaci.2020.01.025. [Epub ahead of print] PMID:32004522
40. De Keyser HEH, Kaye L, Anderson WC, Gondalia R, Theye B, **Szefler** SJ, Stempel DA. [Electronic medication monitors help determine adherence subgroups in asthma.](https://www.ncbi.nlm.nih.gov/pubmed/32094102) Respir Med. 2020 Feb 19;164:105914. doi: 10.1016/j.rmed.2020.105914. [Epub ahead of print] PMID:32094102
41. Wang K, Verbakel JY, Oke J, Fleming-Nouri A, Brewin J, Roberts N, Harada N, Atsuta R, Takahashi K, Mori K, Fujisawa T, Shirai T, Kawayama T, Inoue H, Lazarus S, **Szefler** S, Martinez F, Shaw D, Pavord ID, Thomas M. [Using fractional exhaled nitric oxide to guide step down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/32139458) Eur Respir J. 2020 Mar 5. pii: 1902150. doi: 10.1183/13993003.02150-2019. [Epub ahead of print] PMID:32139458
42. **Szefler** SJ, Fitzgerald DA, Adachi Y, Doull IJ, Fischer GB, Fletcher M, Hong J, García-Marcos L, Pedersen S, Østrem A, Sly PD, Williams S, Winders T, Zar HJ, Bush A, Lenney W. [A worldwide charter for all children with asthma.](https://www.ncbi.nlm.nih.gov/pubmed/32142219) Pediatr Pulmonol. 2020;55:1282-1292 doi: 10.1002/ppul.24713. PMID:32142219
43. Fitzpatrick AM, Bacharier LB, Jackson DJ, **Szefler** SJ, Beigelman A, Cabana M, Covar R, Guilbert T, Holguin F, Lemanske RF, Martinez FD, Morgan W, Phipatanakul W, Pongracic JA, Raissy HH, Zeiger RS, Mauger DT. [Heterogeneity of Mild to Moderate Persistent Asthma in Children: Confirmation by Latent Class Analysis and Association with 1-Year Outcomes.](https://www.ncbi.nlm.nih.gov/pubmed/32156610) J A llergy Clin Immunol Pract. 2020;8:2617-27. doi: 10.1016/j.jaip.2020.02.032. PMID:32156610
44. Fielding SS, Pijnenburg M, de Jongste J, Pike K, Roberts G, Petsky H, Chang AB, Fritsch M, Frischer T, **Szefler** SJ, Gergen P, Vermeulen F, Vael R, Turner SS [Does treatment guided by fractional exhaled nitric oxide improve outcomes in subgroups of children with asthma?](https://www.ncbi.nlm.nih.gov/pubmed/32165403) Eur Respir J. 2020 Mar 12. pii: 1901879. doi: 10.1183/13993003.01879-2019. [Epub ahead of print] PMID:32165403
45. Haselkorn T, **Szefler** SJ, Chipps BE, Bleecker ER, Harkins MS, Paknis B, Kianifard F, Ortiz B, Zeiger RS. [Disease Burden and Long-Term Risk of Persistent Very Poorly Controlled Asthma: TENOR II.](https://www.ncbi.nlm.nih.gov/pubmed/32173511) J Allergy Clin Immunol Pract. 2020;8:2243-53. doi: 10.1016/j.jaip.2020.02.040. PMID:32173511
46. Halpin DMG, Hamelmann EH, Frith PA, Moroni-Zentgraf PM, van Hecke B, Unseld A, Kerstjens HAM, **Szefler** SJ. [Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis.](https://www.ncbi.nlm.nih.gov/pubmed/32180164) Pulm Ther. 2020;6:131-140. doi: 10.1007/s41030-020-00113-w. [Epub ahead of print] PMID:32180164
47. **Szefler** SJ, Casale TB, Haselkorn T, Yoo B, Ortiz B, Kattan M, Busse WW. [Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity.](https://www.ncbi.nlm.nih.gov/pubmed/32298853) J Allergy Clin Immunol Pract. 2020 Apr 13. pii: S2213-2198(20)30332-9. doi: 10.1016/j.jaip.2020.03.033. [Epub ahead of print] PMID:32298853
48. **Szefler** SJ, Goldstein S, Vogelberg C, Bensch GW, Given J, Jugovic B, Engel M, Moroni-Zentgraf PM, Sigmund R, Hamelmann EH. [Forced Expiratory Flow (FEF25-75%) as a Clinical Endpoint in Children and Adolescents with Symptomatic Asthma Receiving Tiotropium: A Post Hoc Analysis.](https://www.ncbi.nlm.nih.gov/pubmed/32399899) Pulm Ther. 2020 May 12. doi: 10.1007/s41030-020-00117-6. [Epub ahead of print] PMID:32399899
49. Papadopoulos NG, Custovic A, Deschildre A, Mathioudakis AG, Phipatanakul W, Wong G, Xepapadaki P, Agache I, Bacharier L, Bonini M, Castro-Rodriguez JA, Chen Z, Craig T, Ducharme FM, El-Sayed ZA, Feleszko W, Fiocci A, Garcia-Marcos L, Gern JE, Goh A, Gómez RM, Hamelmann EH, Hedlin G, Hossny EM, Jartti T, Kalayci O, Kaplan A, Konradsen J, Kuna P, Lau S, Le Souef P, Lemanske RF, Mäkelä MJ, Morais-Almeida M, Murray C, Nagaraju K, Namazova-Baranova L, Garcia AN, Yusuf OM, Pitrez PMC, Pohunek P, Pozo Beltrán CF, Roberts GC, Valiulis A, Zar HJ; Pediatric Asthma in Real Life Collaborators. Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden [published online ahead of print, 2020 Jun 17]. *J Allergy Clin Immunol Pract*. 2020;S2213-2198(20)30599-7. doi:10.1016/j.jaip.2020.06.001
50. Navanandan N, Hamlington KL, Mistry RD, **Szefler SJ,** Liu AH. Oscillometry for Acute Asthma in the Pediatric Emergency Department: A Feasibility Study [published online ahead of print, 2020 Jul 8]. *Ann Allergy Asthma Immunol*. 2020;S1081-1206(20)30480-4. doi:10.1016/j.anai.2020.07.002
51. Ivanova A, Israel E, LaVange LM, Peters MC, Denlinger LC, Moore WC, Bacharier LB, Marquis MA, Gotman NM, Kosorok MR, Tomlinson C, Mauger DT, Georas SN, Wright RJ, Noel P, Rosner GL, Akuthota P, Billheimer D, Bleecker ER, Cardet JC, Castro M, DiMango EA, Erzurum SC, Fahy JV, Fajt ML, Gaston BM, Holguin F, Jain S, Kenyon NJ, Krishnan JA, Kraft M, Kumar R, Liu MC, Ly NP, Moy JN, Phipatanakul W, Ross K, Smith LJ, **Szefler SJ**, Teague WG, Wechsler ME, Wenzel SE, White SR. [The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations.](https://pubmed.ncbi.nlm.nih.gov/32941098/) J Biopharm Stat. 2020 Sep 17:1-12. doi: 10.1080/10543406.2020.1821705. Online ahead of print.PMID: 32941098
52. Lee LA, Pedersen S, Pascoe SJ, **Szefler SJ**, Lenney W. No dose effect observed with chronic fluticasone propionate on growth velocity in children. Pediatr Allergy Immunol. 2020 Sep 23. doi: 10.1111/pai.13378. Epub ahead of print. PMID: 32966707.
53. Menzies-Gow A, **Szefler SJ**, Busse WW. How Do Asthma Biologics Relate to Remission for Asthma? J Allergy Clin Immunol Pract. 2020 Oct 28:S2213-2198(20)31187-9. doi: 10.1016/j.jaip.2020.10.035. Epub ahead of print. PMID: 33130146.
54. Anderson WC 3rd, Gondalia R, De Keyser HE, Kaye L, **Szefler SJ**, Stempel DA. Digital Assessment of Medication Utilization by Age and Diagnosis of Asthma or COPD. J Allergy Clin Immunol Pract. 2020 Nov 16:S2213-2198(20)31222-8. doi: 10.1016/j.jaip.2020.10.065. Epub ahead of print. PMID: 33212238.
55. Mosnaim GS, Stempel DA, Gonzalez C, Adams B, BenIsrael-Olive N, Gondalia R, Kaye L, Shalowitz M, **Szefler S**. The impact of patient self-monitoring via electronic medication monitor and mobile app plus remote clinician feedback on adherence to inhaled corticosteroids: A randomized controlled trial. J Allergy Clin Immunol Pract. 2020 Nov 16:S2213-2198(20)31220-4. doi: 10.1016/j.jaip.2020.10.064. Epub ahead of print. PMID: 33212239.
56. Busse WW, **Szefler SJ**, Haselkorn T, Iqbal A, Ortiz B, Lanier BQ, Chipps BE. Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations. J Allergy Clin Immunol Pract. 2020 Oct 24:S2213-2198(20)31143-0. doi: 10.1016/j.jaip.2020.10.027. Epub ahead of print. PMID: 33223095.

**B. Books**

1. MacLeod SM, **Szefler SJ**. Childhood Asthma and Sustained Release Theophylline. Elsevier Science Publishers (Excerpta Medica), l986.
2. Stempel DS, **Szefler SJ**. Asthma. Pediatric Clinics of North America, Saunders, Philadelphia, 39 (6):pp. 249-280, 1992.
3. Liu AH, **Szefler SJ** (eds). Synopsis Book: Best Articles Relevant to Pediatric Allergy and Immunology. (Suppl) Pediatrics, vol 84, 1994, pp 379-411.
4. Rosenwasser LJ, Borish L, Gelfand E, Leung D, Nelson H, **Szefler SJ** (eds.). Yearbook of Allergy and Clinical Immunology 1994. Mosby, St. Louis, 1994.
5. **Szefler SJ**, Leung DYM. Severe Asthma: Pathogenesis and Clinical Management. New York: Marcel Dekker, Lung Biology in Health and Disease Series, 1995.
6. Liu AH, **Szefler SJ**. Synopsis Book. Best Articles Relevant to Pediatric Allergy and Immunology. Supplement - Pediatrics, vol. 86, 1995, pp. 373-411.
7. Rosenwasser LJ, Borish L, Gelfand E, Leung D, Nelson H, **Szefler SJ** (eds.). Yearbook of Allergy and Clinical Immunology 1995. Mosby, St. Louis, 1995.
8. Klotz U, **Szefler SJ** (eds.). Zilueton: A Pharmacokinetic Profile. Clinical Pharmacokinetics 1995;29 (suppl 2):1-124.
9. Rosenwasser LJ, Borish L, Gelfand E, Leung D, Nelson H, **Szefler SJ** (eds.). Yearbook of Allergy and Clinical Immunology 1996. Mosby, St. Louis, 1996.
10. Rosenwasser LJ, Borish L, Gelfand E, Leung D, Nelson H, **Szefler SJ** (eds.). Yearbook of Allergy and Clinical Immunology 1996. Mosby, St. Louis, 1997.
11. **Szefler SJ** (ed). Meeting the needs of infants and young children with asthma: New developments in nebulized therapy. J Allergy Clin Immunol. 1999;104(4 Pt 2):159-61.
12. **Szefler SJ**, Leung DYM (eds)**.**  *Corticosteroids in Respiratory Allergy: Immunology and Allergy Clinics of North America*, W.B. Saunders Co, Philadelphia, Vol.19 (4), 1999.
13. **Szefler SJ** (ed). Meeting the needs of the modernization act: challenges in developing pediatric therapies. J Allergy Clin Immunol 2000;106 (3 Suppl):115-7.
14. **Szefler SJ**, Leung DYM (eds).  *Severe Asthma: A Multidisciplinary Approach.* New York: Marcel Dekker, 2nd Edition, Lung Biology in Health and Disease Series, 2001.
15. Naspitz C, **Szefler SJ**, Tinkelman D, Warner JO (eds). *Textbook of Pediatric Asthma.*  London: Martin-Dunitz, 2001.
16. Brattsand R, O’Byrne P, Schleimer R, **Szefler SJ** (eds).  *Inhaled Steroids in Asthma: Optimizing Effects in the Airway*. New York: Marcel Dekker, Inc., 2002.
17. Leung DYM, Sampson H, Geha R, **Szefler SJ** (eds) *Pediatric Allergy: Principles and Practice.* 2003, Mosby, St. Louis.
18. Pedersen S, **Szefler SJ (eds.)**. Childhood Asthma: Breaking Down the Barriers. Vol 209, 2006, Executive Ed. C Lenfant, Taylor & Francis Group, New York.
19. Leung DYM, Sampson H, Geha R, **Szefler SJ** (eds). *Pediatric Allergy: Principles and Practice.* Second edition, 2010, Elsevier, London.
20. Leung, DYM, **Szefler SJ**, Bonilla FA, Akdis C, Sampson H. *Pediatric Allergy: Principles and Practice.* Third edition, 2016, Elsevier, London.
21. Bacharier L, **Szefler, SJ**, Section Editors in Allergy and Immunology, Current Opinion in Allergy and Immunology, 2016.
22. Bacharier L, **Szefler, SJ**, Section Editors in Allergy and Immunology, Current Opinion in Allergy and Immunology, 2017.
23. **Szefler SJ**, Holguin, F, Wechsler M. Personalized Medicine for Asthma for the for the Clinician, Elsevier, St. Louis, MO., 2018.
24. Bacharier L, **Szefler SJ.** Section Editors in Allergy and Immunology, Current Opinion in Allergy and Immunology, 2018.

C. Other Publications:

1. **Szefler SJ**, Shen DD. Drug Excretion in Breast Milk. In: Gastroenterology and Nutrition in Infancy. Ed. Emanuel Lebenthal. New York: Raven Press 331-338, l98l.
2. **Szefler SJ**, Ellis EF. Adverse Reactions to Drugs. In: Brennemann-Kelley's Practice of Pediatrics. Philadelphia: Harper and Row 67:1-14, l982.
3. **Szefler SJ**. Using serum measurements to tailor theophylline therapy. J Respir Dis 4:l3-23, l983.
4. **Szefler SJ**. Drug excretion in human breast milk: Potential effect on infant development. J Ped Gast Nutr 2:120-126, l983.
5. **Szefler SJ**. Practical considerations in the safe and effective use of theophylline. Ped Clin N Amer 30:943-954, l983.
6. **Szefler SJ**. Inter- and intra-subject variability in theophylline pharmacokinetics. Br J Clin Practice 38:l0-l6, l984.
7. **Szefler SJ**. The role of troleandomycin in the treatment of asthma. J Respir Dis 6:54-58, l985.
8. **Szefler SJ**. Theophylline and its fickle unpredictability of absorption. Ann Allergy 55:580-583, l985.
9. **Szefler SJ**. Unpredictability of theophylline absorption. J Respir Dis Monograph Series 6:8-l2, l986.
10. Milsap RL, **Szefler SJ**. Special pharmacokinetic considerations in children. In: Applied Pharmacokinetics. Ed. WE Evans, JJ Schentag, WJ Jusko. San Francisco: Applied Therapeutics, Inc. 294-330, 1986.
11. **Szefler SJ**. Is the concentration-time profile for theophylline independent of age? In: Childhood Asthma and Sustained-release Theophylline. Ed. SM MacLeod, SJ Szefler. Amsterdam: Excerpta Medica, Amsterdam 93-l03, 1986.
12. **Szefler SJ.** Theophylline and other Methylxanthine Derivatives. In: Drugs for the Respiratory System. Ed. R Cherniack. New York: Grune and Stratton 2l-4l, 1986.
13. Jenne JW and **Szefler SJ**. Special pharmacologic considerations. In the report of the American Academy of Allergy and Immunology Task Force on guidelines for clinical investigation of nonbronchodilator antiasthmatic drugs. J Allergy Clin Immunol 78:498-506, l986.
14. **Szefler SJ**. Erratic absorption of theophylline from slow-release products in children. J Allergy Clin Immunol 78:710-715, l986.
15. Bartoszek M, **Szefler SJ**. Corticosteroid therapy in adolescent patients. J Adol Health Care 8:84-91, 1987.
16. **Szefler SJ**. Pharmacokinetics of theophylline and other xanthine derivatives. In: Drug Therapy for Asthma: Research and Clinical Practice. Ed. J Jenne, S Murphy. New York: Marcel Dekker, Lung Biology in Health and Disease Series 31:353-387, 1987.
17. Hill MR, **Szefler SJ**. Theophylline update: Current controversies. Sem Respir Med 8:372-380, 1987.
18. Weinberger M, Lindgren S, Bender B, Lerner JA, **Szefler SJ.** Effects of theophylline on learning and behavior: Reason for concern or concern without reason? J Pediatr 111:471-474, 1987.
19. Glynn-Barnhart A, Hill M, **Szefler SJ**. Sustained-release theophylline preparations: Practical recommendations for prescribing and therapeutic drug monitoring. Drugs 35:711-726, 1988.
20. **Szefler SJ.** Are theophylline "levels" really level? J Respir Dis 9(8):52-73,1988.
21. **Szefler SJ**. Management of the patient with severe chronic asthma. Insights In Allergy 3:1-8, 1988.
22. Ball BD, **Szefler SJ**. Troleandomycin: Present status in the treatment of severe asthmatic children. Am J Asthma Allerg Pediatricians 2:27-30, 1988.
23. **Szefler SJ**. Corticosteroid therapy: General Pharmacology. In: Anti-inflammatory Steroid Action: Basic and Clinical Aspects. Ed. R Schleimer, H Claman, A. Oronsky. San Diego Academic Press pp.353-376, 1989.
24. Hill EM, **Szefler SJ**. Drug excretion in breast milk. In: Gastroenterology and Nutrition in Early Childhood. Ed. Emanuel Lebenthal. New York: Raven Press. In press.
25. **Szefler SJ.** What is theophylline's place in today's asthma therapy? J Respir Dis. (Supp - June): S19-S27, 1989.
26. Sly MR, Bierman CW, Brandon ML, Bronstein HA, Chervinsky P, Dockhorn RJ, Easton JG, Finegold I, Friedlaender S, Furukawa C, Gillman SA, Glazer I, Hannaway PJ, Hendeles L, Katz R, Kemp JP, Krumholz RA, Meltzer EO, Miller J, Murphy S, Rowe MS, Schuller DE, Segal AT, Simons FER, **Szefler SJ**, Tobey RE, Weinberger M, Welch MJ, Woehler TR. Pharmacist substitution of slow-release theophylline products. J Allergy Clin Immunol 1989;84:131-2.
27. **Szefler SJ**. Measuring the response to glucocorticoids. J Allergy Clin Immunol. 85:985-987, 1990.
28. **Szefler SJ**. Glucocorticoids and the next generation of agents. 21st Ross Roundtable on Critical Approaches to Common Pediatric Problems, "Pediatric Asthma", 1990, pp. 34-44.
29. Brenner M, **Szefler SJ.** Troleandomycin in the treatment of severe asthma. Immunology and Allergy Clinics of North America. 11:91-102, 1990.
30. **Szefler SJ.** Glucocorticoid therapy for asthma: Clinical pharmacology. J Allergy Clin Immunol. 88:147-165, 1991.
31. **Szefler SJ**. Alternative therapy in asthma: Rationale and guidelines for applications. Update No. 11 for Allergy Principles and Practice, 3rd edition Ed. E Middleton, CE Reed, EF Ellis, NF Adkinson, JW Yuninger, CV Mosby, St. Louis, 1991, 1-14.
32. Nelson HS, **Szefler SJ**, Martin RJ. Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma: beneficial or detrimental? Am Rev Respir Dis. 144:249-259, 1991.
33. **Szefler SJ**. Book review - Immunopharmacology: Principles and perspectives. J Allergy Clin Immunol. 88:281, 1991.
34. **Szefler SJ**. A comparison of aerosol glucocorticoids in the treatment of chronic bronchial asthma. Ped Asthma, Allergy & Immunol. 5:227-235, 1991.
35. Hill MR, **Szefler SJ**. Advances in the pharmacologic management of asthma. In: Pediatric Pharmacology: Therapeutic Principles in Practice. Eds. SJ Yaffe, JV Aranda. W.B. Saunders Co, Philadelphia, 1992, pp. 317-334.
36. Alvarez J, **Szefler SJ**. Alternative therapy in severe asthma. J Asthma. 29:3-11, 1992.
37. Hendeles L, Weinberger M, **Szefler SJ**, Ellis EF. Is theophylline sufficiently effective and safe to justify continued use in children with asthma? J Pediatr. 120:1770-183, 1992.
38. Kamada, AK, Parks DP, **Szefler SJ**. Inhaled glucocorticoid therapy in children: How much is safe? Pediatr Pulmonol. 12:71-72, 1992.
39. Milsap RL, Hill MR, **Szefler SJ**. Special pharmacokinetic considerations in children. In, Applied Pharmacokinetics. Ed. WE Evans, JJ Schentag, WJ Jusko. San Francisco, Applied Therapeutics, Inc. 1992, pp. 10.1-10.22.
40. **Szefler SJ**. Anti-inflammatory therapy in allergic disorders. Med Clin N America. 76:953-975, 1992.
41. Hill MR, **Szefler SJ**, Larsen GL. Asthma pathogenesis and the implications for therapy in children. Ped Clin N America. 39:1205-1224, 1992.
42. Stempel DS, **Szefler SJ**. Management of chronic asthma. Ped Clin N America. 39:1293-1310, 1992.
43. Kamada AK, **Szefler SJ**. Inhaled therapy in infants: Why not nebulize glucocorticoids? Pediatr Pulmonol 13:198-199, 1992.
44. Kamada AK, **Szefler SJ**. Steroid resistance in asthma: Our current understanding. Pediatr Pulmonol 14:180-186, 1992.
45. Kamada AK, **Szefler SJ**. Editorial reply: Inhaled glucocorticoid therapy. Pediatr Pulmonol 14:197-198, 1992.
46. **Szefler SJ**. Principles of Therapeutics. In, Allergy Principles and Practice, Ed. E. Middleton, CE Reed, EF Ellis, NF Adkinson, JW Yuninger. CV Mosby, St. Louis, 1993, pp. 761-777.
47. Zeiger RS, **Szefler SJ**. Troleandomycin therapy in corticosteroid-dependent asthma. In, Bronchial Asthma, Mechanisms and Therapeutics, Third Edition. EB Weiss, MS Segal, M Stein, Eds., Little, Brown. Boston, 1993, pp. 901-909.
48. Hill MR, **Szefler SJ**. Other pharmacologic interventions in nocturnal asthma. In Nocturnal Asthma Medicines and Treatments, R. Martin, Ed. Futura Publishing Company, Inc., Mount Kisco, NY, 1993, pp. 333-356.
49. Kamada AK, **Szefler SJ**, Leung DYM. The growing problem of steroid-resistant asthma. Drug Therapy. 23 (No. 11):55-62, 1993.
50. Barnes PJ, Pedersen S (**Szefler SJ**-contributing author). Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993;148:S1-S26.
51. **Szefler SJ.** Treatment regimen and side effects of treatment measures - Discussant Section. Am J Respir Crit Care Med 149:S51-S53, 1994.
52. Kamada A, **Szefler SJ**. Mechanisms of action of corticosteroids in asthma and rhinitis. In *Asthma and Rhinitis*, Busse WW and Holgate S, editors, Blackwell Scientific, Boston, pp 981-1020, 1994.
53. Frieling W, Kamada AK, **Szefler SJ**. Chapter 30: Drug Therapy (Formulary). In, *Handbook of Pediatrics*, 17th edition, Silver, Kempe, Bruyn and Fulginitis, editors. pp 1255-1266, 1995.
54. Eggleston PA, **Szefler SJ**. Asthma in children. In *Asthma and Rhinitis*, Busse WW, and Holgate S, editors. Blackwell Scientific, Boston, pp. 1380 - 1393, 1995.
55. Stempel DH, **Szefler SJ,** Calabrase D, Irwin RS. Rational Therapy: Asthma, a disease management program. *Institute for Contemporary Pharmacy Research, Inc.,* 1995, Waltham, MA, pp 1-35.
56. Busse W, Banks-Schlegel SP, Larsen GL. (**Szefler SJ**-contributing author). Childhood-versus adult-onset asthma. Am J Respir Crit Care Med 151;1635-1639, 1995.
57. Kamada AK, **Szefler SJ**. Pharmacologic management of severe asthma. **Szefler SJ**, Leung DL (eds.). *Severe Asthma: Pathogenesis and Clinical Management.* New York: Marcel Dekker, Lung Biology in Health and Disease Series, 1995, pp. 165-205.
58. Spahn J, **Szefler SJ**, Leung DYM. Difficult to control asthma: New insights and strategies for management. Szefler SJ, Leung DL (eds.). *Severe Asthma: Pathogenesis and Clinical Management.* New York: Marcel Dekker, Lung Biology in Health and Disease Series, 1995, pp. 497-535.
59. **Szefler SJ**, Leung DYM. Asthma management: Past, present, and future. Szefler SJ, Leung DYM (eds.). *Severe Asthma: Pathogenesis and Clinical Management.* New York: Marcel Dekker, Lung Biology in Health and Disease Series, 1995, pp. 537-557.
60. **Szefler SJ**. Inhaled steroids for asthma: Helpful or Harmful? Current Views in Allergy & Immunology, January 1995.
61. Stempel DA and **Szefler SJ**. Going beyond the National Asthma Education Program: Guidelines for the diagnosis and management of asthma critical need for outcomes assessment. Ann Allergy, Asthma Immunol. 75:457-460;1995. PMID 8603272
62. **Szefler SJ**, Chambers CV. Diagnosis and management of asthma. Am Family Phys Monograph, 1995, No. 2, pp. 1-24. No PMID available.
63. Kamada, AK, **Szefler SJ**. Glucocorticoids and growth in asthmatic children. Pediatr Allergy Immunol. 6:145-154, 1995. PMID 8750310
64. Landwehr LP, Spahn JD, **Szefler SJ**, Leung DYM. Management of steroid resistant asthma. Clin. Immunother. 4:124-137, 1995. No PMID available.
65. **Szefler SJ**, Bender BG, Jusko WJ, Lanier BQ, Lemanske Jr RF, Skoner DP, Stempel DA. Evolving role of theophylline for treatment of chronic childhood asthma. J Pediatr. 127:176-185, 1995. PMID 7636640
66. Leung DYM,Spahn JD, Nimmagadda S, **Szefler SJ.** Induction of corticosteroid resistance *in vitro*. Am J Respir Crit Care Med. 154:S34-S38, 1996. PMID 8756785
67. Kamada AK, **Szefler SJ,** Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, Fish JE, Israel E, Lazarus SC, Lemanske RF, and the Asthma Clinical Research Network. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med. 1996;153:1739-1748. PMID 8665030
68. **Szefler SJ.** Glucocorticoids. *American Thoracic Society* - Up-To-Date Series. CD-ROM Program, 1996.
69. Kamada AK, **Szefler SJ.** Editorial. The role of theophylline in the treatment of asthma. Ann Allergy, Asthma Immunol. 77:1-5, 1996. PMD 8705629
70. **Szefler SJ.** Inhaled glucocorticoids. *Bronchial Asthma*: Index & Reviews, Lippincott - Raven Healthcare, 1996, Vol. 1, Number 2, pp. 3, 17-19.
71. Edsbäcker S, **Szefler SJ**. Glucocorticoid Pharmacokinetics: Principles and clinical applications. In, *Topical Glucocorticoids in Asthma: Mechanisms and Clinical Actions.* Schleimner RP, Busse WW, O'Byrne PM (eds) Lung Biology in Health and Diseases Series, Lenfant C (ed), Marcel Dekker, New York, 1996, pp. 381-445.
72. Nimmagadda S, Spahn JD, Leung DYM, **Szefler SJ.** Steroid resistant asthma. Ann Allergy Asthma Immunol. 77:345-356, 1996. PMID 8933772
73. Spahn JD, **Szefler SJ**. The etiology and control of bronchial hyperresponsiveness in children. In: *Current Opinion in Pediatrics.* Vol 8, issue 6. Nathan DG (ed). Rapid Science Publishers, Philadelphia, 1996, pp.591-596.
74. Biffl H, Kamada AK, **Szefler SJ**. Drug Therapy (Formulary). In: *Pediatric Drug Handbook*. Merenstein GB, Kaplan DW and Rosenberg AA (eds) Appleton & Lange, Norwalk, CT. 1996, pp. 935-975.
75. Spahn JD, Kamada AK, **Szefler SJ**. Glucocorticoid therapy in asthma. In: *Allergic Diseases: Diagnosis and Treatment.* Lieberman P, Anderson J (eds). Humana Press, Totowa NJ, 1997, pp. 331-350.
76. Leung DYM, **Szefler SJ**. Steroid resistant asthma. In *Asthma*. Barnes PJ, Grunstein MM, Leff A, Woolcock AE, eds. Raven Press, New York, 1997; pp. 2041-2057.
77. Spahn JD, Kamada AK, **Szefler SJ**. Oral glucocorticoids. In Asthma. Barnes PJ, Grunstein MM, Leff A, Woolcock AE, eds. Raven Press, New York,1997; pp. 1619-1638
78. Leung DYM, **Szefler SJ**. Diagnosis and management of steroid resistant asthma. In: *Clinics in Chest Medicine: Advanced Lung Disease*. Kotloff RM, Hansen-Flaschen JH (eds). W.B. Saunders Co: Philadelphia, PA, vol. 18, No. 3, 1997. pp 611-625.
79. Kamada AK, **Szefler SJ**. How should inhaled glucocorticoids be compared? J Allergy Clin Immunol. 99:735-737, 1997. PMID 9215238
80. Kamada AK, **Szefler SJ**, Leung DYM. Steroid resistant asthma: mechanisms and clinical implications. Clinical Asthma Reviews. 1:123-128, 1997. No PMID available.
81. **Szefler SJ.** Critical issues for defining the appropriate use of inhaled glucocorticosteroids in asthma: future research initiatives. Clinical Asthma Reviews. 1:123-128, 1997. No PMID available.
82. Kamada AK, **Szefler SJ**. The safety of inhaled corticosteroid therapy in children. Curr Opin Pediatr 9:585-589, 1997. PMID 9425592
83. Spahn JD, Kamada AK, **Szefler SJ**. Oral glucocorticoids. In *Asthma*. Barnes, Grunstein, Leff and Woolcock, eds. Raven Press, New York. 1997, pp 1619-1638.
84. **Szefler SJ,** Leung DYM. Glucocorticoid resistant asthma: Pathogenesis and clinical implications for management. Eur Resp J 1997;10:1640-1647. PMID 9230260
85. Spahn JD, Leung DYM, **Szefler SJ**. New insights into the pathogenesis and management of steroid-resistant asthma. J Asthma 1997;34:177-94. PMID 9168845
86. Spahn JD, Kamada A, **Szefler SJ.** Glucocorticoid therapy in asthma: In, Lieberman P, Anderson J, eds. *Allergic Disease: Diagnosis and Treatment*. Totowa, NJ: Humana Press, 1997, pp. 331-350.
87. Leung DYM, **Szefler SJ**. Steroid resistant asthma: when to suspect, what to do. J Respir Dis. 1998; 19: 13-23. No PMID available.
88. **Szefler SJ,** Spahn JD, Wenzel SE, Leung DYM. Glucocorticoid insensitive asthma: Lessons for future asthma management. In, *Fatal Asthma.* Sheffer AL (ed). Lung Biology in Health and Diseases Series, Lenfant C (ed), Vol 115, Marcel Dekker, New York, 1998, pp. 307-333.
89. **Szefler SJ.** Special issues in managing childhood asthma. J Respir Dis. 19:S35-S41, 1998. No PMID available.
90. Leung DYM, deCastro M, **Szefler SJ**, Chrousos GP. Mechanisms of glucocorticoid resistant asthma. Prepared for Annals of New York Academy of Sciences. Third International Congress of The Society of Neuroimmunology. 1998;840:735-746. PMID 9629300
91. Leung DYM, **Szefler SJ**. New insights into steroid resistant asthma. Pediatr Allergy Immunol. 9:3-12, 1998. PMID 9560836
92. **Szefler SJ**. Inhaled glucocorticoids in pediatric patients with asthma: Overcoming steroid phobia. J Ped Pharm Prac 3:92-99, 1998. No PMID available.
93. **Szefler SJ.** Leukotriene modifiers: What is their position in asthma therapy? J Allergy Clin Immunol. 102(2):170-172, 1998. PMID 9723656
94. Busse WW, Bleeker ER, Creticos PS, Kemp JP, Sullivan SD, **Szefler SJ,** Weiss KB. *Pulmicort Turbuhaler: Clinical Product Monograph*. Published by OCC, Oxford, 1998.
95. **Szefler SJ,** Nelson HS. Alternative agents for anti-inflammatory treatment of asthma. J Allergy Clin Immunol. 102:S23-S35, 1998. PMID 9798721
96. **Szefler SJ**. Early intervention for childhood asthma: Inhaled glucocorticoids as the “preferred” medication. J Allergy Clin Immunol. 1998;102:719-721. PMID 98192826
97. Spahn JD, **Szefler SJ**. Pharmacologic management of pediatric asthma. Immunol Allergy Clin North Am, 1998; 18(1):165-181. No PMID available.
98. **Szefler SJ**. Reply to – Corticosteroid treatment of asthma: now at the crossroads. Resp Med 1999 Feb;93(2):142-4. PMID 10507939
99. Kamada AK, **Szefler SJ**. Pharmacology of the lung and drug therapy. In, Pediatric Respiratory Medicine, Taussig LM, Landau LI (eds.), Mosby, Inc., St. Louis, 1999, pp 264 -285.
100. Leung DYM, Spahn JD, **Szefler SJ**. Immunologic basis of steroid resistant asthma. Allergy Asthma Proc 1999;20 (1):9-14.
101. **Szefler SJ**, Spahn JD, Kamada, AK, Leung DYM**.** Glucocorticosteroids in severe asthma: mechanisms of action and route of administration. In: *Difficult Asthma*, Holgate ST, Boushey H, Fabri LM (eds). Martin Dunitz Limited, The Livery House, London, 1999; pp. 371-387.
102. **Szefler SJ**, Leung DYM**.** Corticosteroid-resistant asthma. In: *Corticosteroids in Respiratory Allergy: Immunology and Allergy Clinics of North America*, Szefler SJ and Leung DYM (eds). W.B. Saunders Co, Philadelphia, Vol.19 (4), 1999; pp. 837-853.
103. **Szefler SJ**, Leung DYM. Severe persistent and corticosteroid insensitive asthma. In Neffen H, Baebna-Cagnani C, Fabbri L, Holgate S, O'Byrne P (eds). *Asthma a Link Between Environment, Immunology and the Airways, Buenos Aires, Argentina, October 17-20, 1999*. Hogrefe & Huber Publishers, Göttingen, Germany, 1999, 177-185.
104. **Szefler SJ**, Spahn JD. Management of severe asthma in children. In Neffen H, Baebna-Cagnani C, Fabbri L, Holgate S, O'Byrne P (eds). *Asthma a Link Between Environment, Immunology and the Airways, Buenos Aires, Argentina, October 17-20, 1999*. Hogrefe & Huber Publishers, Göttingen, Germany, 1999, pp 129-136.
105. Spahn JD, Fost D, **Szefler SJ**. Leukotriene modifying agents in the treatment of asthma. In Neffen H, Baebna-Cagnani C, Fabbri L, Holgate S, O'Byrne P (eds). *Asthma a Link Between Environment, Immunology and the Airways, Buenos Aires, Argentina, October 17-20, 1999*. Hogrefe & Huber Publishers, Göttingen, Germany, 1999, pp 54-61.
106. Spahn JD, **Szefler SJ**. Inhaled glucocorticoids, established and new. In, *New and Exploratory Therapeutic Agents For Asthma.* Yeadon M, Diamant Z (eds). Lung Biology in Health and Diseases Series, Lenfant C (ed), Vol 139, Marcel Dekker, New York, 1998, pp. 307-333.
107. **Szefler SJ**. Asthma: the new advances. Adv Pediatr 2000;47:273-308. PMID 10959447
108. Spahn JD, **Szefler SJ.** Glucocorticoid therapy in asthma: In, Lieberman P, Anderson J (eds). *Allergic Disease: Diagnosis and Treatment*. 2nd Edition, Totowa, NJ: Humana Press, 2000; pp385-404.
109. **Szefler SJ**. Meeting needs of infants and young children with asthma: New developments in nebulized corticosteroid therapy. Introduction.J Allergy Clin Immunol 1999;104:159-161. PMID 10518841
110. **Szefler SJ**. Pharmacodynamics and pharmacokinetics of budesonide: A new nebulized corticosteroid. J Allergy Clin Immunol 1999;104:175-183. PMID 10518844
111. **Szefler SJ**. Clinical need for a nebulized corticosteroid. J Allergy Clin Immunol 1999;104:162-168. PMID 10518842
112. **Szefler SJ**. The changing faces of asthma. J Allergy Clin Immunol 2000;106:139-43. PMID 10984394
113. **Szefler SJ**. Meeting the needs of the modernization act: Challenges in developing pediatric therapies. J Allergy Clin Immunol 2000;106:115-7.
114. Kamada A, **Szefler SJ**. Mechanisms of action of corticosteroids in asthma and rhinitis. In *Asthma and Rhinitis*, Busse WW and Holgate ST (eds), Blackwell Scientific, Boston, 2nd Ed., 2000.
115. Vanden Burgt JA, Busse WW, Martin RJ, **Szefler SJ**, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000;106(6):1209-1226. PMID 11112914
116. Leung DYM, Spahn JD, **Szefler SJ**. Steroid-resistant asthma: new insights and implications for management. In: Severe Asthma: A multidisciplinary approach. **Szefler SJ,** Leung DYM (eds), 2nd edition, Marcel Dekker, Inc. New York. 2001, pp597-619.
117. **Szefler SJ**, Leung DYM. Prevention of severe asthma: promising opportunities. In: Severe Asthma: A multidisciplinary approach. **Szefler SJ**, Leung DYM (eds), 2nd edition, Marcel Dekker, Inc. New York. 2001, pp 621-635.
118. **Szefler SJ**. A review of budesonide inhalation suspension in the treatment of pediatric asthma. Pharmacotherapy 2001;21(2):195-206. PMID 11213857
119. **Szefler SJ**. Challenges in assessing outcomes for pediatric asthma. J Allergy Clin Immunol. 2001;107(5 pt 2):S456-S464 PMID 113444375
120. **Szefler S**J. Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol 2001;108(1):26S-31S. PMID 11449203
121. **Szefler SJ**, Spahn JD, Kamada AK, Leung DYM. Glucocorticoids in severe asthma: mechanisms of action and route of administration. In: *Difficult Asthma.* Holgate ST, Boushey HA, Fabri LM (eds). London: Martin-Dunitz, 2001, pp. 371-387.
122. Spahn JD, **Szefler SJ**. Inhaled Glucocorticoids from Combination Therapy for Asthma and COPD, Editors Martin RJ, Kraft M. Lung Biology in Health and Diseases Series, Lenfant C (ed), Vol 145, Marcel Dekker, New York, 2001, pp.1-52.
123. Spahn JD, Covar RA, Gleason MC, Tinkelman DG, **Szefler SJ**. Pharmacologic management of asthma in infants and small children. In: *Textbook of Pediatric Asthma*. Naspitz CK, Szefler SJ, Tinkelman D, Warner JO (eds.), Martin Dunitz Ltd., London, 2001, pp. 121-147.
124. **Szefler SJ**, Martin RJ and the National Heart, Lung and Blood Institute Asthma Clinical Research Network. Evaluation and comparison of inhaled steroids. In: *Airway Activity and Selectivity of Inhaled Steroids in Asthma - Mechanisms, Models of Evaluation and Clinical Impacts.* R.P. Schleimer, P.M. O’Byrne, S.J. Szefler, and R Brattsand (editors) In, *Lung Biology in Health and Disease*. C. Lenfant (editor). 2002, Vol 163, pp.389-418.
125. Spahn JD, **Szefler SJ**. Childhood asthma: New insights into management. J Allergy Clin Immunol 2002;109:3-13. PMID: 11799358
126. Leung DYM, **Szefler SJ**. Mechanisms of corticosteroid action and insensitivity. In: *Textbook of Respiratory Cell and Molecular Biology*, Wardlaw AJ, Hamid QA (eds), Martin Dunitiz Publishers, London. 2002, pp 437-456.
127. Leung DY, Spahn JD, Szefler SJ. Steroid-unresponsive asthma. Semin Respir Crit Care Med 2002;23:387-98. PMID: 16088632
128. Spahn JD and Szefler, SJ. Inhaled Steroids: Are they all created equal? Resp Med, 2002, 23:377-386. PMID: 16088631
129. **Szefler SJ**, Eigen H. Budesonide inhalation suspension: A nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002;109:729-742. PMID: 11941331
130. **Szefler SJ.** The natural history of asthma and early intervention. J Allergy Clin Immunol 2002; 109:S549-53. PMID: 12063511
131. **Szefler SJ.** Altering the course of asthma: Introduction. J Allergy Clin Immunol 2002;109:S519-20. PMID: 12063506
132. **Szefler SJ,** Simoes EAF. Montelukast for respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2003, 167:290-291. PMID: 12554617
133. **Szefler SJ**. Pediatric Asthma: an approach to pharmacogentics analysis. Chest 2003, 123:434-438. PMID: 12629027
134. Liu AH and **Szefler SJ**. Advances in childhood asthma: hygiene hypothesis, natural history and management. J Allergy Clin Immunol 2003;111:S785-S792. PMID: 12618744
135. **Szefler SJ.** New directions in asthma therapy. In: Leung DYM, Sampson H, Geha R and Szefler SJ (eds) *Pediatric Allergy: Principles and Practice.* 2003, Mosby, St. Louis, pp. 465-472.
136. Covar RA, Spahn JD, **Szefler SJ.** Special considerations for infants and young children. Leung DYM, Sampson H, Geha R, Szefler SJ (eds) *Pediatric Allergy: Principles and Practice.* 2003, Mosby, St. Louis, pp. 379-391.
137. Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, Hindmarch I, Terndrup TE, Simons FER, Spangler DL, **Szefler SJ**, Waldman SA, Weiler J, Wong DF. First do no harm: Managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003;111-S835-842. PMID 12743547
138. **Szefler, SJ**, Pedersen S. Role of budesonide as maintenance therapy for children with asthma. Pediatric Pulmonology 2003;361(1):13-21. PMID 12772218
139. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice G, **Szefler SJ.** Inhaled corticosteroids: Past lessons and future issues. J Allergy Clin Immunol 2003;112 D1-D40. PMID 14515117
140. Szefler SJ, Whelan G, Gleason M, Spahn J. The Need for Pediatric Studies of Allergy and Asthma Medications. Current Allergy and Asthma Reports 2003; 3:478-483. PMID 14531968
141. Spahn JD, Covar R, **Szefler SJ**. Glucocorticoids: B. Clinical Science. In: Adkinson NJ, Bochner BS, Busse WW, Holgate ST, Simons FER, Yunginger JW (eds) *Middleton’s Allergy Principles & Practice*, 6th edition. 2003.
142. **Szefler SJ**. Identifying the Child in Need of Asthma Therapy. Stempel DA and Spahn JD (eds) *Pediatric Clinics of North America: Asthma*. 2003. PMID 12877237
143. Rohatagi S, Appajosyula S, Derendorf H, **Szefler S**, Nave R, Zech K, Banerji D. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetics/pharmacodynamic perspective. J Clin Pharm, 2004; 44:37-47. PMID 14681340
144. Apter AJ and **Szefler SJ**. Advances in Adult and Pediatric Asthma. J Allergy Clin Immunol, 2004; 113:407-414. PMID: 15007338
145. **Szefler SJ**. Clinical Update: Long-term management of young children with asthma. Respiratory Digest, 2004; 6:1-14. No PMID available.
146. **Szefler, S**. Current concepts in asthma treatment in children. In: Current Opinion in Pediatrics: Pulmonary Section. 2004, 16:299-304. PMID: 15167017
147. Silkoff PE, Carlson M, Bourke T, Katial R, Ogren E, **Szefler SJ**. The Aerocrine exhaled nitric oxide monitoring system, NIOX®, is cleared by the FDA for monitoring therapy in asthma. J Allergy Clin Immunol 2004;114:1241-1256. PMID: 15536442
148. Whelan GJ, Spahn JD, **Szefler SJ**. Antiasthmatics. In: Yaffe SJ and Aranda JV (eds) Neonatal and Pediatric Pharmacology. Therapeutic Principles in Practice. Lippincott Williams & Wilkins, 2005.
149. **Szefler SJ** and Apter A. Advances in pediatric and adult asthma. J Allergy Clin Immunol 2005; 115:470-477. PMID: 15753890
150. **Szefler SJ.** Facing the challenges of childhood asthma: what changes are necessary? J Allergy Clin Immunol 2005:115:685-686. PMID: 15805985
151. Bisgaard H and **Szefler SJ**. Understanding mild persistent asthma in children: the next frontier. J Allergy Clin Immunol 2005;115:708-713. PMID: 15805988
152. Covar RA, Macomber B, **Szefler SJ.** Medications as asthma triggers. Immunology and Allergy Clinics of North America, 2005;25:169-190. PMID: 15579370
153. **Szefler SJ.** Airway remodeling: therapeutic target or not? Editorial, Am J Respir Crit Care Med, 2005;171:672-673. PMID: 15790863
154. **Szefler SJ**, Whelan GJ, Leung DYM. Black Box Warning: Wake-up call or over-reaction? J Allergy Clin Immunology, 2006;117:26-29. PMID: 16387579
155. **Szefler SJ**. Therapeutic Approach to Childhood Asthma. In: Busse WW and Lemanske RF (eds) *Asthma Prevention. Lung Biology in Health and Disease Series.* Taylor & Francis Group, New York, 2005, pp. 419-439.
156. Bisgaard H and **Szefler SJ**. US Food and Drug Administration Warning Against Long-Acting 2-gonists Highlights the Orphan Status of Paediatrics in Evidence Based Pharmacotherapy. The Lancet, 2006, 367:286-288. No PMID available.
157. Apter AJ and **Szefler SJ**. Advances in adult and pediatric asthma. J Allergy Clin Immunol, 2006; 117:512-518. PMID: 16522448
158. Wenzel S and **Szefler SJ**. Managing Severe Asthma for the Clinical Pearls Series: Journal of Allergy and Clinical Immunology. J Allergy Clin Immunology 2006; 117:508-511. PMID: 16522447
159. Mjaanes CM, Whelan G and **Szefler SJ**. Corticosteroid Therapy in Asthma: Predictors of Responsiveness. In: Kraft M (ed) *Clinics in Chest Medicine*, W.B. Saunders Co., Philadelphia, 2006, pp 119-132. PMID: 16543057
160. **Szefler SJ** and Pedersen S. The Next 10 Years. In: Szefler SJ and Pedersen S (eds), *Childhood Asthma: Breaking Down the Barriers*, Taylor & Francis Group, New York, 2006, pp. 673-691.
161. **Szefler SJ** and Whelan G. Anticipating and Managing Variable Response to Asthma Therapy. In Childhood Asthma: Breaking Down the Barriers, Szefler SJ and Pedersen S (eds), Taylor & Francis Group, New York, 2006, pp. 403-446.
162. Guilbert T, Martinez FD, **Szefler SJ** for the Childhood Asthma Research and Education (CARE) Network Steering Committee. Correspondence: Inhaled Corticosteroids and Children. N Engl J Med 2006, 355:624-626.
163. **Szefler SJ** for the Childhood Asthma Research and Education (CARE) Network Steering Committee. Correspondence: Bronchial obstruction: a limited, out-of-fashion approach to measure treatment efficacy in childhood asthma? J Allergy Clin Immunology 2006; 117:475-476. PMID 16461158
164. Spahn JD, Covar RA, Jain N, Gleason M, Shimmamoto R, **Szefler SJ**, Gelfand EW. Effect of montelukast on peripheral airflow obstruction in children with asthma. Ann Allergy Asthma Immunol 2006; 96:541-49. PMID: 16680924
165. **Szefler, SJ**. A view from the bus: on the roadmap with the National Institutes of Health Asthma Networks. Editorial. J Allergy Clin Immunology 2007;119:24-27. PMID: 17208584
166. **Szefler SJ**. Advances in pediatric asthma 2006. Advances in Asthma, Allergy and Immunology Series 2007. J Allergy Clin Immunology 2007; 119:558-562. PMID: 17270259
167. Spahn JD and **Szefler SJ**. Steroid Therapy for Asthma in Children. Current Opinion in Pediatrics 2007; 19:300-5. PMID: 17505190
168. **Szefler, SJ.** Advances in Pediatric Asthma 2007. Advances in Asthma, Allergy and Immunology Series 2008. J Allergy Clin Immunology 2008; 121:614-9. PMID: 18234318
169. **Szefler, SJ.** Asthma Progression: can we and should we measure it? J Allergy Clin Immunology 2008; 121:598-600. PMID: 18234308
170. **Szefler SJ.** Asthma exacerbations: Putting a lid on the volcano. J Allergy Clin Immunol 2008; 122:697-9. PMID: 19014760
171. **Szefler SJ.** Individualizing asthma therapy: application of biomarkers. J Asthma 2008; 45(S1):29-31. PMID 17270259
172. **Szefler SJ.** Advances in pediatric asthma in 2008: Where do we go now? J Allergy Clin Immunol 2009;123:28-34. PMID: 19130924
173. **Szefler SJ**, Gergen PJ, Mitchell H, Busse WW for the NIAID Inner City Asthma Consortium. Author’s reply to Clinical use of exhaled nitric oxide measurements. The Lancet, 2009, 373:382.
174. **Szefler SJ**. Managing asthma and allergies in schools: an opportunity to coordinate health care. J Allergy Clin Immunology 2009; 124:201-4. PMID: 19596144
175. **Szefler SJ** and Martin RJ. Lessons learned from variation in response to therapy in clinical trials. J Allergy Clin Immunol 2010; 125:285-92. PMID 20074785 PMIC PMC2904989
176. **Szefler SJ**, Gergen P, Mitchell H, Morgan W. Achieving asthma control in the inner city: Do the NIH asthma guidelines really work? J Allergy Clin Immunol 2010, 125:521-6. PMID 20226288
177. Raissy HH, Kelly HW and **Szefler SJ**. Antiasthmatics. In: Yaffe SJ and Aranda JV (eds) *Neonatal and Pediatrc Pharmacology. Therapeutic Principles in Practice.* Lippincott Williams & Wilkins, Philadelphia, 2010, pp. 574-597.
178. Szefler SJ. Editorial: Defining asthma phenotypes: focusing the picture. J Allergy Clin Immunol 2010;126:939-40. PMID 21050941
179. **Szefler SJ**. Advances in pediatric asthma in 2009: Gaining control of childhood asthma. J Allergy Clin Immunol 2010;125:69-78. PMID 20109738
180. **Szefler SJ**. Guidelines for the Treatment of Childhood Asthma: Gains and Opportunities. In, *Pediatric Allergy: Principles and Practice Editors: DYM Leung, HA Sampson, RS Geha, SJ Szefler*. WB Saunders, Philadelphia, PA, 2010.
181. **Szefler SJ**. New directions in asthma management. In, *Pediatric Allergy: Principles and Practice Editors: DYM Leung, HA Sampson, RS Geha, SJ Szefler*. WB Saunders, Philadelphia, PA, 2010.
182. **Szefler SJ**. Advances in pediatric asthma in 2010: Addressing the major issues. J Allergy Clin Immunolo 2011; 127:102-15. PMID 21211645.
183. Barkovich AJ, **Szefler SJ**, Olson E, Rymer W. Workshop White Paper. Eunice Kennedy Shriver National Institute on Child Health and Human Development. Scientific Vision Workshop on Diagnostics and Therapeutics. <http://www.nichd.nih.gov/vision>
184. **Szefler SJ.** Advancing asthma care: the glass is only half full. J Allergy Clin Immunol 2011;128:485-94. NIHMS #315313. PMID 21798579 PMCID PMC3164913
185. **Szefler SJ,** Busse WW. Adding LABAs to inhaled glucocorticoids for asthma. N Engl J Med 2011; 365:1260-1261. PMID 21991913
186. **Szefler SJ** and Dakhama A. New insights into asthma pathogenesis and treatment. Current Opinion in Immunology 2011;23:801-807. PMID 21840186
187. **Szefler SJ.** Editorial: Personalized medicine for asthma management during pregnancy. Lancet 2011;378:963-4. PMID21907846
188. **Szefler SJ**. Advances in Pediatric Asthma in 2011: Moving forward. J Allergy Clin Immunol 2012; 129:60-68. PMC 3032272; NIHMS 256545. PMID 22196525
189. **Szefler SJ,** Chinchilli VM, Israel E, Denlinger LC, Lemanske RF, Calhoun W, Peters SP for the National Heart, Lung and Blood Institute Asthma Clinical Research Network. Key observations from the NHLBI Asthma Clinical Research Network. Thorax 2012;67:45-455. PMID 22514237 PMCD PMC3709602
190. **Szefler SJ.** Is it time to revise the asthma guidelines? J Allergy Clin Immunol 2011;128:937-8. PMID 21943941
191. **Szefler SJ.** Early asthma: stepping closer to primary prevention. J Allergy Clin Immunol 2012;130:308-10. PMID 22846745
192. **Szefler, SJ** and Busse WB. The LABA controversy in asthma: troublesome times! J Allergy Clin Immunol 2012;130:1256-9. PMID 23195524
193. Chipps BE, Zeiger RS, Borish L, Wenzel SE, Yegin S, Hayden ML, Miller DP, Bleecker ER, Simons ER, **Szefler SJ**, Weiss ST, Haselkorn T for the TENOR Study Group. Key findings and clinical implications from The Epidemiology and Natural History of Asthma; Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 2012;130:332-42. PMID 22694932.
194. **Szefler, SJ**. Advances in Pediatric Asthma in 2012: Moving toward asthma prevention. J Allergy Clin Immunology 2013;131:36-46. PMID 23199603
195. Raissy HH, Kelly HW, Harkins M, **Szefler SJ**. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med 2013; 187:798-803. PMID 23370915
196. **Szefler, SJ**. Advances in pediatric asthma in 2013: coordinating care. J Allergy Clin
 Immunol 2014;133:654-61. PMID 24581430 PMCID PMC3969825
197. **Szefler SJ**. Pediatric Asthma. *In Global Atlas of Allergy, Editors Akdis CA and Agache I.* <http://www.eaaci.org/resources/global-atlas-of-allergy.html>.
198. Cicutto L, Gleason M, **Szefler SJ**. Establishing school-centered asthma programs. J Allergy Clin Immunol 2014;134:1223-1230.
199. **Szefler SJ**. Advances in pediatric asthma in 2014: Moving towards a population health perspective. J Allergy Clin Immunol 2015;135:644-52. PMID 25649079
200. Long A, Rothman K, Chen H, Carrigan G, Szefler SJ on behalf of the EXCELS study authors. Reply to Correspondence: EXCELS study results do not rule out potential cancer risk with omalizumab. J Allergy Clin Immunol 2015;135:289-90. No PMID.
201. Pijnenburg MW, **Szefler SJ**. Personalized medicine in children with asthma. Paediatric Respiratory Reviews, 2015;16:101-107. PMID 25458797
202. **Szefler SJ**. Monitoring and adherence in asthma. The Lancet Respiratory Medicine 2015;3:175-76. PMID 25617214
203. Brand PL, Makela MJ, **Szefler SJ**, Frischer T, Price D. ERS Task Force Monitoring Asthma in Children. Monitoring asthma in childhood: symptoms, exacerbations and quality of life. Eur Respir Rev 2015;24:187-193. PMID 26028631
204. **Szefler SJ**. Examining causes of the urban (inner city) asthma epidemic: implementing new management strategies. Allergy Asthma Proc 2016;37:4-8. PMID 26831839
205. Anderson WC and **Szefler SJ**. New and Future Strategies to Improve Asthma Control in Children. J Allergy Clin Immunol 2015;136:848-59. PMID 26224549
206. Hoch HE, Szefler SJ. Intermittent steroid inhalation for the treatment of childhood asthma. Expert Review of Clinical Immunology. DOI: 10.1586/1744666X.2016.1105741:

To link to this article: http://dx.doi.org/10.1586/1744666X.2016.1105741 PMID 26561351

1. **Szefler SJ**. Update on Severe Asthma in Children. Current Views in Allergy and Immunology, 2015.
2. **Szefler SJ**. New directions in asthma management: a tale of two cities. In, *Pediatric Allergy: Principles and Practice Editors: DYM Leung, HA Sampson, SJ Szefler*. WB Saunders, Philadelphia, PA, 2010, 2016, 360-365.
3. Federico MJ, Hoch HE, Anderson III WC, Spahn J and **Szefler SJ**. Asthma Management for Children: Risk Identification and Prevention. *Advances in Pediatrics*. Volume 63, 2016, pp 103-126, Elsevier, Philadelphia, PA. PMID: 27426897
4. Liu AH, Anderson WC, Dutmer C, Searing D, **Szefler SJ**. Advances in asthma across the lifespan 2015: integrating precision medicine andpopulation health management. J Allergy Clin Immunol 2016;138:397-404. PMID: 27497278.
5. Carr WW, **Szefler SJ**. Inhaled corticosteroids: ocular safety and the HPA axis. Ann Allergy, Asthma and Immunology 2016;117:589-94. PMID: 27979014
6. Liptzin DR, **Szefler SJ**. Evolution of asthma self-management programs in children: from the crisis plan to Facebook. J Peds 2016;179:19-23 PMID:27745749
7. Hoch H E, Anderson III WC, **Szefler SJ**. Modern Molecular Therapies for Application in Managing Childhood Asthma. Kendig and Chernick’s Disorders of the Respiratory Tract in Children. Ninth Edition, 2016, Elsevier, London, in press
8. Spahn J, Malka, J, **Szefler SJ**. Current Application of Exhaled Nitric Oxide in Clinical Practice. J Allergy Clin Immunol, 2016;138:1296-8. PMID: 27664377
9. Abrams EM, **Szefler SJ**, Becker AB. Effect of asthma therapies on the natural course of asthma. Annals of Allergy, Asthma & Immunology 2016;117:627-633. PMID: 28073701
10. Gleason M, Cicutto L, Haas-Howard C, Raleigh BM, **Szefler** SJ. [Leveraging Partnerships: Families, Schools, and Providers Working Together to Improve Asthma Management.](https://www.ncbi.nlm.nih.gov/pubmed/27709456) Curr Allergy Asthma Rep. 2016 Oct;16(10):74. Review. PMID: 27709456.
11. Burbank AJ, **Szefler** SJ. [Current and future management of the young child with early onset wheezing.](https://www.ncbi.nlm.nih.gov/pubmed/28092287) Curr Opin Allergy Clin Immunol. 2017 Apr;17(2):146-152. doi: 10.1097/ACI.0000000000000341. PMID: 28092287
12. **Szefler SJ**, Holguin F, Wechsler M. Introduction for *Personalized Medicine for Asthma for the Clinician*, eds Szefler SJ, Holguin F, Wechsler M, Elsevier, In press.
13. **Szefler SJ**, Holguin F, Wechsler M. Future Directions for *Personalized Medicine for Asthma for the Clinician*, eds Szefler SJ, Holguin F, Wechsler M, Elsevier, In press.
14. Anderson WC, Apter A, Dutmer CM, Searing DA, **Szefler SJ**. Advances in asthma in 2016: Designing individualized approaches to management. J Allergy Clin Immunol 2017;140:671-80. PMID:28709967
15. Fitzpatrick AM, Jackson DJ, Mauger D, **Szefler SJ**. Reply to Coorespondence regarding Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol 2017; 140:213. PMID: 28780972
16. Hamelmann E, Vogelberg C, **Szefler** SJ. [Reply to 'Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents?'](https://www.ncbi.nlm.nih.gov/pubmed/28399660) Expert Opin Pharmacother. 2017 Jun;18(8):837-838. PMID: 28399660
17. Bacharier LB, **Szefler** SJ. [Pediatric asthma - moving ahead faster than ever.](https://www.ncbi.nlm.nih.gov/pubmed/28225363) Curr Opin Allergy Clin Immunol. 2017 Apr;17(2):96-98. PMID: 28225363
18. Kakumanu S, Antos N, **Szefler** SJ, Lemanske RF Jr. [Building school health partnerships to improve pediatric asthma care: The School-based Asthma Management Program.](https://www.ncbi.nlm.nih.gov/pubmed/28177950) Curr Opin Allergy Clin Immunol. 2017 Apr;17(2):160-166. PMID: 28177950
19. Hamelmann E, Vogelberg C, **Szefler** SJ. [Tiotropium for the treatment of asthma in adolescents.](https://www.ncbi.nlm.nih.gov/pubmed/28110558) Expert Opin Pharmacother. 2017 Feb;18(3):305-312. PMID: 28110558
20. Stempel DA, **Szefler** SJ, Pascoe SJ. [Salmeterol and Fluticasone Propionate in Children with Asthma.](https://www.ncbi.nlm.nih.gov/pubmed/27959746) N Engl J Med. 2016 Dec 1;375(22):e46. PMID: 27959746.
21. Gleason M, Cicutto L, Haas-Howard C, Raleigh BM, **Szefler** SJ. [Leveraging Partnerships: Families, Schools, and Providers Working Together to Improve Asthma Management.](https://www.ncbi.nlm.nih.gov/pubmed/27709456) Curr Allergy Asthma Rep. 2016 Oct;16(10):74. Review. PMID: 27709456
22. Abrams EM, **Szefler** SJ, Becker AB. [Does inhaled steroid therapy help emerging asthma in early childhood?](https://www.ncbi.nlm.nih.gov/pubmed/28780183) Lancet Respir Med. 2017;5:827-834. PMID:28780183
23. **Szefler SJ**. Preface. Szefler SJ, Holguin, F, Wechsler M. Personalized Medicine for Asthma for the for the Clinician, 2018, Elsevier, St. Louis, MO, p. ix.
24. **Szefler SJ**, Holguin, F, Wechsler M. Introduction. Szefler SJ, Holguin, F, Wechsler M. Personalized Medicine for Asthma for the for the Clinician, 2018, Elsevier, St. Louis, MO, pp. xiii-xv.
25. **Szefler SJ**, Holguin, F, Wechsler M. Future directions in asthma managementn. Szefler SJ, Holguin, F, Wechsler M. Personalized Medicine for Asthma for the for the Clinician, 2018, Elsevier, St. Louis, MO, pp. 209-211.
26. **Szefler SJ,** Chipps B. [Challenges in the treatment of asthma in children and adolescents.](https://www.ncbi.nlm.nih.gov/pubmed/29625664) Ann Allergy Asthma Immunol. 2018 Apr;120(4):382-388. PMID: 29625664
27. Anderson WC, Gleason MC, Miyazawa N, **Szefler SJ**. Approaching current and new drug therapies for pediatric asthma. Ped Clin N Am, 2017;64:1197-1207. doi: 10.1016/j.pcl.2017.08.001. Review. PMID:2917378
28. Anderson WC, **Szefler SJ**. Controlling the risk domain in pediatric asthma through personalized care. Sem Resp Med, 2018:39:36-44. PMID:2942798
29. Hamelmann E, **Szefler SJ**. Efficacy and safety of tiotropium in children and adolescents. Drugs. 2018;78:327-338. PMID: 29368127
30. **Szefler SJ**, Chipps B. Challenges in the treatment of asthma in children and adolescents. Ann Allergy Asthma Immunol 2018;120:382-388. PMID: 29625664
31. Chipps BE, Bacharier LB, Farrar JR, Jackson DJ, Murphy KR, Phipatanakul W, **Szefler SJ**, Teague WG, Zeiger RS. The pediatric asthma yardstick: Practical recommendations for a sustained step-up in asthma therapy for children with inadeqyately controlled asthma. Ann Allergy Asthma Immunol 2018;120:559-579. PMID: 29653238
32. **Szefler SJ**. Asthma across the lifespan: Time for a paradigm shift J Allergy Clin Immunol 2018;142:773-80. PMID: 29627424
33. Lenney W, Bush A, Fitzgerald DA, Fletcher M, Ostrem A, Pedersen S, **Szefler SJ**, Zar HJ on behalf of the GSK Paediatric Project Advisory Board Committee. Improving the global diagnosis and management of asthma in children. Thorax 2018;0:1-8.
34. **Szefler SJ**. Dr. Elliot F. Ellis: Initiating personalized asthma mangment in children. Ann Allergy Asthma Immunol. 2018;121:3-6 PMID:29758291
35. Messinger AI, Deterding RR, **Szefler SJ**. Bridging technology to day to day asthma management. Am J Resp Crit Care Med 2018; 198:291-292. PMID:29847147
36. **Szefler SJ.** [Boehringer-Ingelheim Satellite Symposium Choosing the Right Controller Therapy in Pediatric Patients with Asthma.](https://www.ncbi.nlm.nih.gov/pubmed/29906344) Pediatr Pulmonol. 2018; 53(S1):S171-S173. PMID:29906344
37. **Szefler SJ.** Steroid refractory inflammatory phenotypes in asthma for Pediatric Pulmonology. Plenary sessions. Ped Pulmonol 2018;53:S17-S19.
38. Abrams EM, Becker AB, **Szefler SJ**. Use of oral corticosteroids in the wheezy toddler. J Pediatrics 2018, 2018 Oct;201:16-20. PMID:30251636
39. Abrams EM, Becker AB, **Szefler SJ**. Current state and future of biologics in the treatment of asthma in children. Pediatric Allergy, Immunology, and Pulmonology, 2018 Sep 1;31(3):119-131. PMID: 30283711
40. Abrams EM, **Szefler** SJ, Becker AB. [What Is the Role of Increasing Inhaled Corticosteroid Therapy in Worsening Asthma in Children?](https://www.ncbi.nlm.nih.gov/pubmed/30446480) J Allergy Clin Immunol Pract. 2019;7:842-847doi: 10.1016/j.jaip.2018.10.004. [Epub ahead of print] PMID:30446480
41. Hoch H, Anderson WC, **Szefler SJ**. Modern molecular therapies for application in managing childhood asthma. Kendig Disorders of the Respiratory Tract in Children, 9th Edition, editors Wilmott RW, Deterding R, Li A, Ratjen F, Sly P, Zar H, Bush A. Elsevier, Inc., St. Louis, MO, 2019, pp. 747-755.
42. Abrams EM, Becker AB, **Szefler** SJ. [Where does worsening asthma end and an asthma exacerbation begin?](https://www.ncbi.nlm.nih.gov/pubmed/30468932) Ann Allergy Asthma Immunol. 2019 329-330. doi: 10.1016/j.anai.2018.11.017. PMID:30468932
43. Lanz MJ, Gilbert I, **Szefler** SJ, Murphy KR. [Can early intervention in pediatric asthma improve long-term outcomes? A question that needs an answer.](https://www.ncbi.nlm.nih.gov/pubmed/30609252) Pediatr Pulmonol. 2019;54:348-357. doi: 10.1002/ppul.24224. PMID:30609252
44. Anderson WC 3rd, **Szefler** SJ. ["To Biologic or Not to Biologic?: The Question of Cost-Effectiveness".](https://www.ncbi.nlm.nih.gov/pubmed/30703438) Ann Allergy Asthma Immunol. 2019;122:367-372. doi: 10.1016/j.anai.2019.01.018. PMID:30703438
45. Lenney W, Adachi Y, Bush A, Fischer GB, Hong J, Ostrem A, Pedersen S, Sly PD, **Szefler SJ**, Tilak R, Zar HJ; GSK Global Children's Asthma Group. [Asthma: moving toward a global children's charter.](https://www.ncbi.nlm.nih.gov/pubmed/30803924) Lancet Respir Med. 2019 2019 Apr;7(4):299-300. Feb 22. pii: S2213-2600(19)30074-8. doi: 10.1016/S2213-2600(19)30074-8. PMID:30803924
46. **Szefler** S, Vogelberg C, Jugovic B, de la Hoz A, Hamelmann E. [Commentary: Treating Pediatric Asthma According Guidelines.](https://www.ncbi.nlm.nih.gov/pubmed/30972315)Front Pediatr. 2019 Mar 27;7:109. doi: 10.3389/fped.2019.00109. eCollection 2019. No abstract available. PMID:30972315
47. Abrams EM, **Szefler** SJ, Becker AB. [Time for Allergists to Consider the Role of Mouse Allergy in Non-Inner City Children with Asthma.](https://www.ncbi.nlm.nih.gov/pubmed/30962154)J Allergy Clin Immunol Pract. 2019 Apr 5. pii: S2213-2198(19)30264-8. doi: 10.1016/j.jaip.2019.03.004. [Epub ahead of print] PMID:30962154
48. Federico MJ, **Szefler** SJ. [High-risk asthma: Never give up.](https://www.ncbi.nlm.nih.gov/pubmed/31054649) Ann Allergy Asthma Immunol. 2019;122(5):441-442. doi: 10.1016/j.anai.2019.03.013. PMID:31054649
49. Hamelmann E, **Szefler** SJ, Lau S. [Severe asthma in children and adolescents.](https://www.ncbi.nlm.nih.gov/pubmed/31074873) Allergy. 2019 May 10. doi: 10.1111/all.13862. [Epub ahead of print] PMID:31074873
50. Mosnaim G, Stempel H, **Szefler** SJ, Stempel DA. [Asthma Control-Time to Rethink Definitions and Criteria.](https://www.ncbi.nlm.nih.gov/pubmed/31076062) J Allergy Clin Immunol Pract. 2019;7(5):1522-1523. doi: 10.1016/j.jaip.2019.02.001. PMID:31076062
51. Guilbert TW, Zeiger RS, Haselkorn T, Iqbal A, Alvarez C, Mink DR, Chipps BE, **Szefler** SJ. Reply. J Allergy Clin Immunol Pract. 2019;7:2102-2103. doi: 10.1016/j.jaip.2019.04.034.
52. Bass PF, Szefler SJ. How to diagnose and treat severe asthma. Contemporary Pediatrics, March 2019, pp. 15-20.
53. Mattes J, Szefler SJ. Mechanisms in children. In, Chung KF, Israel E, Gibson PG,eds. Severe Asthma [ERS monograph]. Sheffield European Respiratory Society, 2019; pp. 231-245 [http://doi.org/10.1183/2312508X.10024318].
54. Guilbert TW, Zeiger RS, Haselkorn T, Iqbal A, Alvarez C, Mink DR, Chipps BE, **Szefler** SJ. [Reply.](https://www.ncbi.nlm.nih.gov/pubmed/31122886) J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):2102-2103. doi: 10.1016/j.jaip.2019.04.034. Epub 2019 May 20. No abstract available. PMID: 31122886
55. Fielding S, Pijnenburg M, de Jongste JC, Pike KC, Roberts G, Petsky H, Chang AB, Fritsch M, Frischer T, **Szefler** S, Gergen P, Vermeulen F, Vael R, Turner S. [Response.](https://www.ncbi.nlm.nih.gov/pubmed/31174655) Chest. 2019 Jun;155(6):1313-1314. doi: 10.1016/j.chest.2019.03.016. No abstract available. PMID: 31174655
56. **Szefler** SJ. [Legends of Allergy and Immunology: Donald Y. M. Leung.](https://www.ncbi.nlm.nih.gov/pubmed/31465550) Allergy. 2019 Aug 29. doi: 10.1111/all.14031. [Epub ahead of print] PMID: 31465550
57. Abrams EM, Hoch HE, Becker AB, **Szefler SJ**. Potential therapeutic options for severe asthma in children: Lessons from adult trials. In, Forno E, Saglani S, “Severe asthma in children and adolescents: Mechansisms and management”, Springer Nature, 2019, in press.
58. Mattes J, Szefler SJ. Mechanism in children. In, Chung KF, Israel E, Gibson P, eds. Severe Asthma. [ERS Monograph]. Sheffield, European Respiratory Society 2019,; pp. [https://doi.org/10.1183/2312508X.10024318
59. Hamelmann E, **Szefler SJ**, Lau S. Severe asthma in children and adolescents. Allergy 2019 doi:10.1111/a,,.13862
60. Stempel H, Federico MJ, Szefler SJ. [Applying a biopsychosocial model to inner city asthma: Recent approaches to address pediatric asthma health disparities.](https://www.ncbi.nlm.nih.gov/pubmed/31678039) Paediatr Respir Rev. 2019; 32:10-15. doi: 10.1016/j.prrv.2019.07.001. PMID: 31678039
61. Hoch H, Kattan M, **Szefler** SJ. [Challenges in managing difficult-to-treat asthma in children: Stop, look, and listen.](https://www.ncbi.nlm.nih.gov/pubmed/31710161) Pediatr Pulmonol. 2020;55:791-794. doi: 10.1002/ppul.24554. [Epub ahead of print] PMID:31710161
62. Szefler SJ. Biomarkers in the context of managing severe asthma. J Prec Respir Med 2019;2:1-9. Doi:10.2500/jprm.2019.40.190009.
63. Abrams EM, Becker AB, Szefler SJ. [Paradigm Shift in Asthma Therapy for Adolescents: Should It Apply to Younger Children as Well?](https://www.ncbi.nlm.nih.gov/pubmed/31904766) JAMA Pediatr. 2020 Jan 6. doi: 10.1001/jamapediatrics.2019.5214. [Epub ahead of print] No abstract available. PMID:31904766
64. Ross KR, **Szefler** SJ. [Introducing telehealth and adherence monitoring to school-centered asthma management.](https://www.ncbi.nlm.nih.gov/pubmed/31977164) Pediatr Pulmonol. 2020;55:565-567. doi: 10.1002/ppul.24663. PMID:31977164
65. Abrams EM, Szefler SJ. Applying various study designs to direct precision medicine, In, EAACI, Global Atlas of Asthma……[accepted fro publication].
66. Federico MJ, McFarlane AE 2nd, **Szefler** SJ, Abrams EM. [The Impact of Social Determinants of Health on Children with Asthma.](https://www.ncbi.nlm.nih.gov/pubmed/32294541) J Allergy Clin Immunol Pract. 2020;8:1808-1814. doi: 10.1016/j.jaip.2020.03.028. PMID:32294541
67. Abrams EM, **Szefler** SJ. [Managing Asthma during COVID-19: An Example for Other Chronic Conditions in Children and Adolescents.](https://www.ncbi.nlm.nih.gov/pubmed/32330469) J Pediatr. 2020;222:221-226. doi: 10.1016/j.jpeds.2020.04.049. PMID:32330469
68. Abrams EM, Szefler SJ. COVID-19 and the impact of social determinants of health [published online ahead of print, 2020 May 18]. *Lancet Respir Med*. 2020;8:659-661. doi:10.1016/S2213-2600(20)30234-4
69. Kaplan A, Szefler SJ, Halpin DMG. Impact of comorbid conditions on asthmatic adults and children. *NPJ Prim Care Respir Med*. 2020;30(1):36. Published 2020 Aug 20. doi:10.1038/s41533-020-00194-9
70. Navanandan N, **Szefler SJ**. Personalized asthma management in pediatric patients based on treatment response. Expert Review of Precision Medicine and Drug Development 2020; DOI: 10.1080/23808993.2020.1834843
71. Gleason M, Cicutto L, **Szefler SJ**. Collaboratng with schools to support children with asthma. In, Pediatric Allergy: {rinciples and Practice, eds Leung, DYM, Akdis CA, Bacharier LB, Cunningham-Rundles C, Sicherer SH, Sampson HA. Elsevier, Inc., 2021, pp. 228-235
72. De Keyser HH, Szefler S. Asthma attacks in children are always preceded by poor asthma control: myth or maxim? Breathe (Sheff). 2020 Sep;16(3):200169. doi: 10.1183/20734735.0169-2020. PMID: 33447278; PMCID: PMC7792762.

D. Contribions to Network studies

1. Phipatanakul W, Mauger DT, Guilbert TW, Bacharier LB, Durrani S, Jackson DJ, Martinez FD, Fitzpatrick AM, Cunningham A, Kunselman S, Wheatley LM, Bauer C, Davis CM, Geng B, Kloepfer KM, Lapin C, Liu AH, Pongracic JA, Teach SJ, Chmiel J, Gaffin JM, Greenhawt M, Gupta MR, Lai PS, Lemanske RF, Morgan WJ, Sheehan WJ, Stokes J, Thorne PS, Oettgen HC, Israel E; PARK Study Team. Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation. Contemp Clin Trials. 2020 Nov 24;100:106228. doi: 10.1016/j.cct.2020.106228. Epub ahead of print. PMID: 33242697.

E. Letters to the Editor

None

F. Abstracts:

1. **Szefler SJ**, Acara M, Pazik M. Isoproterenol excretion and metabolism in the isolated perfused rat kidney. The Pharmacologist 20:22l, l978.
2. **Szefler SJ**, Rocci M, Jusko WJ, Ellis EF. Effect of diphenhydramine on prednisolone elimination kinetics. J Allergy Clin Immunol 63:l63, l979.
3. **Szefler SJ**, Rocci M, Acara M, Jusko WJ. Prednisolone and prednisone metabolism and excretion in the isolated perfused rat kidney. The Pharmacologist 2l:l84, l979.
4. **Szefler SJ**, Wynn R, Shen D, Schentag JJ, Buckwald S, Clarke D. Gentamicin serum concentration in premature neonates. Clin Pharmacol Therap 27:289, l980.
5. Dederich RA, **Szefler SJ**, Ellis EF, Green ER. Intrasubject variation in sustained-release theophylline absorption. J Allergy Clin Immunol 65:l77, l980.
6. **Szefler SJ**, Rose JQ, Ellis EF, Spector SL, Jusko WJ, Green AW. Effect of troleandomycin on methylprednisolone disposition. J Allergy Clin Immunol 65:l8l, l980.
7. **Szefler SJ** Shen D, Gingell RL, Pieroni DR. Quinidine elimination in pediatric patients. Presented at the World Conference on Clinical Pharmacology and Therapeutics, l980 Meeting, London, England.
8. Wynn RJ, **Szefler SJ** Clarke DF, Buckwald S, Shen D, Schentag JJ. A reevaluation of gentamicin dosage regimen in small prematures. Pediatr Res l4:474, l980.
9. **Szefler SJ**, Shen D, Gingell RL, Pieroni DR. Quinidine elimination in pediatric patients. Pediatr Res l4:473, l980.
10. **Szefler SJ**, Ellis EF, Rose JQ, Spector SL, Brenner M, Andrews F, Jusko WJ. Troleandomycin inhibition of methylprednisolone elimination in pediatric and adult patients. Clin Pharmacol Therap 29:285, l98l.
11. Zarowitz BJM, **Szefler SJ**, Lasezkay G. Effect of erythromycin base on theophylline elimination. J Allergy Clin Immunol 67(Suppl):40, l98l.
12. **Szefler SJ** Ellis EF, Brenner M, Rose JQ, Spector SL, Yurchak A, Andrews F, Jusko WJ. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. J Allergy Clin Immunol 69:l30, l982.
13. Milsap R, George D, **Szefler SJ**, Lebenthal E, Jusko W. Pharmacokinetics of prednisolone in pediatric patients with inflammatory bowel disease. Clin Pharmacol Therap 3l:250, l982.
14. **Szefler SJ**, LaForce CF, Miller MF, Ebling W, Brenner M. Effect of erythromycin base on methylprednisolone kinetics. J Allergy Clin Immunol 7l:125, l983.
15. Baswell BJ, Pollack GM, Shen DD, **Szefler SJ**. Predicted dose to dose variability in serum theophylline concentrations in patients on Theo-Dur. Presented at the 35th Annual Carl W. Tempel Symposium, Allergy-Immunology Conference, Fitzsimons Army Medical Center, Aurora, Colorado.
16. Rogers RJ, **Szefler SJ**, Wiener MB, Kalisker A. Intraindividual variation in absorption from a sustained-release theophylline formulation during continuous therapy in asthmatic children. Presented at the 36th Annual Carl W. Tempel Symposium, Allergy-Immunology Conference, Fitzsimons Army Medical Center, Aurora, Colorado, l984.
17. Rogers RJ, **Szefler SJ**, Wiener MB, Kalisker A. Intraindividual variation in absorption from a sustained-release theophylline formulation during continuous therapy in asthmatic children. J Allergy Clin Immunol 73:l33, l984.
18. **Szefler SJ**, Brenner AM, Kalisker A, Jusko WJ. Clinical application of a corticosteroid pharmacokinetic evaluation. New Engl Regional Allergy Proc 6: 267-8, l985.
19. Rogers RJ, Wiener MB, Kalisker A, **Szefler SJ**. Absorption characteristics of two sustained-release theophylline formulations during continuous therapy. New Engl Regional Allergy Proc 6: 274, l985.
20. Haltom JR, **Szefler SJ**. Sustained release theophylline absorption in young children. J Allergy Clin Immunol 75:l05, l985.
21. **Szefler SJ**, Rogers RJ, Wiener MB, Haltom JR. Theophylline bioavailability from sustained release delivery systems: Is one dose enough? Clin Pharmacol Therap 37:232, l985.
22. Conboy C, Ellis E, Jenne J, Shaughnessy T, **Szefler SJ**, Wiener M, Milavetz G, Vaughn L, Weinberger M, Carrico J, Tillson S. Evaluation of whole blood theophylline test requiring no instrument. J Allergy Clin Immunol 75:l28, l985.
23. Haltom JR, **Szefler SJ**. Sustained release theophylline: absorption in young children. Pediatr Res l9:l72A, l985.
24. Bartoszek M, Brenner AM, **Szefler SJ**. Prednisolone and methylprednisolone elimination in children receiving carbamazepine and phenobarbital therapy. J Allergy Clin Immunol 77:l50, l986.
25. Hill MR, Bartoszek M, **Szefler SJ**. A single-point method for predicting total body clearance of prednisolone in severe asthmatics. Drug Intell 20:458, l986.
26. **Szefler SJ** Norton C, Ball BD, Pabst M. Interferon- reverses corticosteroid inhibition of oxygen radical release from human monocytes. J Allergy Clin Immunol 79:195, 1987.
27. Hill M, Cribari J, LaBreque J, **Szefler SJ**. 24-hour theophylline concentration profiles during therapy with slow-release theophylline: Experience with 122 asthmatic children. J Allergy Clin Immunol 79:203, 1987.
28. Pabst MJ, Gross JM, Brozna JP, Goren MB, Norton CE, Ball B, **Szefler SJ**. Inhibition of macrophage priming by glucocorticosteroids and by sulfatide from mycobacterium tuberculosis. J Leukocyte Biology 42:345, 1987.
29. Ball BD, Hill M, Brenner M, Sanks R, **Szefler SJ**. Critical assessment of troleandomycin in severe steroid-requiring asthmatic children. Ann Allergy 60:155, 1987.
30. Vichyanond P, **Szefler SJ**, Larsen GL, Hill M. Penetration of systemic corticosteroids into the lung: A difference between prednisolone and methylprednisolone. J Allergy Clin Immunol 81:277, 1988.
31. Ball BD, Hill M, Harbeck RJ, **Szefler SJ**. Application of corticosteroid pharmacokinetics to severe steroid-requiring asthmatics. J Allergy Clin Immunol 81:316, 1988.
32. Hill M, Harbeck RJ, Brown E, **Szefler SJ**. Overestimation of endogenous cortisol in asthmatics receiving steroids using a commercial immunoassay. J Allergy Clin Immunol 81:317, 1988.
33. Kossoy AF, Hill M, Lin FL, **Szefler SJ**. Are theophylline "levels" a reliable indicator of compliance? J Allergy Clin Immunol 81:320, 1988.
34. Alvarez J, **Szefler SJ**, Hill M. Patterns of theophylline absorption in adolescents: Comparison of two slow-release formulations. J Allergy Clin Immunol 83:181, 1989.
35. **Szefler SJ** Hill M, Ball B, Brenner M. Effect of low-dose troleandomycin (TAO) on methylprednisolone (MPn) elimination. J Allergy Clin Immunol 83:219, 1989.
36. Greos LS, Vichyanond P, **Szefler SJ**, Larsen GL, Bloedow DC, Irvin CG, Hill M. Methylprednisolone (Mpn) persists in the lung longer than prednisolone (Pn) following single-dose administration. J Allergy Clin Immunol 83:220, 1989.
37. Greos LS, **Szefler SJ**, Irvin CG, Larsen GL, Hill MR. Does erythromycin prevent airways inflammation? Presented at the 1989 American College of Allergy and Immunology Annual Meeting.
38. Alvarez J., **Szefler SJ**, Gelfand EW. Troleandomycin therapy modifies the T-lymphocyte response to glucocorticoids in asthmatics. J Allergy Clin Immunol 85:195, 1990.
39. Greos LS, Surs W, **Szefler SJ**, Wenzel SE, Hill MR. Macrolide antibiotics inhibit human neutrophil chemotaxis. J Allergy Clin Immunol 85:195, 1990.
40. Greos LS, **Szefler SJ**, Larsen GL, Irvin CG, Hill MR. Troleandomycin reduces airways inflammation. Am Rev Respir Dis 141:A933, 1990.
41. **Szefler SJ**, Ando R, Cicutto LC, Surs W, Hill MR, Martin RJ. Leukocyte ß-adrenergic receptors and circulating autocoids in nocturnal asthma. Am Rev Respir Dis 141:A756, 1990.
42. Dove A, **Szefler SJ**, Hill MR, Larsen GL, Accurso FJ. Altered prednisolone pharmacokinetics in patients with cystic fibrosis. Am Rev Respir Dis 141:A87, 1990.
43. Hill MR, Kamada AK, Brown E, **Szefler SJ**. Glucocorticoid pharmacokinetics in severe asthmatics. J. Allergy Clin. Immunol. 87:312, 1991.
44. Alvarez J, Leung DYM, Surs W, Kamada AK, Gelfand EW, **Szefler SJ**. Steroid resistant asthma: immunologic and pharmacologic features. J. Allergy Clin. Immunol. 87:311, 1991.
45. Altman L, Findlay S, Lopez M, Morris R, Pinnas J, Ratner P, **Szefler S**, Welch M, Lukacsko P. An open-label study of adrenal function in adult asthmatics during daily treatment with 800, 1200, or 1600 µg of inhaled triamcinolone acetonide. J. Allergy Clin. Immunol. 87:310, 1991.
46. Greos LS, Melton V, Nelson HS, **Szefler SJ**, Hill MR. The effect of prednisone and methylprednisolone in allergic asthma. J. Allergy Clin. Immunol. 87:310, 1991.
47. Kamada AK, Hill MR, **Szefler SJ**, Brenner AM. Troleandomycin therapy in severe steroid requiring asthma: effects on bone metabolism. J. Allergy Clin. Immunol. 87:258, 1991.
48. Brenner AM, Kamada AK, Hill MR, **Szefler SJ.** Safety of troleandomycin therapy in chronic severe asthmatic children. J. Allergy Clin. Immunol. 89:344, 1992.
49. Kam JC, Surs W, Trumble AE, **Szefler SJ**, Leung DYM. The combined effects of interleukin (IL)-2 and IL-4 alter the binding affinity of the glucocorticoid receptor. J. Allergy Clin. Immunol. 89:340, 1992.
50. Sher ER, Surs W, Kam JC, Kamada AK, Harbeck R, Leung DYM, **Szefler SJ**. Characterization of T lymphocytes and glucocorticoid receptors in steroid resistant asthma. J. Allergy Clin. Immunol. 89:285, 1992.
51. Kamada AK, Hill MR, Brenner AM, **Szefler SJ**. Glucocorticoid reduction with troleandomycin in chronic, severe asthmatic children: implications for future trials and clinical application. J. Allergy Clin. Immunol. 89:285, 1992.
52. Kam JC, **Szefler SJ**, Surs W, Leung DYM: The altered binding affinity of the glucocorticoid receptor in steroid resistant asthma is maintained by interleukin (IL)-2 and IL-4. J Allergy Clin Immunol 91:223, 1993.
53. Kamada AK, Leung DYM, Surs W, Adinoff AD, **Szefler SJ**: Identification of a second subtype of steroid resistant asthma: decreased number of glucocorticoid receptors. J Allergy Clin Immunol 91:223, 1993.
54. Leflein JG, Kamada AK, Hill MR, Brown E, Nelson HS, **Szefler SJ**: Triamcinolone acetonide delivery via a jet nebulizer. J Allergy Clin Immunol 91:164, 1993.
55. Gleason MC, Kamada AK, Nelson HS, **Szefler SJ**: "As needed" (prn) administration of inhaled beta-adrenergic agonists: Clinical experience in pediatric patients. J Allergy Clin Immunol 91:165, 1993.
56. Clayton MH, Leung DYM, Surs W, **Szefler SJ**: Evidence for glucocorticoid resistance in patients with atopic dermatitis: Characterization of glucocorticoid receptors. J Allergy Clin Immunol 91:317, 1993.
57. Leung DYM**,** Martin RJ, **Szefler SJ**, Sher ER Ying S, Ming Q, Kay AB, Hamid Q. The airways of steroid resistant vs steroid sensitive asthma are associated with different patterns of cytokine gene expression. J Allergy Clin Immunol 93:197, 1994 .
58. Welch MJ, Segal A, Tobey R, **Szefler S**, Simons FE. Inhaled corticosteroids (ICS8, 1994.ergy Clin Immunol 93:19) (a subcommittee of the AAAI Committee on Drugs. J Allergy Clin Immunol 93:198, 1994.
59. Spahn JD, Leung DYM, Surs W, Nimmagadda SR, **Szefler SJ.** Effect of prednisone treatment on glucocorticoid receptor binding parameters in poorly controlled asthma. J Allergy Clin Immunol 93:226, 1994.
60. Nimmagadda SR, **Szefler SJ**, Surs W, Spahn JD, Leung DYM. Effect of allergens on glucocorticoid receptor binding affinity in patients with asthma. J Allergy Clin Immunol 93:227, 1994.
61. Kamada AK, Spahn JD, Surs W, Brown E, Leung DYM, **Szefler SJ**. Glucocorticoid receptor and pharmacokinetic analyses in the evaluation of difficult to control asthmatic patients. J Allergy Clin Immunol 93:259, 1994.
62. Pincus DJ, Bakke M, **Szefler S**, Martin RJ. Chronotherapy of asthma with inhaled steroids: The role of dosage timing. J Allergy Clin Immunol 93:259, 1994.
63. Wood R, et al. (**Szefler SJ** co-investigator) 0.5% nebulized nedocromil sodium reduces asthma symptoms in children 2-4 years of age. J Allergy Clin Immunol 93:260, 1994.
64. Raub JB, Spahn JD, Surs W, **Szefler SJ**, Leung DYM. Induction of altered glucocorticoid receptor binding affinity in peripheral blood mononuclear cells by Il-2 & IL-4 is dose dependent. J Allergy Clin Immunol 95:215, 1995.
65. Nimmagadda SR, Leung DYM, Spahn JD, Surs W, **Szefler SJ**. Mechanisms underlying allergen induced glucocorticoid receptor binding abnormalities. J Allergy Clin Immunol 95:256, 1995.
66. Spahn JD, Hamid Q, Surs W, **Szefler SJ**, Leung DYM. IL-13 mRNA expression in steroid resistant asthma: Diminished glucocorticoid receptor binding affinity is induced by Il-13. J Allergy Clin Immunol 95:385, 1995.
67. Landwehr LP, Spahn JD, Kamada AK, Surs W, Leung DYM, **Szefler SJ**. Effects of Hydrocortisone vs. synthetic glucocorticoids on lymphocyte activation in steroid resistant (SR) asthmatics. J Allergy Clin Immunol 95:387, 1995.
68. Nimmagadda SR, **Szefler SJ**, Spahn JD, Surs W, Leung DYM. IL-2 and IL-4 mediates allergen induced glucocorticoid (GC) receptor (R) binding abnormalities. J Allergy Clin Immunol 97:239, 1996.
69. Prager SS, Leung DYM, Nimmagadda SR, Surs W, Spahn JD, **Szefler SJ**. Superantigens alter glucocorticoid receptor binding (GCR) affinity *in vitro*. J Allergy Clin Immunol 97:244. 1996.
70. Spahn JD, **Szefler SJ**, Nimmagadda SR, Gelfand EW, Leung DYM. Intravenous immune globulin (IVIG) enhances glucocorticoid (GC) sensitivity. J Allergy Clin Immunol 97:688, 1996.
71. Klemm DJ, Surs W, Spahn JD, **Szefler SJ,** Leung DYM. Alterations in glucocorticoid (GC) receptor (R) binding to DNA contributes to steroid resistant (SR) asthma. J Allergy Clin Immunol 97:716, 1996.
72. Spahn J, **Szefler S**, Surs W, Leung DYM. IL-15 induces diminished glucocorticoid receptor (GCR) binding affinity in vitro. J Allergy Clin Immunol 99:S495, 1997.
73. Leung DYM, Wenzel S, **Szefler SJ**, Spahn JD, Surs W, Chrousos GP, Hamid Q. Association of steroid resistant (SR) asthma with increased numbers of cells expressing glucocorticoid receptor (GR) . J Allergy Clin Immunol 99:S496, 1997.
74. Wenzel SE, **Szefler SJ**, Leung DYM, Rex MD, Sloan SI, Martin RJ. Bronchoscopic evaluation of severe asthma: persistent neutrophilic inflammation despite high dose glucocorticoids. J Allergy Clin Immunol 99:S496, 1997.
75. Chan M, Leung DYM, **Szefler SJ**, Spahn JD. Patterns of steroid response in difficult-to-control asthma. J Allergy Clin Immunol 99:S496, 1997.
76. Nimmagadda SR, Spahn JD, Nelson H, Leung DYM, **Szefler SJ**. Fluticasone propionate (FP) 1000 µg bid appears to improve glucocorticoid (GC) receptor (GCR) binding affinity while reducing eosinophil cationic protein (ECP) levels and oral GC requirements in severe steroid dependent asthma. J Allergy Clin Immunol 99:S320, 1997.
77. Lanz MJ, Leung DYM, **Szefler SJ**, White CW. Use of exhaled nitric oxide (eNO) to monitor inflammation in children with severe asthma. J Allergy Clin Immunol 99:S375, 1997.
78. Wamboldt F, Bender B, O'Connor S, McTaggart S, Meltzer L, Gavin L, Wamboldt M, Milgrom H, **Szefler S**, Kamada A, Kastner W, Iklé D, Rand C. Reliability of the model MC-311 MDI chronolog. Am J Respir Crit Care Med 155 (part 2 of 2): 259, 1997.
79. Chu HW, Trudeau JB, **Szefler SJ**, Martin RJ, Leung DYM, Wenzel SE. Collagen deposition in endobronchial biopsy specimens from severe asthmatics, as compared to asthmatic and normal control groups. Am J Respir Crit Care Med 155 (part 2 of 2): 502, 1997.
80. Fost DA, **Szefler SJ**, Brown EE, Martin RJ, Leung DYM, Spahn JD. Non-antimicrobial effects of clarithromycin. J Allergy Clin Immunol 101 (Part 2): S4, 1998.
81. Hauk PJ, Wenzel SE, Trumble AE, Strickland I, **Szefler SJ,** Leung DYM. Increased T cell receptor (TCR)-BV8+ T cells in bronchoalveolar lavage (BAL) of poorly controlled (PC) asthmatics: a potential role for microbial superantigens. J Allergy Clin Immunol 101 (Part 2): S236, 1998.
82. Spahn JD, Chan MTS, **Szefler SJ**, Leung DYM, Gelfand EW. Glucocorticoid (GC) sparing effect of intravenous gammaglobulin: a mechanism of action. J Allergy Clin Immunol 101 (Part 2): S152, 1998.
83. Wamboldt FS, Spahn JS, Klinnert MD, Gavin LA, **Szefler SJ**, Leung DYM. Clinical outcomes of glucocorticoid (GC)-insensitive asthma. J Allergy Clin Immunol 101 (Part 2): S178, 1998.
84. Wanger J, Kamada A, Gelfand EW, **Szefler SJ**, Bucher-Bartelson B, Irvin CG. Reproducibility and sensitivity of forced oscillations (FO) in detecting airflow limitation. Am J Respir Crit Care Med 157:A87, 1998.
85. Togias A, Pearlman D, Boushey H, **Szefler SJ**, Srebo S, Edwards L, Shah T. Association of older age with lower pre- and post-bronchodilator FEV1 % predicted in asthma. Am J Respir Crit Care Med 157:A163, 1998.
86. O'Conner S, Bender B, Rojas S, Gavin L, Kamada AK, Wamboldt M, Milgrom H, **Szefler SJ**, Rand C, Wamboldt F. Measuring adherence with the doser CT in children with asthma. Am J Respir Crit Care Med 157:A274, 1998.
87. Anderson W, Boushey H, Togias A, Pearlman D, **Szefler SJ,** Yancey S, Wisniewski M, Shah T. Effects of salmeterol on PEFR and symptom assessment immediately prior and following an asthma exacerbation. Am J Respir Crit Care Med 157:A401, 1998.
88. **Szefler SJ**, Vanden Burgt J, Vogel J, Donnell D. Improved therapeutic index for new HFA-BDP aerosol. Am J Respir Crit Care Med 157:A405, 1998.
89. **Szefler SJ**, Furlong A, Shah T, Knobil K. Time to onset of effect of fluticasone propionate in patients with asthma. Am J Respir Crit Care Med 157:A414, 1998.
90. Covar R, **Szefler SJ**, Leung DYM, Brown EE, Spahn JD. Factors associated with prednisolone clearance in patients with difficult to control asthma. J Allergy Clin Immunol. 2000; 105(1,pt 2):S10 (#30).
91. Covar RA, **Szefler SJ**, Martin RJ, Sundström DW, Murphy JR, Young DA, Silkoff P, Spahn JD. Relationships between exhaled nitric oxide and measures of disease activity among children with mild to moderate asthma. J Allergy Clin Immunol. 2002;109(1 pt 2):454A.
92. Nayak A, **Szefler SJ**, Pedersen S. Efficacy of beclomethasone dipropionate (BDP) extrafine aerosol following switch from conventional BDP in children with asthma. J Allergy Clin Immunol. 2002;109(1 pt 2):712A.
93. Nayak A, **Szefler SJ**, Pedersen S. Long-term safety of extrafine and conventional beclomethasone dipropionate aerosols in pediatric asthma. J Allergy Clin Immunol. 2002;109(1 pt 2):721A.
94. Donnell D, Nayak A, **Szefler SJ**, Pedersen S. Efficacy of beclomethasone dipropionate (BDP) extrafine aerosol following switch from conventional BDP in children with asthma. J Allergy Clin Immunol. 2002;109(1 pt 2):750A.
95. Strunk RC, Sternberg AL, Bacharier LB, **Szefler SJ**. Nocturnal awakening due to asthma in children with mild to moderate asthma in the Childhood Asthma Management Program. J Allergy Clin Immunol. 2002;109(1 pt 2):1097A. PMID: 12209085
96. Spahn JD, **Szefler SJ**, Jenkins HA, Covar RA, Brown EE, Gelfand EW. Can we alter the progression of severe asthma with any currently available therapy? J Allergy Clin Immunol. 2002;109(1 pt 2):1099A.
97. Jenkins HA, **Szefler SJ**, Covar RA, Jones M, Brown EE, Gelfand EW, Spahn JD. New insight into the clinical characteristics of adults vs. children with severe asthma. J Allergy Clin Immunol. 2002;109(1 pt 2):1100A.
98. Wamboldt F, Bender B, Ho J, Milgrom H, Rojas S, **Szefler SJ**, Tran Z, and Wamboldt M. Correlates of MDI adherence: a replication study. Am J Respir Crit Care Med. 165:A197, 2002.
99. Bender B, **Szefler SJ**, Ellison M, and Murphy J. Prediction and management of patient attrition in the childhood asthma management program. Am J Respir Crit Care Med. 165:A198, 2002.
100. Macomber B, Covar R, Whelan G, **Szefler S**. A Unique Asthma Phenotype Characterized by Frequent Asthma Exacerbations. J Allergy Clin Immunol. 2005;115:S6.
101. Liu AH, Morgan WJ, Schiltz AM, James RL, **Szefler SJ**, Mitchell H, Busse WW. Exhaled Breath Condensates Nitrite Levels Inversely Correlates with pH. J Allergy Clin Immunol 2005;115:S214.
102. Whelan GJ, Spahn JD, Brown EE, **Szefler SJ**. Subpotentcy of a compounded budesonide for nebulization product in a patient with poorly controlled asthma. J Allergy Clin Immunol 2006;117:S12.
103. Miller MK, Lee JH, Dorer D, Vaghar A, Israel E, Kraft M, Martinez F, Miller D, Shapiro G, Tarone R, **Szefler SJ**. Enrollment update of the epidemiologic study of Xolair: Evaluating the long-term safety and clinical effectiveness in patients with moderate to severe asthma (EXCELS). J Allergy Clin Immunol 2006;117:S12.
104. **Szefler SJ**, Lee JH, Haselkorn T, Mink DR, Deniz Y, Simons FE. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2006; 117:S827.
105. Patel N, Schiltz AM, Harbeck R, Covar R, Wood SM, DeMichele SJ, Gelfand EW, **Szefler SJ**, Liu AH. Sputum mediators in children with mild persistent asthma indicate immune dysregulation and correlate with lower lung function. J Allergy Clin Immunol 2007;119:S81.
106. Haselkorn T, **Szefler SJ**, Simons FER, Mink DR, Chipps BE, Wong DA, Borish L. Allergy, serum IgE and lung function in children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2007;119:S85.
107. **Szefler SJ**, Covar R, Macomber B, Stewart L, Gleason M, Engelhardt K, Murphy J, Liu A, Wood S, DeMichele SJ, Wennberg A, Gelfand E. Safety and tolerance of a novel medical food (NMF) in children with mild persistent asthma. J Allergy Clin Immunol 2007;119:S172.
108. Szefler PA, Krawiec ME, Newell JD, **Szefler SJ**, Hendershot RW. A tale of two pediatric patients: using high resolution CT (HRCT) to distinguish severe asthma and bronchiolitis obliterans (BO). J Allergy Clin Immunol 2007;119:S174.
109. Covar R, Macomber B, Stewart L, Gleason M, Engelhardt K, Murphy J, Liu A, Wood S, DeMichele S, Gelfand E, **Szefler SJ**. Effect of a novel medical food (NMF) on biomarkers of inflammation and airway hyperresponsiveness in children with mild persistent asthma. J Allergy Clin Immunol 2007;119:S249.
110. Koenig JQ, Mar TF, Hallstrand T, **Szefler SJ**, Covar R. Relationship between airway inflammation and air pollution in children with asthma in Denver CAMP. Am J Respir Crit Care Med. 175:A539, 2007.
111. Hendershot RW, **Szefler SJ**, Martin RJ, Szefler PA, Krawiec ME. Bronchoalveolar lavage (BAL) Chlamydia + PCR increases morbidity in severe pediatric asthma. Am J Respir Crit Care Med. 175:A838, 2007.
112. Klinnert MD, Tamesis GP, Liu AH, **Szefler SJ**, Covar RA. Predictors for persistent asthma in low income children: 7 year follow-up from The Childhood Asthma Prevention Study (CAPS). J Allergy Clin Immunol 2008;121:S224.
113. Covar RA, Szefler P, Murphy J, Liu A, Spahn JD, Harbeck R, Efaw BJ, Sundstrom D, **Szefler SJ**. Sputum protease/anti-protease imbalance distinguishes progressive airflow limitation in adolescents with asthma: CAMP continuation study. J Allergy Clin Immunol 2008;121:S255.
114. Kruzick T, Covar R, Gleason M, Cicutto L, White M, **Szefler SJ**. Does insurance coverage equal asthma control in school-aged children? J Allergy Clin Immunol 2009; 123:S43.
115. Haselkorn T, Fish JE, Zeiger RS, **Szefler SJ**, Miller DP, Chipps BE, Weiss ST, Wenzel SE, Borish L, Bleecker ER. Asthma control and risk of future asthma exacerbations: evaluation of the impairment domain of the NHLBI Guidelines in the TENOR Cohort. J Allergy Clin Immunol 2009; 123:S80.
116. Goleva E, Covar R, Sutherland ER, Martin RJ, **Szefler SJ**, Leung DY. Increased prevalence of abnormalities in glucocorticoid pharmacokinetics among clinically steroid resistant obese asthmatics. J Allergy Clin Immunol 2009; 123:S81.
117. Cicutto L, Anderson M, Bracamontes M, Ceballos M, Colmenero C, Covar R, Gleason M, Frederico M, White M, **Szefler SJ**. Denver Public Schools Asthma Program: Changes in Inhaler Technique and Confidence. Am J Respir Crit Care Med 2009; 179:A2452.
118. Zeiger RS, Yegin A, Simons ER, Haselkorn T, Rasouliyan L, **Szefler SJ**, Chipps BE for the TENOR Study Group. Evaluation of the impairment domain components of the NHLBI Guidelines in classifying asthma control and predicting future asthma exacerbations. Chest 2010; 138:150A.
119. Meltzer LJ, Sundstrom D, White M, Phillips M, Graves S, **Szefler SJ**. Experimentally manipulated sleep extension in adolescents with asthma: feasibility and preliminary findings. Sleep 2013; Abstract 0993.
120. Long AA, Rahmaoui A, Rothman KJ, Guinan EC, Eisner MD, Bradley MS, Iribarren C, Chen H, Carrigan G, Rosen K, **Szefler SJ**. Incidence of malignancy in omalizumab and non-omalizumab treated patients with moderate-to-severe asthma: The EXCELS Study. Am J Respir Crit Care Med 2013;187:A3869.
121. Xingnan L, Moore WC, Ampleford EJ, Li H, Hawkins G, Hastie AT, Boushey HA, Busse WW, Castro M, Erzurum SC, Israel E, Lemanske RF, **Szefler SJ**, Wasserman SI, Wenzel SE, Peters SP, Meyers DA, Bleecker ER. Phenotypic/Genetic characteristics of atopic/non-atopic early/late onset asthma. Am J Respir Crit Care Med 2013;187:2395.
122. Schwartz DA, Yang IV, Pedersen BS, Liu A, O’Connor GT, Teach SJ, Kattan M, Misiak RT, Gruchalla R, Steinbach SF, **Szefler SJ**, Gill MA, Calatroni A, David G, Hennessy CE, Davidson E, Von Mutius E, Ege MJ, Genuneit J, Horak E, Braun-Farlander C, Shabalin AA, Gergen P, Togias A, Busse WW. DNA methylation changes and childhood asthma in the inner city. Am J Respir Crit Care Med 2013;187:A2121.
123. Covar R, Forssen A, **Szefler SJ**, Schwartz DA, Liu AH. Divergent effects of endotoxin and mold exposure on asthma exacerbations in The Childhood Asthma Management Program (CAMP). J Allergy Clin Immunol 2014;133:AB164.
124. Cicutto L, Gleason M, White M, Haas-Howard C, Shocks, D, **Szefler SJ**. Building Bridges for Better Asthma Care: A program connecting schools, students with asthma and their health care providers for optimizing outcomes. Am J Respir Crit Care Med. 2014;189:A2453.
125. Chipps BE, Haselkorn T, Paknis B, Bleecker E, Borish L, Kianifiard F, Foreman A, Mendelson M, **Szefler SJ**, Weiss S, Zeiger RS. The epidemiology and natural history of asthma: outcomes and treatment regimens: more than decade follow-up (TENOR 2). Ann Allergy Asthma Immunol 2015;115:A22.
126. Gleason MC, Villarreal M, Hollenbach JP, Haas-Howard C, Cloutier MM, McGinn M, Cicutto L, Langton C, Mitchell H, **Szefler SJ**. Building Bridges transforms the approach to school-centered asthma care and improves outcomes for children with asthma. Am J Respir Crit Care Med 2015;191:A7828.
127. Dunn RM, Lehman E, Chinchilli VM, Martin RJ, Boushey HA, Israel E, Kraft M, Lazarus SC, Lemanske RF, Lugogo N, Peters SP, Sorkness CA, **Szefler SJ**, Wechsler ME. Impact of gender and age on the response to therapy in the asthma clinical research network. Am J Respir Crit Care Med 2015;191:A4271.
128. Hoch HE, Calatroni A, **Szefler SJ.** Validation of predictors for Fall asthma exacerbations in inner city children. Am J Respir Crit Care Med 2015;191:A2639.
129. Hollenbach JP, Villarreal M. Cloutier MM, Mitchell H, Langton C, Vinick C, Gleason M, Williams S, Haas-Howard C, Cicutto L, **Szefler SJ**. Reducing school absenteeism among inner-city children: preliminary results from the 2013-14 Building Bridges: advancing education by improving asthma management in inner-city children program. Am J Respir Crit Care Med 2015;191:A3806.
130. Yang IV, Pedersen BS, Liu AH, O’Connor GT, Teach SJ, Kattan M, Misiak RT, Gruchalla R, Steinbach SE, **Szefler SJ**, Gill MA, Calatroni A, David G, Hennessy CE, Davidson EJ, Gergen P, Togias A, Busse WW, Schwartz DA. Am J Respir Crit Care Med 2015;191:A5379.
131. Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Hamelmann E, Engel M, **Szefler S**. Tiotropium Respimat add-on therapy in children with symptomatic asthma. Eur Resp J 2015;46(Suppl 59) PA3604.
132. Dunn R, **Szefler SJ**. Severe asthma in pediatric patients. Pathophysiology and unmet needs. Annals ATS 2016:13:S103-104.
133. Goldstein S, **Szefler SJ**, Vogelberg C, Bensch G, Given J, El Azzi G, Monroni-Zentgraf P, Engel M, Sigmund R, Hamelmann E. Once-daily tiotropium Respimat add-on therapy improves FEF 25-75% in children and adolescent patients with persistent symptomatic asthma. Am J Respir Crit Care Med 2016;193:A3817.
134. **Szefler SJ**, Harper T, Laki I, Boner A, El Azzi G, Moroni-Zentgraf P, Engel M, Hayman A, Hamelmann E. Once-daily tiotropium Respimat add-on therapy improves lung function in children with severe symptomatic asthma. Am J Respir Crit Care Med 2016;193:A3818.
135. **Szefler SJ**, Rupp N, Boner A, El Azzi G, Moroni-Zentgraf P, Engel M, Hamelmann E. Safety and tolerability of once-daily tiotropium Respimat add-on therapy in children with severe symptomatic asthma. Am J Respir Crit Care Med 2016;193:A3819.
136. Liptzin DR, Gleason MC, Wagner B, **Szefler SJ**. Evaluating asthma exacerbations after participation in a school-centered asthma program: the Step Up Asthma Program. Am J Respir Crit Care Med 2016;193:A2164.
137. Haselkorn T, Zeiger RS, Borish L, Paknis B, Bleecker ER, Foreman A, Kianifard F, Weiss ST, Chipps BE, **Szefler SJ**. Prevalence and risk factors for persistent very poorly controlled (VPC) asthma after more than a decade in the TENOR II Cohort. Am J Respir Crit Care Med 2016;193:A1025.
138. Yang I, Liu AH, Pedersen B, O’Connor GT, Teach SJ, Kattan M, Misiak RT, Gruchalla RS, Steinbach SF, **Szefler SJ**, Gill MA, Calatroni A, David GL, Hennessy CE, Davidson EJ, Zhang W, Gergen PJ, Togias A, Busse WW, Schwartz DA. DNA methylation and childhood asthma in the inner city. J Allergy Clin Immunol 2015;135:AB163.
139. Hollenbach JP, Cloutier MM, Steciak D, Mitchell H, Villarreal M. Williams S, Gleason MC, **Szefler SJ**. Agreement between caregiver report and hospital and school records. J Allergy Clin Immunol 2015;135:AB166.
140. Esquivel AT, Busse WW, Calatroni A, Gergen PJ, Grindle K, Gruchalla RS, Kattan M, Kercsmar C, Khurana Hershey GK, Kim H, Lebeau P, Liu AH, **Szefler SJ**, Teach SJ, Pongracic JA, West JBB, Wildfire J, Gern JE. Omalizumab decreases rates of cold symptoms in inner-city children with allergic asthma. J Allergy Clin Immunol 2015;137:AB87.
141. Borish L, **Szefler SJ**, Zeiger RS, Foreman A, Greenberg S, Hasslekorn T, Klanifard F, Mendelson M, Paknis B, Weiss ST, Chipps BE. Predominance of atopic asthma in patients with severe or difficult-to-treat asthma in the TENOR II Cohort. J Allergy Clin Immunol 2015;137:AB213.
142. Hamelmann E, Vogelberg C, Bernstein JA, Harper T, Moroni-Zentgraf P, Engel M, El Azzi G, Finnigan H, **Szefler SJ**. Once-daily tiotropium Respimat add-on therapy improves PEF in particpants aged 6-17 years with symptomatic asthma. Eur Resp J 2016;48(Suppl 60) PA1241.
143. Vogelberg C, **Szefler SJ**, Hamelmann E, Boner A, Moroni-Zentgraf P, Engel M, El Azzi G, Finnigan H, Vandewalker M. Safety of tiotropium Respimat add-on therapy in patients aged 6-17 years with symptomatic asthma. Eur Resp J 2016;48(Suppl 60) PA1251.
144. Stempel D, **Szefler S**, Pedersen S, Zeiger R, Mitchell H, Liu A, Raphiou I, Kral K, Yeakey A, Buaron K, Prillaman B, Lee L, Yun Kirby S, Pascoe S. Safety of salmeterol/fluticasone propionate (FSC) compared to fluticasone propionate (FP) in 4-17 yr olds with asthma. Eur Resp J 2016;48(Suppl 60) OA4798.
145. Ortiz B, Chipps BE, Zeiger RS, Haselkorn T, Foreman A, Kianifard F, Paknis B, **Szefler SJ**. Long-term outcomes from a pediatric subgroup of TENOR I: 10 years follow up. J Allergy Clin Immunol 2017;139:AB101.
146. Vandewalker ML, Hamelmann E, Engel M, El Azzi G, Moroni-Zentgraf P, Unseld A, Vogelberg C, **Szefler SJ**. Once-daily tiotropium Respimat add-on therapy has a safety profile comparable with placebo in children and adolescents. J Allergy Clin Immunol 2017; on line.
147. Zeiger R, Chipps B, Ortiz B, Kianiford F, Paknis B, Haselkorn T, Foreman A, **Szefler S**. Long-term assessment of the burden of atopic sensitization in patients with severe/difficult-to-treat asthma. Ann Allergy Asthma Immunol 2017;119:S58.
148. **Szefler S**, Antonova J, Trzaskoma B, Ortiz B, Paknis B, Iqbal A, Goldstein S. Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma. Eur Resp J 2017;50(Suppl 61) PA587.
149. Hoch H, Kempe A, Brinton J, **Szefler S**. Assessing the utility of asthma medication monitoring sensors in a group of high-risk asthmatic children.Eur Resp J 2017;50(Suppl 61) PA598.
150. Fielding S, Pijnenburg M, DeJongste J, Pike K, Roberts G, Petsky H, Chang A, Fritsch M, Frischer T, Szefler S, Gergen P, Vermeulen F, vael R, Turner S. By how can exhaled nitric oxide vary without a change in clinical status? Eur Resp J 2017;50(Suppl 61) PA4497.
151. Turner S, Fielding S, Pijnenburg M, De Jongste J, Pike K, Roberts G, Petsky H, Chang A, Fritsch M, Frischer T, **Szefler S**, Gergen P, Vermeulen F, Vael R. Are there subgroups of children with asthma where FeNO guided treatment is associated with reduced risk for asthma attacks? Eur Resp J 2017;50(Suppl 61) PA1330.
152. Stempel D, Szefler S, Hoch H, Tuffli M, Barrett M, Van Sickle D. Daily pattern of 2-agonists: Understanding real-life use of rescue medication. Eur Resp J 2017;50(Suppl 61) PA3959.
153. Vogelberg C, Hamlemann E, Engel M, El Azzi G, Dan Vulcu S, **Szefler S**. Safety profile of tiotropium add-on therapy in pediatric patients by gender. Eur Resp J 2018;52(Suppl 62) PA608.
154. Hoch H, Kaye L, Anderson W, Gondalia R, Barrett M, Tuffi M, Van Sickle D, **Szefler S**, Stempel D. Comparing objective inhaler use among COPD and asthma populations. Eur Resp J 2018;52(Suppl 62) PA2272.
155. Turner S, Fielding S, Pijnenburg M, De Jongste J, Pike K, Roberts G, Petsky H, Chang A, Fritsch T, **Szefler S**, Gergen P, Vermeulen F, Vael R. Do changes in spirometric indices and FeNO predict asthma outcomes in children? An individual patient data analysis using results from seven FeNO trials. Eur Resp J 2018;52(Suppl 62) PA5011.
156. Anderson W, Hoch H, Gondalia R, Kaye L, Theye B, Barrett M, Van Sickle D, **Szefler S**, Stempel D. Frequency of improper inhaler technique identified by electronic medication monitor (EMM) actuation timing. Ann Allergy Asthma Immunol 2018;121:S7.
157. Anderson W, Hoch H, Gondalia R, Kaye L, Barrett M, Van Sickle D, **Szefler S**, Stempel D. Asthma control evaluated with electronic medication monitor (EMM)-defined occsions of short-tacting beta-agonist inhaler use. Ann Allergy Asthma Immunol 2018;121:S40.
158. Hoch H, Kaye L, Gondalia R, Theye B, Barrett M, Van Sickle D, **Szefler S**, Stempel D. Benefit of smartphone alerts to improve adherence to inhaled asthma controllers. Ann Allergy Asthma Immunol 2018;121:S40.
159. Haselkorn T, **Szefler S**, Chipps B, Bleecker E, Mink D, Kianifard F, Ortiz B, Zeiger R. Predictors of future severe asthma exacerbation after a decade follow-up: results from TENOR II. Ann Allergy Asthma Immunol 2018;121:S44.